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Major Director: Dr. Amanda J. Dickinson,                                                   
Assistant Professor, Department of Biology 
 
 
Among the most prevalent and devastating types of human birth defects are 
those affecting the mouth and face, such as orofacial clefts. Children with 
malformed orofacial structures undergo multiple surgeries throughout their lifetime 
  
and struggle with facial disfigurements, speech, hearing, and eating problems. 
Therefore, facilitating new research in cranio- and orofacial development is 
paramount to prevention and treatment of these types of birth defects in humans. 
Xenopus laevis has emerged as a new tool for dissecting the mechanisms governing 
facial development. Thus, molecular analyses accompanied by quantitative 
assessment of morphological changes during orofacial development of this species 
could be very powerful for understanding how these defects arise. In this 
dissertation, I present such a study. I first establish a quantitative protocol to 
describe size and shape changes in facial morphology of wild-type Xenopus 
embryos. I then utilize this method on embryos in which retinoic acid signaling or 
folate metabolism have been disrupted to correlate morphological changes with 
their underlying mechanisms. Finally, I demonstrate the utility of Xenopus as a 
system for chemical genomics to uncover other regulators of orofacial development.  
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INTRODUCTION  
 
 
 
Orofacial anomalies, such as cleft lip/palate, are among the most common 
birth defects, occurring in about 1 in every 1000 births annually in the United 
States (CDC 2016). Children born with these abnormalities experience immense 
difficulties in eating, hearing, speech, and psychosocial development (CDC 2016). 
Median clefts, also classified as median facial dysplasia or frontonasal dysplasia 
(OMIM 136760, (Allam, Wan et al. 2011)), are a category of orofacial defects that 
occur at the midline of the face and arise due to malformation of the primary palate 
early in development (Diewert and Wang 1992; Meng, Bian et al. 2009). These 
defects are severe in humans, and can be difficult to surgically correct (Mossey, 
Little et al. 2009). Often, they present as part of a syndrome accompanied by other 
developmental anomalies (reviewed in (Dickinson 2016)). They can also arise from 
midface hypoplasia due to growth deficiency in the midface tissues (Dickinson 
2016). For example, human midface hypoplasia can result from mutations in 
Hedgehog pathway genes that disrupt the development of the facial midline 
(Brugmann, Allen et al. 2010). Additionally, studies in zebrafish, mouse, and 
Xenopus have uncovered several other genes associated with midface hypoplasia 
and median clefts such as Alx and Six2 family members, PDGF, homeobox genes, 
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and retinoic acid receptors; all of which produce median clefts strikingly similar to 
those seen in humans (Diewert and Wang 1992; Lohnes, Mark et al. 1994; 
Beverdam, Brouwer et al. 2001; Eberhart, He et al. 2008; Dupe and Pellerin 2009; 
Kennedy and Dickinson 2012; He and Soriano 2013; Vasudevan and Soriano 2014). 
Median clefts are multifactorial, and their etiology is complicated by a 
variety of factors that regulate primary palate development including genetics, 
environment, and maternal nutrition (Jugessur and Murray 2005; Jiang, Bush et al. 
2006; Meng, Bian et al. 2009; Dixon, Marazita et al. 2011). Therefore, 
understanding the consequences of disrupting these signaling pathways in the 
developing primary palate is critical to understanding and preventing these defects. 
Further, median clefts are often associated with changes in dimensions and shape of 
the orofacial region; therefore, quantification of orofacial morphology is imperative 
for understanding how these defects arise (Martinelli, Scapoli et al. 2006; 
Martinelli, Girardi et al. 2014). Here, I combine traditional measurements of facial 
dimensions with geometric morphometrics to develop a quantitative method 
describing the early Xenopus laevis orofacial region during normal and abnormal 
development. I also utilize chemical genomics to identify regulators of orofacial 
orofacial development and investigate their role in the formation of median clefts. 
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CHAPTER I: QUANTIFICATION OF THE OROFACIAL REGION 
DURING NORMAL DEVELOPMENT 
 
 
 
Xenopus laevis has become an important tool for elucidating the cellular and 
molecular mechanisms that regulate orofacial development. However, there is 
neither a quantitative description, nor tools to assess defects in the orofacial 
anatomy of Xenopus. Therefore, in this first chapter I provide the first qualitative 
and quantitative analyses of orofacial development in early Xenopus laevis tadpoles 
using facial measurements and geometric morphometrics. This combination allows 
for a more comprehensive statistical analysis of both size and shape of the orofacial 
region than current protocols, which largely utilize only one or the other (Scheuer, 
Holtje et al. 2001; Farkas, Katic et al. 2002; Parsons, Kristensen et al. 2008; 
Cooper, Parsons et al. 2010). Further, I present here a simple way to assess both the 
medial and lateral planes of the face without requiring sophisticated three-
dimensional imaging equipment used in current studies (Klingenberg, Wetherill et 
al. 2010; Bugaighis, Mattick et al. 2014). 
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INTRODUCTION 
 
 
 
The orofacial region of the early Xenopus tadpole (60–100 hpf) consists of 
the embryonic mouth and the surrounding paired bilaterally symmetrical maxillary, 
mandibular and nasal prominences, and single medial frontonasal prominence 
(Helms, Cordero et al. 2005; Szabo-Rogers, Smithers et al. 2010). The embryonic, 
or primary, mouth develops in the most anterior region of the embryo, in which 
ectoderm is directly juxtaposed with the underlying endoderm (Dickinson and Sive 
2006; Dickinson and Sive 2007; Soukup, Horacek et al. 2013). Through a series of 
morphological changes that include basement membrane dissolution, apoptosis, cell 
intercalations, and perforation; the embryonic mouth creates an opening between 
the foregut and the external environment at 66 hpf in Xenopus (Dickinson and Sive 
2006). 
At the same time the embryonic mouth is forming, the surrounding facial 
prominences grow, merge and begin to differentiate (Jiang, Bush et al. 2006). Each 
prominence is a partitioned region of the face, in which complex interactions of 
ectoderm, endoderm, mesoderm, and neural crest allow for proliferation, migration, 
and differentiation into the structures of the face and mouth (Graham, Okabe et al. 
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2005; Chai and Maxson 2006; Noden and Francis-West 2006; Szabo-Rogers, 
Smithers et al. 2010; Cordero, Brugmann et al. 2011). Maxillary, nasal, and 
frontonasal prominences fuse dorsal to the embryonic mouth forming the upper jaw 
and primary palate (Diewert and Wang 1992; Jiang, Bush et al. 2006; Szabo-Rogers, 
Smithers et al. 2010; Jin, Han et al. 2012; Kennedy and Dickinson 2012). In 
amniotes, outgrowth of the maxillary prominences forms the secondary palate and 
creates a separation between nasal passages and the mouth (reviewed in (Ferguson 
1988; Greene and Pisano 2010)). The formation and shaping of the embryonic 
mouth is seemingly tied to that of the surrounding facial region. For example, we 
find that abnormalities in facial growth can often lead to failure of mouth 
perforation. In addition, failure in migration and fusion of the nasal and/or 
maxillary prominences can result in a range of orofacial clefts, which collectively 
comprise one of the most common classes of birth defects in humans (Kouskoura, 
Fragou et al. 2011; Levi, Brugman et al. 2011). 
Xenopus is amenable for orofacial studies for several reasons, including their 
ex-utero development, large and easily accessible face throughout facial 
development, and the ease of chemical treatments and face transplants (Dickinson 
and Sive 2009; Wheeler and Liu 2012; Jacox, Dickinson et al. 2014). Further, 
orofacial development is well conserved across vertebrates (Szabo-Rogers, Smithers 
et al. 2010). Xenopus offers several advantages for studying primary palate 
development and orofacial defects over other model organisms. For example, the 
Xenopus orofacial region is completely unencumbered by the head flexure that 
prevents visualization of the mouth in mouse, chick, and zebrafish embryos.  
  6 
While we begin to uncover the morphological changes and molecular 
mechanisms regulating orofacial development in Xenopus, sophisticated analyses 
are hindered by the lack of quantitative anatomical description of orofacial 
development and tools to assess different degrees of orofacial anomalies. There are 
several different methods that can be used to quantify anatomical development of 
the orofacial region. Proportion indices or ratios of specific facial dimensions have 
long been used to predict birth defects and as a measure of attractiveness in humans 
(Farkas, Katic et al. 2001; Scheuer, Holtje et al. 2001; Sarver and Ackerman 2003; 
Rossetti, De Menezes et al. 2013). Geometric morphometrics is another tool that has 
recently become important in quantitatively describing facial form and diagnosing 
human craniofacial anomalies (Singh, Rivera-Robles et al. 2004; Young, Wat et al. 
2007; Bugaighis, O'Higgins et al. 2010; Klingenberg, Wetherill et al. 2010; 
Bejdova, Krajicek et al. 2012). By identifying landmarks of anatomical features on 
the face, and aligning these landmarks via a mathematical algorithm to eliminate 
information regarding size and orientation; morphometrics can show subtle 
differences in face shape amongst samples (Zelditch, Lundrigan et al. 2004). 
The combination of facial measurements and geometric morphometrics that I 
present here allows for a more comprehensive statistical analysis of both size and 
shape of the orofacial region than current protocols which largely utilize only one 
or the other (Scheuer, Holtje et al. 2001; Farkas, Katic et al. 2002; Parsons, 
Kristensen et al. 2008; Cooper, Parsons et al. 2010). Further, I present a simple way 
to assess both the medial and lateral planes of the face without requiring 
sophisticated three-dimensional imaging equipment used in current studies 
  7 
(Klingenberg, Wetherill et al. 2010; Bugaighis, Mattick et al. 2014). Here, I take a 
simple yet unique approach by combining the more traditional measurements of 
orofacial dimensions with geometric morphometrics to first quantify orofacial 
development in early tadpoles of Xenopus laevis. 
 
  8 
 
 
METHODS 
 
 
 
1. ADULT XENOPUS LAEVIS 
Adult male and female Xenopus laevis are housed in an Aquatic Habitats XR5 
system located in its own 400 ft2 room in the VCU Life Sciences Aquatic facility. 
The system contains nine 40-gallon tanks and it is equipped with intense physical 
and biological filtration. Adults are kept on a 12-hour light cycle, 10% water 
changes daily are performed daily, and they are fed four to five times a week with a 
diet of Xenopus Nasco pellets.  
Adult Xenopus laevis females were injected with approximately 500 µL 
human chorionic gonadotropin (HCG, Sigma) using a 26.5 or 30 gauge needle to 
induce egg laying. Males were euthanized using a pH neural 1% benzocaine bath. 
Testes were extracted surgically followed by severing of the spinal cord. These 
protocols are approved by the VCU Institutional Animal Care and Use Committee 
(protocol number   =   AD20261). 
2. TADPOLE COLLECTION AND CARE 
Eggs were collected from two different females on the same day and 
fertilized using standard methods (Sive, Granger et al., 2000). Embryos and 
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tadpoles were correspondingly maintained as two large groups in 20–30 mL of 0.1X 
Modified Barth's Saline solution (MBS, pH 7.8), and this solution was changed 
daily. At five consecutive time points a group of 10 randomly chosen embryos were 
fixed from each group with 4% paraformaldehyde (PFA) for 12 hours at 4°C. While 
performing two experiments simultaneously I was able to remove some variation in 
fixation time. However, each time point still consisted of individuals with slight 
variation in developmental stage, I used Nieuwkoop and Faber (1994) to establish a 
range of stages for each time point, and these are shown in Table 1.1. 
3. PHOTOGRAPHING TADPOLE FACES FOR QUANTIFICATIONS 
The heads of fixed tadpoles were severed with a Sklar sterile disposable 
scalpel by making two incisions. The first incision was at the posterior end of the 
gut to remove pressure from the scalpel. A second incision on the anterior side of 
the gut, just behind the heart, was then made to completely remove the head.  
To image tadpole heads, black modeling clay was flattened along the bottom 
of a 15 mm Petri dish, and filled with PBT. A straight teasing needle was pressed 
into the clay at a 45° angle. Holding the needle there, the Petri dish was slowly 
moved horizontally to create a depressed line. The glass pipette tool was then used 
to make circular depressions along each row. Embryo heads were positioned in the 
holes in the clay for imaging. For frontal views, pairs of forceps were used to 
position embryo heads posterior side down inside the circular depressions. Using 
the forceps to manipulate both the embryo head and the surrounding clay, embryos 
were positioned such that they were facing the camera and were not tilted backward 
or to either side. The surrounding clay was then gently pushed around the head 
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using forceps and/or the glass pipette tool to secure the head in place. For lateral 
views, forceps were used to position embryo heads inside the circular depressions 
such that they were on their side, facing the same direction, and flat against the 
clay. Embryo heads and the surrounding clay were manipulated so that the cement 
glands of all the embryos were positioned downward at the same angle. The rows 
drawn with the teasing needle served as a guide to ensure accuracy when taking 
lateral measurements. Frontal and lateral images of tadpole heads were captured 
using a Stemi 2000-C stereoscope (Zeiss) fitted with an AxioCamICC1 camera. 
4. ANALYSIS OF CRANIOFACIAL DIMENSIONS IN TADPOLES 
Axiovision40 V.4.8.1.0 software (Zeiss) was used to perform all standard 
measurements. On lateral images of tadpole faces, the snout length, which is from 
the bottom of the eye to the most anterior point on the face, above the cement 
gland, was measured. On frontal images of tadpole faces, the midface area was 
measured as the region between the top of the eyes to the top of the cement gland 
and the left and right lateral peripheries of the face. Facial width was measured 
from each lateral periphery of the face, just below the eyes. Facial height was 
measured as the distance between the top of the eyes and the top of the cement 
gland at the midline. The distance between each corner of the mouth was measured 
to determine mouth width, and the distance between the dorsal and ventral edges of 
the mouth at the midline was measured to determine mouth height. 
ImageJ software (NIH) was used to measure the roundness of the mouth by 
outlining the mouth and applying the following inverse aspect ratio: 
4*area/(π*major axis2). The midface angle was measured as the angle between the 
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center of the dorsal lip and center of the eyes, and was also determined with 
ImageJ. Correlations and proportions were calculated using Microsoft Excel. All 
measurements are expressed as mm or mm2.  
5. STATISTICAL ANALYSES 
Simple linear regression analysis was performed on many of the 
measurements, proportions, and correlations using R statistical computation 
software (version 3.0.1; R Foundation, 2013) to obtain r2 values, regression 
equations, and P-values. Since the time points used were not distributed equally we 
used a non-parametric statistical analysis (Kruskal-Wallis) using Microsoft Excel to 
determine statistical relationships among developmental time points. If the Krustal-
Wallis P-value was less than the alpha value 0.05, t-tests assuming equal variance 
were performed between consecutive time points using Excel. 
6. GEOMETRIC MORPHOMETRICS 
Discrete landmarks of the orofacial region were established on tadpole faces. 
A total of 38 orofacial landmarks and 16 mouth landmarks were placed on tadpole 
faces using the Pointpicker plugin of ImageJ (NIH). Facial landmarks 1–20 outlined 
the midface region from the center of the eyes to the top of the cement gland (Fig. 
1.3). This eliminated variation due to forebrain or cement gland size. Landmarks 21 
and 22 were the center of each nostril, and landmarks 23–38 outlined the mouth 
opening. The 16 landmarks used to outline the mouth (Fig. 1.3, blue) were then 
examined independently, to identify shape changes in the mouth without reference 
to the rest of the face. The coordinates of all of these landmarks were analyzed in 
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MorphoJ 1.05f (Klingenberg, Wetherill et al. 2010). A Procrustes superimposition 
was implemented to remove information concerning scale or size, position, and 
orientation. Variance within each group was determined by performing a principal 
component analysis (PCA), and visualized as transformation grids where the closed 
circle of the vectors was set as the oldest tadpole group (100 hpf). The line of the 
vector, then, represented the relative change in landmark position compared to the 
youngest tadpole group (60 hpf). Similarly, the scale factor used on PCA 
transformation grids was set to reflect the approximate position of youngest tadpole 
group on the bivariate plots. To study statistical relationships among groups, a 
canonical variate analysis (CVA) was performed. This analysis was also visualized 
as a three-dimensional transformation grid with similar vector designations. The 
scale factor for the CVA transformation grids was set to the default- except where 
noted- and the sign designation was set as negative or positive depending on the 
position of youngest tadpole groups. 
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RESULTS 
 
 
 
A) QUALITATIVE CHANGES IN OROFACIAL DEVELOPMENT IN THE EARLY 
TADPOLE 
As an initial analysis, I qualitatively examined the faces of early tadpoles 
from 60–100 hpf, which encompassed Nieuwkoop and Faber time points 39–46. At 
60 hpf the face had an almost round appearance (Fig. 1.1A). Dentritic pigment cells 
have migrated into the dorsal region of the midface, and the highly pigmented 
transient cement gland (Sive, Hattori et al. 1989; Sive and Bradley 1996) covered 
much of the ventral portion of the face (Fig. 1.1A,A'). The embryonic mouth was 
still covered by the buccopharyngeal membrane, which consists of intercalated 
endoderm and ectoderm derived cells (Dickinson and Sive 2006; Dickinson and 
Sive 2007). While tadpoles at 70 hpf only seemed to increase slightly in size, they 
did have a perforated mouth. It is this perforation that ultimately creates the 
opening to the foregut (Fig. 1.1B; Dickinson and Sive 2006). In sagittal views, the 
mouth region appeared as a depression above the cement gland (Fig. 1.1B'). At 82 
hpf, the overall size of the face continued to increase, particularly in the width 
dimension (Fig. 1.1C). Pigmentation of the midface area increased and the 
developing nostrils became visible as an opaque un-pigmented region (Fig. 1.1C). 
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The mouth also widened during this time point, becoming flatter and less round in 
appearance. This change in mouth shape corresponds with slight anterior protrusion 
of a “snout” in lateral views (Fig. 1.1C'). By this time, the facial prominences have 
merged above the embryonic mouth to separate the mouth and the brain (Kennedy 
and Dickinson 2012). By 90 hpf the face was more transparent and significantly 
larger (Fig. 1.1D). In particular, the width and the snout length have increased, 
correlating with jaw cartilage development (Nieuwkoop 1994; Fig. 1D,D'). At 100 
hpf these same features (transparency, facial width and snout size) appear to have 
all increased (Fig. 1.1E,E'). 
B) QUANTITATIVE CHANGES IN THE DIMENSIONS OF THE MIDFACE AND THE 
MOUTH DURING EARLY TADPOLE DEVELOPMENT 
In this section, I expand the qualitative analysis by formulating a quantitative 
description of the changes in orofacial dimensions. First, I use traditional types of 
craniofacial measurements, express them as proportions, and find correlations 
between different dimensions to quantitatively describe orofacial development. 
Linear regression of snout length with developmental time showed a 
significant linear increase over time (r2   =   0.888 from y   =   0.04327x – 1.54167; 
p   =   0.01061; Fig. 1.2A,A'). I also found that the snout length varied substantially 
within each time point. Such variation may be due to technical error, since accurate 
measurements depended on placing the tadpoles at precisely the same angle. 
Despite this, Kruskal-Wallis nonparametric analysis showed an overall significant 
difference in snout length over the time points observed (p   =   1.98E-6). T-tests 
between each consecutive time points indicated that statistically significant changes 
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occurred between 82–90 hpf (p   =   0.004685) and 90–100 hpf (p   =   0.022115). Such 
snout lengthening is consistent with the progressive enlargement and protrusion of 
the jaw cartilages over this developmental phase (Nieuwkoop 1994). 
I determined by linear regression analysis that the midface area increased 
from 60–100 hpf (r2   =   0.9588 from y   =   0.2512x – 9.4719; P   =   0.002328; Fig. 
1.2B,B'). The overall significant difference among time points (p   =   1.73E-8) is due 
to changes between each consecutive time point (t-tests; Fig. 1.2B,B'). In 
accordance with other published data, the increase in area observed at early time 
points (60–70 hpf) is likely due to proliferation of facial prominences (Kennedy and 
Dickinson 2012), while increases at later time points (82–100 hpf) can be attributed 
to the development of the jaw cartilages and muscle (Nieuwkoop and Faber 1994). 
The midface angle reflects the midface area while also accounting for 
changes in width and height (see correlations below). Regression of this angle 
against the time points showed a linear increase over time (r2   =   0.8755 from 
y   =   7.651x – 175.876; p   =   0.01246; Fig. 1.2C,C'). There was an overall significance 
among time points (p   =   0.000048), and a significant change in midface angle 
occurred between 82 and 90 hpf  (p   =   0.020261). 
The face width increased linearly from 60–100 hpf (r2   =   0.9669 from 
y   =   0.1958x – 6.9988; P   =   0.001673; Fig. 1.2D,D'), with an overall significant 
difference among time points (p  =   3.28E-8). The significant difference observed 
between 60 and 70 hpf (p   =   5.55E-05) was likely due to proliferation of facial 
prominences that occur during this phase. The changes seen between 70 and 82 hpf 
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(p   =   1.54E-05) and 90 and 100 hpf (p   =   3.2E-05); are consistent with the outgrowth 
of jaw structures. 
The face height did not increase linearly over the time observed (r2   =   0.2949 
from y   =   0.0175x – 0.20377; p   =   0.2006; Fig. 1.2E,E'). However, there was a 
significant difference among time points, albeit with a higher P-value than 
calculated for the other dimensions (p   =   0.005097). This overall difference was not 
due to statistical significance between any consecutive time points, but rather 
because of differences between early tadpoles (60, 70, and 82 hpf) and the latest 
time point chosen (100 hpf; p   =   0.000342, p   =   7.3E-5, and p   =   0.000548, 
respectively). 
This data, not surprisingly, indicates that the face is steadily increasing in 
size. In addition, the most substantial changes occur in the dimensions of width and 
anterior lengthening of the snout. Such changes are consistent with development of 
the jaw in Xenopus tadpoles. I was next interested in how these changes in facial 
development affected the size and shape of the mouth. 
First, I calculated the shape of the mouth using a measure for roundness. To 
do this measurement, the mouth was outlined and then a formula describing the 
proportion of height to width or aspect ratio was applied using ImageJ. At 60 hpf, 
tadpoles had high roundness values, while older tadpoles had less round mouths. 
Roundness indeed decreased linearly over time (r2   =   0.9718 from 
y   =   −0.0912x   +   4.04998; p   =   0.001311; Fig. 1.2F,F') and the overall difference 
between all the groups was significant (p   =   8.22E-7). The most significant changes 
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occurred between time points 70–82 hpf (t-test, p   =   0.00732) and 82–90 hpf (t-test, 
P   =   0.042908). This correlates with the outgrowth of the developing jaw cartilages 
and muscle, which appear to alter the shape of the mouth opening. 
There was a positive linear relationship between mouth width and time 
(r2   =   0.7291 from y   =   0.02995x +   1.41248; p   =   0.04155; Fig. 1.2G,G') and the 
overall difference among time points was found to be significant (p  =   3.28E-8). I 
found that significant changes were seen between 60 and 70 hpf (p   =   0.000666) just 
after buccopharyngeal perforation, as well between 90 and 100 hpf (p  =   0.003698) 
at a time when the tadpole has developed the ability to open and close its mouth. 
The mouth height did not change substantially over time. However, a 
regression analysis did show a slight linear decrease (r2   =   0.7679 from 
y   =   −0.01094x +   0.54480; p   =   0.03261; Fig. 1.2H,H'). In addition, I found an 
overall significant difference over time (p  =   0.008875). T-tests of consecutive time 
points, however, did not show any significant difference. Instead, I noted 
significant differences between youngest and oldest time points (60–100 hpf: 
p   =   0.003375). There was a large amount of variability in the mouth height data. 
Such variability may be due to technical issues. For example, the mouth shape, 
especially the height, can be altered by the angle, at which the tadpole is 
photographed. In addition, the jaws can move at later time points, which allow the 
mouth to open and close. Tadpoles may have been fixed at various degrees of 
opening or closure- resulting in this variability of the mouth height measurement. 
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To give a sense of how the shape of the early tadpole face changes over time, 
I determined the proportional changes in the height of the face to the width of the 
face. Regression analysis of this proportion over our time points showed a linear 
decrease, presumably due to an increase in facial width (r2   =   0.8789, y   =   −0.08423x 
+   3.96652, p   =   0.01194, Fig. 1.2I). The difference among time points was 
significant (P   =   0.000435), and comparison of consecutive time points showed that 
this was due to the difference between 70 and 82 hpf  (p   =   0.001108). I was also 
interested in how the shape of the mouth changed over time and therefore expressed 
the proportion of mouth height to mouth width. This proportion also decreased 
linearly when regressed against the time points (r2   =   0.9826 from y   =   −0.06616x 
+3.00432; p   =   0.0006365). There was an overall significant difference 
(p   =   0.000056), and this difference occurred between the consecutive later time 
points (Fig. 1.2I). These changes in proportion of width to height indicate that the 
shape of the orofacial region becomes wider relative to height, which is consistent 
with the qualitative observations. 
To determine the relationship between changes in the face and mouth, I 
expressed the dimensions of the face as ratios to the dimensions of the mouth. 
Regression of the face to mouth height ratio with each time point showed a linear 
increase (r2   =   0.9187 y   =   0.7635x −25.9639; p   =   0.006515; Fig. 1.2J). The overall 
difference amongst time points was significant (P   =   0.000344), and changes 
occurring between 70 and 82 hpf were significantly different (p   =   0.016362). On the 
other hand, the proportional change in the face width to the mouth width did not 
show a linear relationship with time (r2   =   0.845 from y   =   0.232 × −2.1679; 
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p   =   0.1959; Fig. 1.2J). There was, however, an overall significant difference in the 
width ratio among time points (p   =   0.01) due to changes between 60 and 70 hpf, as 
well as 82 and 90 hpf (p   =   0.007937, p   =   0.011788, respectively). Thus, the 
proportion of the mouth to the face width remains the same throughout this 
developmental period, suggesting that changes in width of the whole face and 
mouth are possibly dependent on each other. 
To determine if changes in midface angle were due to changes in face height 
or width, I also performed a regression analyses with these dimensions. These 
results indicate that midface angle positively correlates with face width 
(p   =   0.01746), but not with face height (p   =   0.1886, Fig. 1.2K). These results 
indicate that changes in facial width for the most part account for the increase in 
the midface angle. Further, this correlation also emphasizes that an important 
contributor to the changes seen in face shape is lateral expansion. I was also 
interested in how anterior growth of the snout correlated with the shape of the 
mouth and area of the face. When mouth roundness was regressed against the snout 
length over time, an inverse linear relationship existed (r2 =0.7838, p   =   0.0292, Fig. 
1.2L). It is possible that such a correlation exists because the increased snout length 
is due to the formation of jaws and when the jaws become incorporated into the 
mouth a new more narrow mouth opening is created. You could imagine that this 
would be a necessary change to allow for the mouth to go from a static round 
structure to a dynamic narrower structure that can open and close. I also determined 
that the snout length showed a positive linear relationship with the midface area 
when regressed (p   =   0.002726, Fig. 1.2L). This matches the expectation that as the 
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facial prominences grow and jaw cartilages develop, both the midface and snout 
length increase. 
C) GEOMETRIC MORPHOMETRIC ANALYSIS OF OROFACIAL SHAPE CHANGES 
DURING EARLY TADPOLE DEVELOPMENT 
Quantitative analysis indicates that the tadpole orofacial region changes in 
size most substantially with anterior growth of the snout, and widening of the face 
and mouth. Proportional indices of height to width for both the face and mouth also 
indicate gradual changes in shape of the orofacial region. However, this view is 
rather unsophisticated and does not capture subtle changes or all shape 
modifications over time. Therefore, in this section I use geometric morphometric 
analyses to describe changes in orofacial shape during early tadpole development. 
Thirty-eight facial landmarks represented the outline of the midface, and 
distinguishing features such as the nostrils, mouth, and eyes. I chose these 
landmarks to describe the overall shape of the orofacial region (described in more 
detail in Fig. 1.3). Sixteen landmarks around the mouth were also assessed 
separately to determine shape changes in the mouth independent of changes 
occurring in the rest of the midface. After identifying face and mouth landmarks on 
images of various early tadpole time points, the data was entered into the MorphoJ 
program to perform analysis. Landmark data was aligned via Procrustes 
superimposition to remove information concerning scale, size, position, and 
orientation. Thus, the position of orofacial landmarks at each developmental time 
point represents changes in shape of that region over time. 
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D) PCA SHOWS SHAPE CHANGES IN THE OROFACIAL REGION AS THE EARLY 
TADPOLE DEVELOPS 
The first morphometric test I ran was a Principal Component Analysis (PCA). 
This is a multivariate statistical method that converts a set of observations 
described by several possibly correlated variables into a new set of orthogonal 
variables, known as principal components (Abdi and Williams 2010). In doing so, 
the number of variables within a sample is reduced without losing information 
about the complexity of the sample. The first principal component accounts for the 
largest source of variance within the sample set, with each subsequent component 
accounting for the remaining variance. When the first two principal components 
(PC) are plotted against each other, samples that are most similar will cluster 
together. In addition, graphical representations can show overall shape changes. 
Such an analysis can be used to discriminate groups within a sample set, in addition 
to assessing variation within those groups. 
By plotting the first two PC of orofacial landmarks I observed the variance 
among individual tadpoles within each developmental time point. Each of the time 
points analyzed were distinguished primarily along the first principal component 
(PC1) axis and less so along the second principal component (PC2) (13.681%) axis 
(Fig. 1.4A). There was some overlap amongst time points; and individual tadpoles 
within each group were widely distributed. Such variance represents the range of 
developmental rates within the two clutches of tadpoles. Different genetics may 
also influence variability in individual tadpoles especially since our Xenopus are 
not highly inbred. Different developmental rates and genetic variability could result 
in the overlap in facial features at consecutive time points. However, even with this 
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overlap, the PCA shows a clear separation of orofacial shape over the time points 
chosen (Fig. 1.4A). 
In the PCA analysis the PC1 accounted for 56.874% of the variation in shape, 
and provided the most information about shape changes during early tadpole 
development. In a transformation grid of this PC, where the closed circle end of the 
vectors represented landmarks of the oldest tadpoles, I observed a shift in dorsal 
and ventral facial landmarks. These shifts illustrate the change from a roundish 
orofacial region to a flatter or wider shaped face with respect to height (Fig. 1.4B). 
PC1 also captured the shift in the ventral edge of the mouth which illustrates a less 
round mouth shape. Further, midface expansion and changes in the position of the 
nostrils were also captured by this PC (Fig. 1.4B). PC2 captured 13.681% of the 
variation that contributes to orofacial shape changes. In this PC, the ventral shifts 
in lateral or peripheral face landmarks were distinguished, and dorsal shifts in the 
landmarks along the dorsal edge of the mouth (Fig. 1.4C). The third principal 
component PC3 captured much less of the variance (6.055%) that contributes to 
shape changes during early tadpole orofacial development. However, this PC 
illustrated a lateral shifting of mouth landmarks that further illustrate a flattening of 
the mouth shape (Fig. 1.4D). 
A PCA analysis of the mouth landmarks alone was also performed to 
determine if it could provide additional information about mouth shape changes 
independent of the shape changes in the surrounding face. I expected a higher 
degree of overlap in this data since variation was high in our standard 
measurements above (section B), and because the mouth shape is not complex 
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during tadpole development. Indeed, the PCA of mouth landmarks showed 
considerable variance within the tadpoles at each of the time points. The early 
tadpoles (60, 70 hpf) were distinguished from the oldest tadpoles (90, 100 hpf) 
along the PC1 axis (Fig. 1.4E). The overlap amongst the time points also indicates 
that the shape of the mouth did not differ greatly at each time point, as predicted. 
The greatest variation in mouth shape was captured in PC1 (74.045%), and clearly 
illustrates a dorsal or ventral shift in landmark positions (Fig. 1.4F). Such shifts 
can be accounted for by changes in mouth shape from round to a flattened shape. 
PC2 represented a small percentage of variance (7.910%), and did not capture 
significant shape changes in the mouth (Fig. 1.4G). The change in mouth shape was 
captured differently in the orofacial PCA analysis, where the shifts in ventral 
landmarks were captured in PC1 and the dorsal landmark shifts were captured in 
PC2. This difference is easily explained by the fact that shape changes are captured 
differently when considered in conjunction with other landmarks from surrounding 
orofacial region. 
Information about size can be captured by morphometric analysis using the 
centroid size, which is the average distance of all the landmarks from the geometric 
center of the shape. When the centroid size is plotted against time it can show the 
rate of size change. When I plotted the log of centroid size against time we 
illustrated an almost linear increase in the rate that geometric size changed (Fig. 
1.4H). Linear increases in snout length, midface area, midface angle and face width 
are consistent with this morphometric analysis of size. 
  24 
PCA of differences in orofacial and mouth shape over time provides a more 
sophisticated view of how the tadpole face changes during development. Consistent 
with my traditional analysis I described above, the PCA demonstrated a widening of 
the face and mouth relative to the height. This analysis also showed more subtle 
changes. For example, much of the widening of the face relative to the height 
occurs in the midface region. Also, the position of the nostrils changes as the snout 
grows anteriorly. While these results were informative about shape changes and 
variation between time points, they could not provide statistical shape differences 
between time points. Therefore, my next analysis uses a different morphometric 
test, specifically a canonical variate analysis (CVA), to accomplish this task. 
E) CVA INDICATES SIGNIFICANT OROFACIAL SHAPE CHANGES BETWEEN 
SPECIFIC TIMES IN EARLY TADPOLE DEVELOPMENT 
CVA describes the variation among groups of a sample set relative to the 
variance within each group (Darlington 1973). By categorizing samples into 
discrete groups a priori, CVA reduces the within-group variance and thereby 
maximizes differences between each group. This method translates variance into 
components called canonical variates. When two of these variates are plotted 
against each other (using Procrustes and Mahalanobis distances), the distance 
between groups reflects their statistical relationship- such that groups highly 
different from each other will have a larger distance between them. Further, CVA of 
Procrustes landmarks can be displayed as a three-dimensional transformation grid to 
represent relative changes in landmark position. 
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A CVA analysis was performed to statistically compare orofacial and mouth 
shape changes between tadpole time points. Procrustes distances and corresponding 
statistical measures were generated for all orofacial and mouth landmarks using 
MorphoJ (Table 1.1). From this, it could be determined that some groups were 
statistically different in orofacial or mouth shape while others were not (see 
italicized procrustes P-values in Table 1.2). To summarize, my results indicated 
that the orofacial shape and mouth shape was not distinctly different between the 
earliest groups (60 and 70 hpf) in my analysis. In addition, I found that the mouth 
shape was not distinctly different between the later stages 82–90 hpf, and 90–100 
hpf. 
Data generated by a CVA were also illustrated in graphical outputs. First, I 
plotted the first two canonical variates against each other for all orofacial 
landmarks (Fig. 1.5A). By doing so, I could visualize the relationship among the 
five tadpole time points in my study. Each time point was discriminated from the 
others primarily along the first canonical variate (CV1) axis, and less so along the 
second canonical variate (CV2) axis. Early time points (60, 70, 82 hpf) could be 
best distinguished from later ones (90, 100 hpf), as illustrated by greater distances 
between clusters (also see Table 1.2). The similar positions of points from 60 and 
70 hpf along the CV1 axis demonstrates their similarity. The CV1 accounted for 
83.209% of the statistical differences in shape between all groups, and illustrates 
much of the shape changes when viewed on a transformation grid (Fig. 1.5B). The 
vectors depicted landmark shifts (where the closed circle or lollipop represents the 
oldest tadpole group) that demonstrate widening of the face, changes in nostril 
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position and flattening of the mouth opening as the tadpoles develop. CV2 only 
captured 8.209% of the shape differences; however it demonstrates the overall shift 
in the dorsal mouth opening edge landmarks that contribute to the development of a 
flatter shaped mouth opening (Fig. 1.5C). 
The CVA of the mouth landmarks alone showed fewer differences between 
consecutive stages, indicating a gradual change in mouth shape (see Table 1.2). A 
plot of the first two canonical variates against each other showed less clustering of 
points, but stages were distinguished along the CV1 axis with further separation 
along the CV2 axis (Fig. 1.5D). CV1 accounted for 68.302% of the statistical 
differences in mouth opening shape and transformation grid of this CV illustrated 
the massive dorsal and ventral shift of the mouth landmarks (Fig. 1.5E). The CV2 
accounted for 17.775% of the differences in shape of the mouth opening. However, 
little information could be determined from the CV2 transformation grid except for 
some minor shifts that might account for differences in mouth opening shape at 100 
hpf (Fig. 1.5F,D). 
The CVA of orofacial and mouth shape was consistent with the PCA. 
However, by removing variation, this analysis statistically illustrated when the 
orofacial and mouth shapes were similar or distinct from each other during early 
tadpole development. For example, the CVA indicated that the greatest shape 
differences occur between early and late time points. This information emphasizes 
that developmental changes in the face and mouth occur gradually at early tadpole 
stages. 
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DISCUSSION 
 
 
 
A) QUANTITATIVE ANALYSIS OF THE XENOPUS OROFACIAL REGION  
Quantitative analyses, such as geometric morphometrics and proportional 
indices, are commonly used tools to evaluate human facial form. For example, these 
analyses have been used to define everything from evolutionary relationships and 
ethnically specific features, to perception of trustworthiness and beauty (Robinson 
2012; Sardi and Ramirez Rozzi 2012; Kleisner, Priplatova et al. 2013; Rossetti, De 
Menezes et al. 2013). Geometric morphometrics has been particularly useful for 
predicting facial morphology associated with many birth defects, including cleft 
palate (Farkas, Katic et al. 2001; Scheuer, Holtje et al. 2001; Bugaighis, Mattick et 
al. 2014). While several similar craniofacial morphometrics analyses have also been 
applied to mouse models of cleft palate (Wang and Diewert 1992; Young, Wat et al. 
2007; Parsons, Kristensen et al. 2008), few quantitative studies of orofacial 
anatomy have been performed in other model organisms. This is surprising, since 
chick, zebrafish, and Xenopus are widely used to study the molecular mechanisms 
regulating facial development (for examples see (Brugmann, Goodnough et al. 
2007; Eberhart, He et al. 2008; Dickinson and Sive 2009; Schilling and Le Pabic 
2009; Liu, Rooker et al. 2010; Kennedy and Dickinson 2012; Smith, Hu et al. 
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2013)). For this reason, I have performed among the first quantitative descriptions 
of the Xenopus orofacial development and morphological changes that may be 
related to orofacial clefting. 
B) OROFACIAL CHANGES IN THE ANATOMY OF THE EARLY TADPOLE ACCOUNT 
FOR DEVELOPMENT OF THE PRIMARY PALATE AND ASSOCIATED STRUCTURES 
Anatomical development of frog tadpoles has been described quantitatively in 
ecological and toxicological contexts (Mouche, Malesic et al. 2011; Lima and 
Pederassi 2012). While quantitative analyses of later stage Xenopus tadpoles and 
metamorphs is more common (Rose 2009; Vandenberg, Adams et al. 2012), there 
are no quantitative descriptions of the craniofacial anatomy during early 
development. In this study, I provide the first anatomical description of changes in 
the orofacial region during mouth formation. One of the most obvious changes I 
observed is that the orofacial region widens relative to the height by almost two 
fold over the interval examined. This shape change allows for the creation of a wide 
flat head, which is a particular anatomical trait of frog tadpoles likely necessary to 
accommodate the large branchial apparatus used for filter feeding (Feder, Seale et 
al. 1984; Hayes 2009). This widening and flattening of the head during the early 
tadpole period corresponds with the development of the cartilaginous jaw elements, 
including the branchial apparatus (Kerney, Gross et al. 2007; Schmidt, Schuff et al. 
2011; Kennedy and Dickinson 2012). Jaw development not only corresponds with 
increased width of the orofacial region, but also the formation of a snout or anterior 
protrusion surrounding the mouth opening. Another notable yet more subtle change 
in the orofacial anatomy is that the midface, a region dorsal to the mouth, widens 
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more with respect to the rest of the face during the period we examined. This 
midface region, corresponds to the upper jaw and primary palate and includes the 
suprarostral and ethmoid cartilages, associated muscles (Schmidt, Schuff et al. 
2011; Schmidt, Piekarski et al. 2013), and the soft tissues lining the roof of the oral 
cavity. I focused on this time of development with a specific interest in primary 
palate development and corresponding changes in orofacial anatomy. Finally, our 
lab has an interest in understanding how the shape of the mouth opening depends on 
surrounding facial development. Initially, before the buccopharyngeal membrane 
perforates, the embryonic mouth opening is roundish in shape. As the orofacial 
region widens, the mouth opening also becomes wider in a correlative relationship. 
My quantitative measurements and morphometric data also illustrate that the mouth 
opening becomes flatter over this early tadpole period. Such a widening and 
flattening of the mouth opening shape could facilitate the ability to close the mouth. 
Indeed, by 100 hpf the tadpole is able to open and close its mouth by moving its 
jaws. Thus, during the early tadpole stages, the anatomy of the mouth becomes 
more complex going from a simple opening to the foregut to a structure that 
includes movable jaws. 
Overall my analysis illustrates a linear change in size and gradual shape 
changes in the orofacial region and mouth opening shape during this larval period. 
This analysis provides quantitative information about the changes in the orofacial 
region as the mouth and primary palate region develops. This data further provides 
the foundation upon which we can formulate a deeper understanding of the 
mechanisms that regulate primary palate formation and defects in this structure. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
In this chapter, I used a comprehensive quantitative analysis that combines 
size measurements and morphometrics to describe anatomical changes in the 
orofacial region during normal development. Over the early tadpole period, the face 
expands and changes shape primarily in the width and snout length dimensions 
accounting for the development of the upper jaw and primary palate. The mouth 
opening also changes its shape as it incorporates the jaws and is able to close. 
Importantly, incorporating these quantitative analyses of orofacial anatomy into 
such future molecular and developmental studies will aid in dissecting the 
mechanisms governing the complex morphogenetic processes that take place during 
craniofacial development. 
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FIGURES 
 !
Figure 1.1. Orofacial development during 
early tadpole stages.  (A–E)  Frontal views; 
(A'–E')  Lateral views. Scale bars   =   200 µM. 
cg, cement gland. Mouth opening outlined 
in red dots.  
  32 
Figure 1.2. Changing orofacial dimensions during early tadpole stages.  (A–E)  Schematics depicting each 
measurement taken; (A'–E')  Bar graphs of changes in measurements at  each developmental t ime point;  (A,A')  
Snout length; (B,B')  Midface area; (C,C')  Midface angle; (D,D')  Face width; (E,E')  Face height;  (F,F')  Mouth 
roundness; (G,G')  Mouth width; (H,H')  Mouth height.  Significance determined using t-tests assuming equal 
variance and is denoted by a l ine with an asterisks above it .  The end of each line represents two values 
compared in t-test .  (I,  J)  Line graphs of how proportions of the mouth and face dimensions change with each 
developmental t ime point;  (I)  Proportions of height to width; blue diamonds   =   face height/face width, red 
squares   =   mouth height/mouth width; (J)  Proportions of height to width for the face and mouth; blue 
diamonds   =   face height/mouth height;  red squares   =   face width/mouth width. (K, L)  Scatterplots showing 
correlations between various facial  dimensions; (K)  Correlations between midface angle and face width or face 
height,  blue diamonds   =   face width, red squares   =   face height;  (L)  Correlations between snout length and mouth 
roundness or midface area, blue diamonds   =   mouth roundness,  red squares   =   midface area; cg, cement gland.  
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Figure 1.3. Morphometric landmarks for the orofacial region (red and blue) and mouth (blue).  
Numbers indicate the order,  in which landmarks were placed. For accuracy, ImageJ was used to 
reposition landmarks after placement such that they were always in the same relative position in each 
image. Mouth landmarks (blue) were also analyzed independently.  The first  landmark was placed in 
the center of the right eye, with the next three landmarks following a straight l ine to outline the right 
periphery of the face. Landmark five was placed on the right periphery that was in l ine with the top 
of the cement gland. The next four landmarks were placed in a straight l ine from this landmark to the 
left  periphery of the face. The next four landmarks were placed in a straight l ine to the center of the 
left  eye to outline the left  periphery of the face. Landmark 14 was placed in the center of the midface 
between both eye landmarks. Landmarks 15 and 16 were placed in l ine with these landmarks on the 
inside periphery of each eye. Landmark 17 was placed in the center of landmarks 14 and 15, and 
landmark 18 was placed in between landmarks 14 and 16. Landmarks 19 and 20 were placed in the 
center of the two landmarks already outlining the bottom and inside periphery of the eye. Landmarks 
21 and 22 were placed in the center of each nostril .  Landmarks 23–38 outlined the mouth (blue 
numbers).  Landmarks 23 and 25 were placed on outer corners of the mouth opening, while landmarks 
24 and 26 were placed on the center extremes of the dorsal and ventral edges of the mouth opening, 
respectively. Each subsequent landmark was placed in such a  way that i t  was in the middle of the 
landmarks already placed on the mouth opening.  
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Figure 1.4. Principal component analysis (PCA) of orofacial and mouth 
landmarks.  (A–D)  PCA results for orofacial landmarks; (A)  Bivariate plot of 
PC1 (56.874%) and PC2 (13.681%) for orofacial landmarks; (B)  
Transformation grid of PC1 for orofacial landmarks, scale factor   =   0.15; (C)  
Transformation grid of PC2 for orofacial landmarks, scale factor   =   −0.1; (D)  
Transformation grid of PC3 for orofacial landmarks, scale factor   =   0.15. (E–
G)  PCA results for mouth landmarks; (E)  Bivariate plot of PC1 and PC2 for 
mouth landmarks; (F)  Transformation grid of PC1 for mouth landmarks, 
scale factor   =   0.15; (G)  Transformation grid of PC2 for mouth landmarks, 
scale factor   =   0.1. Closed circle end of vector represents oldest tadpole t ime 
point observed. The line of the vector represents the change in position of 
that landmark relative to the earliest  t ime point.  (H)  Morphometric change in 
size is  shown by plotting log centroid size relative to t ime.  
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Figure 1.5. Canonical variate analysis (CVA) of orofacial and mouth landmarks.  (A–C)  CVA results for 
orofacial landmarks; (A)  Bivariate plot of CV1 and CV2 for orofacial landmarks; (B)  Transformation grid 
of CV1 for orofacial landmarks, scale factor   =   −10.0; (C)  Transformation grid of CV2 for orofacial 
landmarks, scale factor   =   10.0. (D–F)  CVA results for mouth landmarks; (D)  Bivariate plot of CV1 and CV2 
for mouth landmarks; (E)  Transformation grid of CV1for mouth landmarks, scale factor   =   −10.0; (F)  
Transformation grid of CV2 for mouth landmarks, scale factor   =   −10.0. Closed circle end of vector 
represents oldest tadpole t ime point observed. The line of the vector represents the change in position of 
that landmark relative to the earliest  t ime point.  
 
  36 
Table 1.1.  Approximate hours post ferti l ization (hpf) at which tadpoles were fixed for 
analysis and corresponding stages. 
Experiment hpf at 
23C 
Stage 
Normal development (timecourse) 60 
70 
82 
90 
100 
39-40 
40-41 
42-43 
43-44 
45-46 
ATRA or RAR inhibitor treatment groups 80 41-42 
Morphants 82 42-43 
 
Table 1.2. CVA of early tadpole orofacial and mouth opening shape changes. Matrix of MorphoJ computed 
Procrustes distances and P-values (in parentheses and italics). Lightly shaded cells contain orofacial shape 
comparisons and darkly shaded cells contain mouth opening comparisons. Statistical significance is indicated by an 
asterisk. 
hpf 60 70 82 90 100 
60   0.0837 
(0.0824) 
0.1639 
(0.0001)* 
0.2520 
(<0.0001)* 
0.2608 
(<0.0001)* 
70 0.0720 
(0.0558) 
  0.1006 
(0.0050)* 
0.1942 
(0.0001)* 
0.1987 
(<0.0001)* 
82 0.2066 
(0.0001)* 
0.1504 
(0.0075)* 
  0.1221 
(0.0023)* 
0.1331 
(<0.0001)* 
90 0.2821 
(<0.0001)* 
0.2317 
(0.0001)* 
0.0944 
(0.0887) 
  0.0977 
(0.0011)* 
100 0.2760 
(<0.0001)* 
0.2250 
(0.0004)* 
0.0910 
(0.1143) 
0.0491 
(0.6212) 
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CHAPTER II: QUANTIFICATION OF THE OROFACIAL 
REGION WHEN DEVELOPMENT IS PERTURBED 
 
 
 
Model organisms such as Xenopus are widely used to better understand the 
molecular mechanisms underlying defects arising in the orofacial region, such as 
cleft palate. Therefore, in this chapter, I present the method of combining 
traditional size measurements with geometric morphometrics described in Chapter 1 
with the goal of distinguishing between different orofacial phenotypes when normal 
development is perturbed. This analysis will allow for better differentiation between 
subtle craniofacial defects such as those arising from synergistic effects of genes 
and/or environmental factors. Additionally, this quantification method could also 
reveal even slight improvement or rescue of an orofacial defect. This therefore 
makes it a useful guide in analyzing potential therapeutics. 
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INTRODUCTION 
 
 
 
Morphogenesis of the orofacial region is characterized by growth, 
convergence, and differentiation of the seven facial prominences. This process is 
governed by complex interactions of endoderm, mesoderm, ectoderm, and neural 
crest and is tightly regulated by a number of signaling cues (Greene and Pisano 
2010; Szabo-Rogers, Smithers et al. 2010; He and Chen 2012; Saito, Yamamura et 
al. 2012; Swartz, Nguyen et al. 2012). Two factors, retinoic acid signaling and 
folate metablism, have both been suggested to contribute to orofacial development. 
Further, supplementation of either molecule during pregnancy has been shown to 
reduce the incidence of cleft lip/palate by 39% and 53%, respectively (Boyles, 
Wilcox et al. 2009). Therefore, investigation into their distinct roles during 
palatogenesis could be particularly useful in understanding how such defects arise.   
A) RETINOIC ACID 
Retinoic acid is a morphogen long known to influence various aspects of 
craniofacial development (Mark, Ghyselinck et al. 2004; Sandell, Sanderson et al. 
2007; Abe, Maeda et al. 2008; Ackermans, Zhou et al. 2011). A series of oxidation 
reactions converts Vitamin A to the signaling molecule, retinoic acid (RA); the final 
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step of this process is the conversion of the aldehyde form of vitamin A into RA by 
the enzyme Raldh2. This allows RA to translocate into the nucleus and bind to the 
retinoic acid receptor (RAR). RAR’s form heterodimers with retinoid X receptor 
(RXR) that are bound to retinoic acid response elements (RARE’s) in the promoter 
regions of target genes and initiate transcription (Duester 2008). Retinoic acid is 
critical in the patterning of the anterior-posterior axis, as well as many organs such 
as the heart, hindbrain, and craniofacial region (Pedigo, Zhang et al. 2007). Because 
of this, embryos deficient in retinoic acid often do not survive to term (Durston, 
Timmermans et al. 1989).  
Several animal studies support the role of retinoic acid signaling during 
orofacial development. For example, Raldh2/Raldh3 double knockout mice exhibit 
severe orofacial defects, including cleft lip (Halilagic, Ribes et al. 2007). 
Compound knockout of murine RARα /RARγ also induces median facial clefts, 
indicating a role of these receptors in facial development (Dupe and Pellerin 2009).  
Additionally, we have previously uncovered a conserved role for retinoic acid 
signaling during formation of the primary palate and upper lip in Xenopus (Kennedy 
and Dickinson 2012). We found that decreased retinoic acid signals result in a 
subsequent decrease in growth of the maxillary and nasal facial prominences. This 
results in a cleft at the midline of the primary palate and upper lip that closely 
resembles median orofacial clefts in humans (Allam, Wan et al. 2011).  
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B) FOLIC ACID 
The relationship between folate supplementation during pregnancy and 
prevention of neural tube defects was first recognized a little over fifty years ago 
(reviewed in (Wilcox, Lie et al. 2007)). Since this discovery, several studies have 
suggested a strong association between defective folate metabolism and birth 
defects in humans including neural tube, heart, and craniofacial defects, low birth 
weight, and neurodevelopmental disorders (Nieuwkoop and Faber 1994; Zhao, Guo 
et al. 1999; Sive, Granger et al. 2000; Pitkin 2007; Cross and Powers 2008; Cooper, 
Parsons et al. 2010; Allam, Wan et al. 2011; Barnett, Yazgan et al. 2012). However, 
the underlying cause of folate’s protective nature is still unclear.  
The terms “folate” and “folic acid” are often used interchangeably when 
describing the B-vitamin family. Transport of folate across the cell membrane is 
dependent on oxidative state. Reduced folates bind to the reduced folate carrier 
protein (RFC), which transports them across the membrane via facilitative anion 
exchange. Alternatively, membrane-anchored folate receptors endocytose oxidized 
folic acid. Intracellular folate metabolism is crucial in mediating the one-carbon 
transfer reactions necessary for cellular processes such as nucleotide biosynthesis 
and the regeneration of methionine from homocysteine (Bhaskar, Murthy et al. 
2011). The principal one-carbon unit shuttle molecule is tetrahydrofolate (THF). 
Reduction of this protein from dihydrofolate is catalyzed by the enzyme 
dihydrofolate reductase (DHFR) and is critical in downstream reactions involved in 
DNA synthesis and methylation. Acceptance of methyl groups from serine and 
glycine by THF converts it to 5,10-methyleneTHF, which is directly involved in the 
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conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP) catalyzed by thymidylate synthase (TS). This step is crucial 
in de-novo synthesis of thymine and is rate limiting in mammalian DNA synthesis. 
5-10-methyleneTHF is converted into 10-formylTHF to participate in purine 
biosynthesis. Alternatively, methylene-THF reductase (MTHFR) irreversibly 
converts 5-10-methyleneTHF to 5-methylTHF to drive production of the 
methylating agent, S-adenosyl-L-methionine (SAM, Fig.ure 1)(Gonzales, Yang et 
al. 2005). 
The involvement of folate metabolism in vital cellular processes makes it 
particularly important during periods of rapid growth, such as embryonic 
development (Klingenberg, Wetherill et al. 2010). Certainly, DNA synthesis and 
histone methylation are altered due to changes in folate metabolism during 
neurulation, heart development, and in diseases such as cancer (Tang, Santillano et 
al. 2005; Beaudin and Stover 2009; Lee, Hong et al. 2011; Momb, Lewandowski et 
al. 2013; Wang, Wang et al. 2014). Further, folate deficiency induced orofacial 
defects have been shown in model organisms and human association studies 
(Burgoon, Selhub et al. 2002; Tang, Santillano et al. 2005; Wilcox, Lie et al. 2007; 
Wehby and Murray 2010; Li, Shi et al. 2011; Lee, Bonner et al. 2012; Momb, 
Lewandowski et al. 2013; Kao, Chu et al. 2014).  
In order to investigate changes in orofacial morphogenesis induced by 
abnormal development, I have again turned to the frog, Xenopus laevis. In this 
chapter, I show that disruption of either the retinoic acid or folate pathways during 
Xenopus facial development results in statistical changes in orofacial size and 
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shape. Such morphological changes are accompanied by defects in the embryonic 
mouth, including median facial clefts.  
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METHODS 
 
 
 
1. ADULT XENOPUS LAEVIS 
Adult Xenopus laevis were housed and cared for according to the IACUC 
protocol described in Chapter 1.  
2. TADPOLE COLLECTION AND CARE  
Eggs were collected from two different females on the same day and 
fertilized using standard methods (Sive, Granger et al. 2000). Embryos were 
cultured in 0.1X Modified Barth’s Solution (MBS) using standard protocols until 
they reached desired stages for treatment (Sive, Granger et al. 2000). Prior to 
treatment, the vitelline membrane was mechanically removed using two pairs of 
sharpened forceps. 
3. MORPHOLINOS AND CHEMICAL TREATMENTS 
Antisense morpholinos (MOs) (Summerton 2007) were purchased from 
Genetools. The RALDH2 morpholino was designed and validated by (Strate, Min et 
al. 2009), and used in our previous studies (Kennedy and Dickinson 2012). My 
advisor, Amanda Dickinson, designed splice-blocking DHFR morpholinos to bind to 
exon 2-intron 2 boundary. A standard control morpholino was used as a control for 
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these experiments. Dr. Dickinson injected morpholinos at the one cell stage into 
fertilized eggs from two different females and then maintained in 0.1X MBS until 
82 hpf. At this time the morphant and control tadpoles were fixed overnight in 4% 
PFA at 4°C. Microinjections were carried out using an Eppendorf microinjector and 
Zeiss stereoscope as described by (Tandon, Showell et al. 2012). 
Stock solutions were created of RAR inhibitor (BMS-453, Tocris (3409), 10 
mM in DMSO), methotrexate (MTX, Sigma, A6770, 100 mM in DMSO) and folinic 
acid (Sigma, F7878, 100 mM in water) and were diluted as described in results 
section. All chemical treatments were done in 0.1% DMSO in 0.1X MBS and 0.1% 
DMSO was used as the control. 
Tadpoles from two different females were exposed to a retinoic acid receptor 
(RAR) inhibitor (BMS-453, Tocris (3409),) or all-trans retinoic acid (ATRA, Sigma 
(R2625)). At 26 hpf, 10 embryos from each female were incubated in 24 well 
culture dishes in a 1 mL volume of 0.1X MBS with a total of 1% DMSO in 
combination with either 2 µM of RAR inhibitor or 2 µM of ATRA. Controls 
consisted of 1% DMSO alone. Tadpoles were washed out of the treatments (three 
times, 10 min each) at 35 hpf, and transferred into large petri dishes in 20 mL of 
0.1XMBS. At 80 hpf the treated and control tadpoles were fixed overnight in 4% 
PFA at 4°C. Before photographing, the tadpoles were washed at least three times for 
1 hr each in phosphate buffered saline with 0.1% Tween (PBT). 
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4. PHOTOGRAPHING TADPOLE FACES FOR QUANTIFICATIONS 
The heads of the tadpoles were severed with a Sklar sterile disposable 
scalpel, and then mounted in clay-lined dishes containing PBT for imaging as 
described in Chapter 1. Using a Stemi 2000-C stereoscope (Zeiss) fitted with an 
AxioCamICC1 camera, images of frontal and lateral views of the tadpole faces were 
collected. 
5. ANALYSIS OF CRANIOFACIAL DIMENSIONS IN TADPOLES 
Axiovision40 V.4.8.1.0 software (Zeiss) was used to perform all standard 
measurements. On images of tadpole faces, the snout length, midface area, facial 
width, facial height, mouth width, and mouth height as described in Chapter 1. 
ImageJ software (NIH) was used to measure the roundness of the mouth and 
midface angle as described in Chapter 1. Correlations and proportions were 
calculated using Microsoft Excel. Data collected for the treatment groups were 
scaled so that the controls equaled 100. This allowed us to graphical compare all the 
measurements. 
6. STATISTICAL ANALYSES 
Simple linear regression analysis was performed on many of the 
measurements, proportions, and correlations using r statistical computation software 
(version 3.0.1; r Foundation, 2013) to obtain r2 values, regression equations, and P-
values. Student’s T-tests assuming unequal variance were used to determine 
statistical significance between treatment groups and their respective controls. 
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7. GEOMETRIC MORPHOMETRICS 
Discrete landmarks of the orofacial region were established on tadpole faces. 
A total of 38 orofacial landmarks and 16 mouth landmarks were placed on tadpole 
faces using the Pointpicker plugin of ImageJ (NIH) as described in Chapter 1. The 
coordinates of all of these landmarks were analyzed in MorphoJ 1.05f (Klingenberg, 
Wetherill et al. 2010) via Procrustes superimposition, principal component analysis 
(PCA), canonical variate analysis (CVA), and discriminant function analysis (DFA) 
as described in Chapter 1.  
8. IN SITU HYBRIDIZATION 
In-situ hybridizations were performed as described (Sive, Granger et al. 
2000), omitting the proteinase K treatment. DHFR cDNA used to transcribe in-situ 
hybridization probe was from Open Biosystems and Dharmacon (Clone Id: 6933368, 
Genbank # BC084841.1). This 812 kb sequence was very specific to DHFR and had 
less that 4% sequence identity with other genes in Xenopus laevis. 
 
  47 
 
 
RESULTS 
PART 1.  
 
 
 
A.1) PERTURBATION OF RETINOIC ACID SIGNALING RESULTS IN OROFACIAL 
DEFORMITIES 
Our previous work indicates that retinoic acid signaling is important for 
orofacial development (Kennedy and Dickinson 2012). However, we only have 
qualitative information about how perturbation of this signaling pathway affects 
orofacial anatomy. Therefore, in this section I take a comprehensive approach to 
assess the orofacial dimensions and shape changes in tadpoles having too little or 
too much retinoic acid signals. Retinoic acid signaling was perturbed in three ways. 
First, embryos were treated with all-trans-retinoic-acid (ATRA) to increase 
endogenous levels of retinoic acid throughout the head over a specific period (26–
35 hpf) of orofacial development. Retinoic acid (RA) signals were decreased using 
both a chemical inhibitor and antisense mediated loss of function. Specifically, RA 
receptor (RAR) function was decreased over early orofacial development (26–35 
hpf) using an established chemical inhibitor that prevents retinoic acid binding to 
its receptor. This inhibitor preferentially targets RAR gamma, which is expressed in 
the maxillary prominences at the time of exposure (Kennedy and Dickinson 2012). 
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In addition, antisense morpholinos that bind to the start site of RALDH2 were 
injected into embryos and prevent its translation (injections performed by Amanda 
Dickinson, RALDH2 MO). RALDH2 is an enzyme required for conversion of retinal 
to retinoic acid and its expression compliments RAR gamma expression (Kennedy 
and Dickinson 2012). However, these RALDH2 morpholinos were injected at the 
one cell stage and result in decreased RALDH2 protein throughout development 
having more drastic effects than RAR inhibitor treatment. In this section, I quantify 
the effects of each perturbation on orofacial and mouth opening shape. 
B.1) QUALITATIVE DESCRIPTION OF OROFACIAL CHANGES IN TADPOLES WITH 
DISRUPTED RETINOIC ACID SIGNALS 
My first goal was to provide a qualitative assessment of how each 
perturbation of retinoic acid affected orofacial development to confirm published 
reports. ATRA and RAR inhibitor experiments were performed together with shared 
controls. These controls (called control treated tadpoles) resembled wild type 
tadpoles at 80 hpf with no obvious abnormalities in orofacial or mouth shape (Fig. 
2.1.1A,A'). Treatment of tadpoles with excess ATRA induced a variety of defects in 
the orofacial region (Fig. 2.1.1B,B'). For example, the entire face appeared 
narrower, the mouth was smaller and in some treated tadpoles the mouth did not 
completely perforate (Fig. 2.1.1B). In addition, the optic cup appeared partially 
formed and failed to cover the lens. As a result, the lens protruded abnormally (Fig. 
2.1.1B,B'). ATRA treatment also resulted in a lack of snout extension and severe 
hypoplasia of the midface, creating apparent protrusions of both the forebrain and 
posterior portion of the face (Fig. 2.1.1B'). When tadpoles were treated with the 
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RAR inhibitor, they exhibited a variety of facial anomalies that resembled ATRA 
treated tadpoles. For example, these tadpoles appeared to have narrower faces, 
smaller mouths and protruding lens (Fig. 2.1.1C). Most notably, RAR inhibitor 
treated tadpoles had median clefts in the mouth that extended into the primary 
palate (Kennedy and Dickinson 2012) (Fig. 2.1.1C). When viewed laterally, it was 
apparent that the snout in RAR inhibitor treated tadpoles did not extend as far as 
that seen in controls (Fig. 2.1.1C'). Morpholino experiments were performed at a 
different time than the treatments, and control morpholino injected tadpoles (control 
morphants; Control MO) were fixed at 82 hpf. These controls were also were 
similar to wild-type counterparts (Fig. 2.1.1D,D'). Consistent with our previous 
work, RALDH2 morpholinos also resulted in tadpoles (RALDH2 morphants) with 
orofacial defects that included hypoplasia or median clefts in the primary palate, 
and resulted in an abnormal mouth shape (Kennedy and Dickinson 2012). RALDH2 
morphants also appeared to have narrower faces and smaller eyes (Fig. 2.1.1E,E'), 
similar to the RAR inhibitor and ATRA treatment groups. 
C.1) PERTURBATION OF RETINOIC ACID SIGNALING AFFECTS OROFACIAL 
DIMENSIONS 
In this section, I provide the first quantitative assessment of orofacial 
dimensions in Xenopus when retinoic acid signaling is perturbed. For graphical 
comparisons, the values for treatment groups were scaled relative to controls and 
control morphants- which were both set to 100. 
To determine how altering retinoic acid might affect development of the 
upper jaw I first measured the snout length. This measure varied substantially 
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within each treatment group likely due to slight differences in tadpole stage, genetic 
background, or inconsistent placement for measurement. Despite this variation, the 
snout length was significantly decreased in all treatment groups compared to their 
respective controls (Control-ATRA p   =   2.881E-7, Control-RAR inhibitor p   =   9E-5, 
Control-RALDH2 p   =   8E-12; Fig. 2.1.2A,A'). 
Since retinoic acid signaling is important for primary palate development I 
was interested in how perturbations of this pathway changed dimensions in the 
midface, the region where formation of the primary palate occurs. I used four 
measures of the midface region including midface area, width, height, and angle as 
in Chapter 1. The midface area, which included the region encompassing the mouth, 
nostrils and eyes, was not significantly different between controls and ATRA 
treated tadpoles (p   =   0.9573; Fig. 2.1.2B,B'). However, this measurement was 
significantly decreased in both tadpoles exposed to RAR inhibitor and RALDH2 
morphants (Control-RAR inhibitor p   =   0.0001, Control MO-RALDH2 MO 
p   =   0.0056; Fig. 2.1.2B,B'). I saw a similar pattern in midface angle, or the angle 
between the dorsal midline of the mouth and eyes. The midface angles were 
statistically similar between ATRA treated tadpoles and controls (t-test, 
p   =   0.1025), but statistically decreased in retinoic acid (RA) deficient tadpoles 
(Control-RAR inhibitor p   =   2E-14, Control MO-RALDH2 MO p   =   2E-11; Fig. 
2.1.2C,C'). The face width, or distance from the left and right lateral peripheries 
just below the eyes, decreased significantly in all groups when compared to their 
respective controls (Control-ATRA p   =   1E-6, Control-RAR inhibitor p   =   2E-10, 
Control MO-RALDH2 MO p   =   4E-14; Fig. 2.1.2D,D'). Conversely, the face height, 
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a measure from the top of the cement gland to the top of the eyes, significantly 
increased in all the groups (t-test, Control–ATRA p   =   3E-6, Control-RAR inhibitor 
p   =   0.0254, Control MO-RALDH2 MO p   =   4E-5; Fig. 2.1.2E,E'). The increased 
height would suggest that the midface expands in a dorso-ventral dimension; 
however, I do not believe this is the case. Rather, it appears that retinoic acid 
perturbation results in an anterior shift in forebrain location and thus an apparent 
increase in the dorsal height of the face. 
I also determined that the mouth opening shape changed in all treatment 
groups in such a way that they were statistically more round (Control–ATRA 
p   =   5E-6, Control-RAR inhibitor p   =   0.0003, Control MO-RALDH2 MO p   =   1E-13; 
Fig. 2.1.2F,F'). This change in mouth opening shape is also reflected by measures 
of mouth width and height. Mouth width was significantly decreased (Control–
ATRA p   =   1E-25, Control-RAR inhibitor p   =   3E-14, Control MO-RALDH2 MO 
p   =   8E-18; Fig. 2.1.2G,G'), while the mouth height was significantly increased 
(Control–ATRA p   =   0.02167, Control-RAR inhibitor p   =   0.00011, Control MO-
RALDH2 MO p   =   1.3E-11; Fig. 2.1.2H,H') in all treatment groups compared to 
controls. Maintained mouth roundness in tadpoles with altered retinoic acid 
signaling suggests that the mouth did not incorporate the necessary jaw elements 
that would create a narrow mouth opening. 
To better understand how defects in retinoic acid signaling affect the shape 
of the face and mouth opening, I analyzed the changes in proportions of height to 
width. I found that these proportions decreased over time (see Fig. 2.1.2I), 
reflecting a widening and shortening of the face and mouth. In this section, I 
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determined that the normal proportion of height to width for both the orofacial 
region and mouth opening was altered when retinoic acid signaling was perturbed. I 
determined that there was a significant increase in the proportion of face height to 
face width in all treatment groups (Control-ATRA p   =   3.97E-6, Control-RAR 
inhibitor p   =   5.29E-6 Control MO-RALDH2 MO p   =   7.18E-11; Fig. 2.1.2I). Such 
increases ranged from 1.5 to 2.2 fold, and reflect the narrowing of the face width in 
response to an increase or decrease in retinoic acid signals. The changes in 
proportion of mouth height to width were also significantly different in all groups 
(ATRA-Control p   =   2.07E-9, RAR inhibitor p   =   0.002219, and RALDH2 MO 
p   =   2.81E-12; Fig. 2.1.2I). Proportional changes were most drastic in ATRA treated 
tadpoles and RALDH2 morphants, with 4.97 and 5.96 fold differences, respectively. 
RAR inhibitor treatment resulted in only a 1.5 fold increase in the proportion of 
mouth height to width. While this was statistically significant it was not as dramatic 
as changes seen in the other treatment groups. However, when examining the mouth 
shape in RAR inhibitor treated tadpoles, I visualized a clear median cleft. These 
results emphasize that important shape changes cannot always be adequately 
captured by these standard types of measurements alone, and require more 
sophisticated approaches such as geometric morphometrics. 
In my developmental analysis (see Chapter 1) we noted that there was a 
correlation between changes in orofacial width and mouth width (Fig. 1.2J). Thus, I 
initially believed that changes in the face would result in the same changes in the 
mouth. Therefore, I tested this hypothesis by determining if the proportion of face 
and mouth dimensions changed when retinoic acid signaling was disrupted (Fig. 
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2.1.2J). First, I compared the proportional changes in facial width to mouth width. 
ATRA treated tadpoles showed a statistically significant (t-test, p   =   3.33E-10) 3.54 
fold increase in the ratio of face width to mouth width. This indicates that the width 
of the mouth did not decrease proportionally with the width of the face (Fig. 
2.1.2J). Decreased retinoic acid signals, either by RAR inhibitor treatment or 
RALDH2 MO, induced more modest increases in face width to mouth ratios (1.61 
fold and 1.4 fold, respectively). However, these increases were significant in both 
groups (Control-RAR inhibitor p   =   4.69E-6, Control MO-RALDH2 MO p   =   5.77E-
5). Such changes in proportion therefore refute my hypothesis and indicate that face 
narrowing does not necessarily result in a similar change in mouth opening shape. 
This idea is even further emphasized when we examined the proportion of face to 
mouth height. ATRA treated tadpoles had a similar face to mouth height ratio as 
controls, indicating that these two dimensions changed proportionally (t-test, 
p   =   0.698285; Fig. 2.1.2J). Tadpoles treated with the RAR inhibitor showed a 
modest, but statistically significant 1.51 fold increase in this proportion 
(p   =   0.000562). Conversely, RALDH2 morphants exhibited a 0.5 fold decrease in 
the proportion of face to mouth height that was also statistically relevant (t-test, 
p   =   3.2E-6; Fig. 2.1.2J). These changes in the proportion of face to mouth width 
and height indicate that a general change in the facial shape does not necessarily 
reflect the same change in the shape of the mouth. 
As early tadpoles develop, I found that the midface angle positively 
correlated with width but not with height (Chapter 1). I therefore tested whether 
disruption of retinoic acid signals during early tadpole development resulted in 
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similar relationships, as determined by regression analysis. While it appeared that 
midface angle and width or height were linearly correlated these relationship did 
not prove to be significant (linear regressions, midface angle–width r2   =   0.7778, 
from y   =   0.8311x +11.4072; p   =   0.07704; midface angle-height, r2   =   −0.005385 from 
y   =   −0.4558x +152.7454; p   =   0.4258; Fig. 2.1.2K). 
Also during early tadpole development, there was a clear correlation of snout 
length with both mouth roundness and midface area (Chapter 1). Therefore, I was 
curious if this relationship was maintained when retinoic acid signaling was 
perturbed. Again, while there appeared to be a correlation, a linear regression 
analysis indicated that these relationships were not significant (snout length-
roundness r2   =   0.7249 from y   =   −3.643x   +   443.264; p   =   0.09633; snout length-area 
r2= 0.1304 from y   =   0.3271x – 67.2137; p   =   0.3517; Fig. 2.1.2L). These results are 
consistent in demonstrating that changes in the orofacial region in response to 
altered RA signals result in the uncoupling of orofacial features. 
D.1) GEOMETRIC MORPHOMETRIC ANALYSIS OF TADPOLES WITH PERTURBED 
RETINOIC ACID SIGNALING 
Traditional measurements of orofacial features provided a simple quantitative 
description of the anatomical changes in the tadpole midface when retinoic acid 
levels have been altered. However, I was unsatisfied with the lack of details 
conveyed about the subtle shape changes, especially those concerning the formation 
of median clefts in these tadpoles. Therefore, I used geometric morphometrics to 
analyze shape changes in the orofacial region and mouth opening in tadpoles with 
altered levels or RA signals. 
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E.1) PC ANALYSIS SHOWS OVERALL SHAPE CHANGES IN THE MIDFACE AND 
MOUTH SHAPE 
Initially I performed a PCA to illustrate the trends and variation in shape 
change within groups (ATRA or RAR inhibitor treated or in RALDH2 morphants). 
The first two PC generated from this analysis of orofacial landmarks demonstrated 
the variance among tadpoles within each of these groups. Both control groups were 
distinguished from all other treated groups primarily along the PC1 axis, and ATRA 
treated tadpoles were further distinguished from all other groups along PC2 (Fig. 
2.1.3A). Individuals within the treatment control group and control morphant group 
clustered tightly together and overlapped with one another (Fig. 2.1.3A). This 
suggests that both control groups are close in stage and orofacial shapes vary little 
with each other. Individuals in treatment groups were more widely dispersed, 
indicating a high degree of variance within each group. Such variance in the 
different groups was likely due to factors such as genetic background or minor 
developmental differences at time of treatment or fixation. The variance observed in 
RALDH2 morphants may also be attributed to slightly different quantities of 
morpholino injected into each individual embryo. Next I visualized each PC for 
orofacial landmarks on a transformation grid. This allowed me to view the relative 
change in landmark position in treatment groups compared to controls (controls 
were represented by being the end of the stick). The PC1 captures the most 
variation in shape changes (55.031%) and illustrates how perturbations in retinoic 
acid signaling specifically result in narrowing of the orofacial region (Fig. 2.1.3B). 
Most notably, this grid also captures the considerable reductions in the midface 
both dorsal and ventral to the mouth illustrated by significant warping (Fig. 
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2.1.3B). In addition, the mouth landmarks shifted more medially and ventrally, 
reflecting the rounder shaped mouth opening (Fig. 2.1.3B). The PC2 described less 
of the variance (23.072%) capturing mostly the shifts in mouth landmarks that 
distinguish the ATRA treated tadpoles (Fig. 2.1.3A,C). 
I next analyzed the PC generated by PCA of the mouth landmarks alone to 
determine whether this would better capture changes in mouth opening shape. Most 
of the variance was captured in PC1 (79.382%), with much of the remaining 
variance captured by PC2 and PC3 (5.258% and 4.761%, respectively). A bivariate 
analysis of PC1 and PC3 discriminated treatment groups from controls primarily 
along PC1 (Fig. 2.1.3A’). There is overlap of control groups with the RAR inhibitor 
treated tadpoles likely due to the fact that only a few landmarks associated with the 
median cleft change in tadpoles exposed to RAR inhibitor. There is also some 
overlap in ATRA and RALDH2 treated tadpoles (Fig. 2.1.3A’). This variance likely 
reflects the fact that each treatment resulted in some similar shape changes, and that 
these changes can vary considerably within an experiment depending on an 
individual's level of exposure and genetic background. The transformation grid of 
PC1 mouth landmarks illustrates the change from a wide, flat mouth opening in the 
control groups to a narrower more round shaped mouth opening in tadpoles where 
retinoic acid was perturbed (Fig. 2.1.3B’). In addition, this analysis captured the 
production of the steep angle created in the dorsal edge of the mouth, which is 
consistent with a median cleft in the primary palate (Fig. 2.1.3B’). The PC3 
transformation grid further captured the median cleft by illustrating a dorsal shift in 
the medial most landmark on the dorsal edge of the mouth (red arrow, Fig. 2.1.3C’). 
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This analysis proved to best capture the overall shape changes associated with the 
median clefts observed in tadpoles with altered retinoic acid signaling. 
F.1) CANONICAL VARIATE AND DISCRIMINANT FUNCTION ANALYSIS SHOWS 
STATISTICALLY DIFFERENT OROFACIAL AND MOUTH SHAPE CHANGES IN 
TADPOLES WITH PERTURBED RETINOIC ACID SIGNALING 
While the PCA illustrated shape changes across the different groups of 
tadpoles with altered retinoic acid signaling, it did not statistically compare these 
groups. Therefore, I next performed a CVA to distinguish significant differences in 
the shape of the mouth and orofacial region when tadpoles were exposed to either 
ATRA or RAR inhibitor or injected with RALDH2 morpholinos. Using MorphoJ, 
the procrustes distances and statistical measures of the differences amongst groups 
were generated (Table 2.1). This analysis showed that all groups were significantly 
different from each other (P-values were less than 0.05) when considering either 
orofacial or mouth landmarks (Table 2.1). These results indicate that even though 
there is considerable variation within groups, the shape changes generated are 
robust and distinct enough to generate statistical differences. To illustrate the 
relationships amongst groups generated by the CVA of orofacial and mouth 
landmarks, I generated graphical outputs in MorphoJ (Fig. 2.1.4A,B). The bivariate 
analysis of the first canonical variate (CV1) and the second canonical variate (CV2) 
for orofacial landmarks best illustrated discreet differences in orofacial shape. CV1 
captured most of the orofacial shape differences between groups (92.918%) and 
discriminated the groups along its axis (Fig. 2.1.4A). The CV2, which only 
accounted for 3% of the shape differences, further defined the differences between 
groups along the y-axis, especially tadpoles exposed to RAR inhibitor and ATRA. 
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While these RAR inhibitor and ATRA groups appeared close to each other 
graphically, they did not overlap statistically (Table 2.1). This data indicates that 
tadpoles exposed to ATRA and RAR inhibitor were more similar to each other than 
to their controls. This was not surprising since many orofacial shape features were 
similar between the two groups. I also generated a CVA graphical output of the 
mouth landmarks alone. The tadpole groups having perturbed retinoic acid signaling 
were distinguished from the controls by plotting the CV1, which captures 78.369% 
of the shape differences, and CV2, which captured 15.434%. Interestingly, in this 
analysis the two different control groups overlapped significantly, likely because 
shape of the mouth in these tadpoles did not differ greatly (Fig. 2.1.4B). 
While the CVA was able to statistically compare all the groups, I was most 
interested in understanding how the orofacial shapes changed when each group was 
compared to its respective control. Such a pairwise analysis in morphometrics can 
be generated by a discriminant function analysis (DFA), which uses the same 
principles as a CVA using two samples rather than many (Cohen 2002). A DFA was 
performed to compare each of the groups with altered retinoic acid signals (ATRA, 
RAR inhibitor, or RALDH2 morphants) with their respective controls. The results 
of this analysis showed that all orofacial shapes generated by retinoic acid 
perturbation were statistically different than their control counterparts (Table 2.2). 
These differences were best illustrated when the DFA analysis was viewed as a 
transformation grid, where the landmarks of perturbed tadpoles were represented as 
the lollipop or closed circle of the vector. The transformation grid generated when 
ATRA treated tadpoles were compared with their controls illustrated major shifts in 
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all landmarks that would account for a narrowing of the orofacial region (Fig. 
2.1.4C). In addition, warping of the grid is consistent with hypoplasia in the regions 
dorsal and ventral to the mouth opening (Fig. 2.1.4C). The mouth shape in these 
treated tadpoles is longer dorso-ventrally, narrower in width and comes to a point at 
the top (Fig. 2.1.4C,D). When a DFA was used to compare the RAR inhibitor 
treated tadpoles and controls, the transformation grid also illustrated shifts in 
landmarks consistent with a narrowing of the face relative to the height. However, 
warping in the grid is predominantly localized to the region dorsal to the mouth 
opening (Fig. 2.1.4E). The mouth shape in RAR inhibitor treated tadpoles is less 
narrow and comes to a point dorsally accounting for a median cleft (Fig. 2.1.4E,F). 
A DFA transformation grid comparing the RALDH2 and control morphants again 
showed dramatic shifts in most landmarks accounting for a narrower orofacial shape 
(Fig. 2.1.4G). Similar to the transformation grid for the ATRA treatment, warping 
occurs in the regions dorsal and ventral to the mouth opening (Fig. 2.1.4G). The 
mouth shape In RALDH2 morphants is also longer dorso-ventrally and narrower, 
creating a somewhat rounder shape (Fig. 2.1.4G,H). 
DFA analysis illustrates shape changes that are consistent with our 
qualitative observations and traditional measurements (Figs. 2.1.2, 2.1.3, 2.1.4). 
For example, the narrowed faces observed in this analysis are also reflected in the 
increased height to width ratios shown in Figure 2.1.2I. The roundness 
measurements and mouth height to width ratios also shows significant narrowing of 
the mouth opening, especially in ATRA treated and RALDH2 morphants. This is 
mirrored in the DFA where mouth shapes are most dramatically different in these 
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two groups. Therefore, such consistency suggests confidence in my morphometric 
analyses. 
The DFA has also been useful in capturing subtle changes and the differences 
in orofacial and mouth shapes created by the various methods of perturbing retinoic 
acid signaling. For example, the RAR inhibitor treatment transformation grid 
illustrates major warping dorsal to the mouth, whereas the other groups also have 
major warping ventrally. Such differences in the orofacial regions may also account 
for the differences in mouth opening shape among the groups. RALDH2 morphants 
compared to controls have much more dramatic shifts in landmarks, most notably in 
the position of the nostrils relative to the rest of the face. The degree of shifting of 
landmarks can also provide a quantitative assessment of the change in shape that 
has not been possible in our previous studies. Therefore, this analysis has been 
useful in identifying differences that may reflect different molecular effects of the 
three methods of retinoic acid perturbation. Most notably, this DFA successfully 
captures the shape changes in the orofacial region and mouth opening that were not 
resolved by standard traditional methods in section C.1. This is especially true in 
illustrating abnormalities such as a median cleft in the shape of the mouth opening. 
In summary, my CVA and DFA were able to quantitatively capture the 
abnormalities in orofacial anatomy after retinoic acid signaling disruption. 
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PART II. 
 
 
 
A.2) DHFR IS EXPRESSED IN THE DEVELOPING FACE OF XENOPUS 
One of the key steps in the folate pathway is the reduction of dihydrofolate to 
tetrahydrofolate by the enzyme dihydrofolate reductase (DHFR), so understanding 
its role in the developing face could provide important insight into general 
requirements for folate during orofacial development. Therefore, I first performed 
in-situ hybridization to localize mRNA in the head during early specification and 
growth of the face (Fig. 2.2.1) in order to determine when and where DHFR is 
expressed during orofacial development. At stages 20–35, DHFR mRNA was 
observed generally throughout presumptive facial tissues. DHFR mRNA also 
appeared to be enriched in the eyes and brain during this period. At stage 20 (24 
hpf), the neural tube has completely closed and neural crest cells are specified (van 
Ede et al. 2002). DHFR is expressed at low levels throughout the entire embryo at 
this time point, but enriched in the presumptive head and neural tube (Fig. 2.2.1A-
A”). This expression domain is similar at stage 24 (26 hpf), but becomes more 
defined at stage 26, as the eye forms and neural crest cells populate the facial 
prominences (Mayor, Morgan et al. 1995; Fig. 2.2.1B-B”,C- C”). By stage 29 (35 
hpf), DHFR expression is almost entirely restricted to the head and developing 
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nervous system, with high enrichment in the eyes, brachial arches, tissues 
surrounding the presumptive mouth, and the notochord (Fig. 2.2.1D- D”). This 
enrichment was similar at stage 35 (50 hpf; Fig. 2.2.1D- D”). These results suggest 
DHFR has a role in the developing face and prompted further investigation DHFR 
function during orofacial development.  
B.2) PHARMACOLOGICAL INHIBITION OF DHFR FUNCTION INDUCES OROFACIAL 
ABNORMALITIES 
To better define when DHFR is important in orofacial development I 
inhibited DHFR function using a pharmacological approach. I bathed embryos in the 
DHFR antagonist, methotrexate (MTX), over early facial development (st. 20–31, 
22–37 hpf; 2 experiments; n = 40; Fig. 2.2.2A). Phenotypic analyses were then 
performed on stage 42 and 43 (80–87 hpf) tadpoles, when the effects of MTX were 
more obvious. I saw an overall increase in the severity of the facial phenotypes with 
concentrations ranging from 50–440 µM of MTX (Appendix B). This was consistent 
with concentrations used in zebrafish (Lee et al., 2012). Further, there was 
considerable variability in facial phenotypes at each concentration (Appendix B). 
Such inconsistencies in MTX effectiveness have also been reported in humans and 
are thought to be due to a number of factors (described in detail in Appendix B; 
Zhao and Goldman, 2003). Approximately 75% of the faces of embryos treated with 
220 µm MTX had a severe or moderate appearance, in which faces appeared smaller 
and underdeveloped (Fig. 2.2.2B–E). I therefore chose this concentration for 
subsequent analyses, as it clearly produced an orofacial defect in the majority of 
treated embryos, and exhibited less variability in severity compared to the other 
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concentrations tested. Upon quantification, I found that the intercanthal distance 
and the face height were significantly reduced by MTX treatment (t-test; P-vals < 
0.001; 2 experiments, n=40; Fig. 2.2.2F,G). To verify that MTX treatment affected 
facial development via inhibition of DHFR, we attempted to rescue the MTX 
phenotype with application of folinic acid. When embryos were treated with both 
folinic acid and MTX, they qualitatively resembled controls (rescue treatment 
performed by Amanda Dickinson; Fig. 2.2.2A,D). I quantified the facial dimensions 
in these embryos and found no statistical difference compared to controls via t-test, 
thereby verifying the specificity of MTX to DHFR function (Fig. 2.2.2F,G). This 
data indicates that DHFR function is specifically required for orofacial development 
during early specification events in the face.  
C.2) QUANTIFICATION OF FACIAL DIMENSIONS REVEALED SPECIFIC CHANGES IN 
OROFACIAL SHAPE IN EMBRYOS WITH DECREASED DHFR FUNCTION 
Based on casual observations that embryos treated with the DHFR inhibitor 
were smaller in size, it is possible that reduction of folate metabolism results in an 
overall delay in growth. If this were the case, the face would decrease in size 
unaccompanied by a change in the shape of facial features. To investigate this, I 
performed geometric morphometrics to evaluate changes in face shape (Kennedy 
and Dickinson 2014; Kennedy and Dickinson 2014). Briefly, 31 facial landmarks 
were chosen to best represent the shape of the midface (Fig. 2.2.2H). MorphoJ 
analysis software aligned the landmarks using superimposition algorithms to 
eliminate differences in the size of the embryos. Canonical variate analysis (CVA) 
was then applied to landmark data to reveal how controls, embryos treated with 
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MTX, and MTX-treated embryos rescued with folinic acid differed in facial shape 
(Fig. 2.2.2I). As indicated by the spread of points on the graph, there is 
considerable variation among individuals (CV1=79.95%, CV2=20.05%; Fig. 
2.2.2I). Despite such variability, none of the groups overlapped, and the distances 
between MTX-treated embryos and controls or rescue embryos were both 
significantly different (P-vals < 0.05). While there was also an observable 
difference between controls and the rescue group, they were more similar to each 
other than either was to the MTX treated group (Procrustes distances: Control-
Rescue = 0.0794; Control-MTX = 0.2365; Rescue-MTX = 0.1794, p-vals < 0.05; 
Fig. 2.2.2I).  
I next performed a discriminant function analysis (DFA) to analyze 
differences in facial shape between controls and MTX-treated embryos. In the 
transformation grid generated by pairwise DFA of these groups, the most striking 
changes in landmark position were those on the lateral edges of the face as well as 
those around the mouth (p < 0.0001, Fig. 2.2.2J, top grid). Warping of the grid 
showed shape changes in the midface, which is consistent with the facial narrowing 
seen in MTX treated embryos (Fig. 2.2.2J, top grid). When the same analysis was 
performed on control and rescue embryos, the largest changes observed were at the 
periphery of the face. In fact, the mouths of the control and rescue groups were very 
similar, providing evidence that the folinic acid treatment did indeed rescue the 
changes in mouth shape induced by MTX treatment (Fig. 2.2.2J, bottom grid). 
There is a considerable amount of time between the MTX treatment, which 
occurred during early facial specification events, and stage 42 (80 hpf) when the 
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jaw elements of the face form and the facial dimensions were analyzed. Therefore, I 
also examined the size and shape of the face at stage 40 (66 hpf) to determine if 
similar changes in face dimensions and shape could also be detected (2 experiments, 
n=20). At stage 40 (66 hpf; Fig. 2.2.3A), the intercanthal distance was also 
significantly reduced in MTX-treated embryos compared to controls (p < 0.001), 
while the facial height was not statistically different (p = 0.3479; Fig. 2.2.3B). 
Transformation grids generated by DFA of MTX treated embryos compared to 
controls revealed similar, albeit less dramatic, shifts in landmark position on the 
lateral edges of the face. This suggests that MTX treatment has already induced a 
slight narrowing of the face by this stage. Indeed, the warping of the grid dorsal to 
the mouth opening is similar to that visualized at stage 42 (80 hpf), further 
demonstrating the early effects of MTX treatment. The position of the mouth 
landmarks reflects earlier malformation of the mouth shape, as they shift in the 
same direction as the landmarks in stage 42 transformation grids (80 hpf; Procrustes 
distance= 0.1436, p < 0.05; 2 experiments, n=10; Fig. 2.2.3B). 
In summary, these facial analyses show that MTX treated embryos do indeed 
exhibit differences in facial shape, refuting the simplistic interpretation that folate 
signaling resulted in a generic developmental delay and thus a smaller embryo. 
Further, treatment with folinic acid, which bypasses the inhibition of folate 
signaling by MTX, partially rescues these facial shape changes. 
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DISCUSSION 
 
 
 
A) DECREASED RETINOIC ACID SIGNALING AFFECTS OROFACIAL ANATOMY AND 
CAN RESULT IN CLEFTS IN THE PRIMARY PALATE 
Retinoic acid signaling is a critical modulator of primary palate development 
in Xenopus (Kennedy and Dickinson 2012). Perturbation of this signaling pathway 
by RALDH2 antisense loss of function or chemical inhibition of RAR receptors 
results in a median cleft in the primary palate. Data from our previous work 
suggests that one possible mechanism is that retinoic acid signaling promotes 
midface growth that is required for formation of the primary palate structures. 
Indeed, we have shown that decreased retinoic acid results in an approximate 50% 
reduction in mitosis in the region that will form the primary palate (Kennedy and 
Dickinson 2012). Further, we have also shown that the cartilages associated with 
the upper jaw are reduced or missing (Kennedy and Dickinson 2012). Therefore, in 
the current study I was interested in whether these changes in orofacial 
development correlated with quantifiable changes in orofacial anatomy. My results 
undeniably indicate that measures of midface width, area and snout length are 
decreased in tadpoles with deficiencies in retinoic acid signaling. Morphometric 
analysis also indicates major shape changes in the midface region relative to the 
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rest of the face that would be consistent with a midface hypoplasia. Such hypoplasia 
or deficiency in tissue likely accounts for the formation of a median cleft especially 
since retinoic acid receptors are not found in the progenitors of the mouth itself 
(Kennedy and Dickinson 2012). Therefore, the gap in the dorsal oral cavity and 
misshapen mouth opening is likely a direct consequence of the failure of the 
primary palate to meet above the oral cavity. Similar median clefts were reported in 
mice with loss of RAR function (Lohnes, Mark et al. 1994; Dupe and Pellerin 2009) 
and retinoic acid deficiencies have been reported to result in various forms of 
orofacial clefts in humans (Fan, Li et al. 2007). Further, many cases of human 
median clefts are also attributed to a deficiency in midface tissue (Allam, Wan et al. 
2011). Not only do these studies support a conserved role for retinoic acid signaling 
in midface development but also that median clefts may be caused by a general 
deficiency in cell proliferation. 
Not surprisingly, the two methods used to decrease retinoic acid signals had 
somewhat different effects on orofacial growth and shape. Specifically, the 
RALDH2 morphant phenotype included more severe changes in orofacial anatomy. 
Such a phenotype likely reflects the additional effects and longer duration of the 
RALDH2 morpholinos. For example, RALDH2 has been shown to regulate anterior-
posterior patterning during gastrulation and early development of the posterior 
branchial arches, both of which could affect the overall size and shape of the 
craniofacial region (Durston, Timmermans et al. 1989; Ruiz i Altaba and Jessell 
1991; Kaiser, Merrill et al. 2003; Niederreither, Vermot et al. 2003; Mark, 
Ghyselinck et al. 2004). This study indeed illustrates a more dramatic decrease in 
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orofacial width, area and snout length in RALDH2 morphants compared to inhibitor 
treated tadpoles. Further, my morphometric analysis showed a statistically distinct 
difference in the phenotypes of tadpoles with decreased RALDH2 protein compared 
to RAR inhibitor treated tadpoles. In particular, the anatomical shape changes in the 
RALDH2 morphants are consistent with both upper and lower orofacial 
deficiencies; whereas RAR inhibitor treated tadpoles had relatively less anatomical 
changes in the lower face. RAR gamma, the primary target of the inhibitor, is only 
expressed in the presumptive dorsal facial prominences during the treatment time 
and therefore, I would not expect effects on lower jaw development. Using different 
methods to abrogate retinoic acid signaling therefore has the potential to help us 
better understand the different and numerous roles of retinoic signaling in 
craniofacial development. 
B) ECTOPIC EXPOSURE TO RETINOIC ACID ALSO CAUSES SIMILAR BUT DISTINCT 
CHANGES IN OROFACIAL ANATOMY 
Since ectopic exposure to retinoic acid is thought to have different effects on 
embryonic development than deficiency of this pathway (Morriss-Kay 1993), the 
effects of retinoic acid exposure on orofacial anatomy are somewhat surprising. 
Specifically, ATRA treated tadpoles shared similar features (such as decreased 
orofacial width and snout length and rounder, less wide shaped mouth openings) 
with RALDH2 morphants and RAR inhibitor treated tadpoles. Such similar defects 
in Xenopus tadpoles exposed to ATRA have also been reported previously (Vieux-
Rochas, Bouhali et al. 2010) and these abnormalities were attributed to the failure 
of cranial neural crest cells to differentiate into appropriate maxillary and 
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mandibular jaw structures. Inappropriate levels of a morphogen, such as retinoic 
acid, can have several different effects on cells including altered gene expression 
(Villeneuve, Gisbert et al. 2005; Abe, Maeda et al. 2008) and apoptosis (Sulik, 
Cook et al. 1988). Therefore, it is possible that ectopic retinoic acid exposure could 
result in changes in orofacial cell fate and/or cell death that result in lack of 
differentiation and tissue deficiency in the midface. Consequently, tadpoles treated 
with retinoic acid have similar changes in orofacial anatomy as those with deficient 
retinoic acid signals. However, it is possible that too much or too little retinoic acid 
may each result in midface hypoplasia via different mechanisms. This is supported 
by my morphometric study where I could statistically distinguish between tadpoles 
having excess retinoic acid and those with deficiencies despite their apparent 
similar phenotype. 
Exposure to excessive amounts of retinoic acid has long been known to be 
teratogenic to humans and other vertebrates. Pregnant women exposed to excessive 
retinoic acid such as isotretinoin (Accutane) are at a higher risk for having a child 
with cleft palate (Lammer, Chen et al. 1985; Ackermans, Zhou et al. 2011). Studies 
in mice also showed that ectopic exposure to isotretinoin causes midface reductions 
and orofacial clefts (Willhite, Hill et al. 1986). Excess retinoic acid in chicks 
causes severe clefting in the primary palate and a missing upper beak due to the 
failure in frontonasal growth (Tamarin, Crawley et al. 1984). Therefore, it is likely 
that perturbations in retinoic acid signaling have conserved effects across the 
vertebrates. In summary, this study lays an important groundwork for future studies 
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aimed at better understanding how normal and abnormal levels of retinoic acid 
signaling influence orofacial development. 
C) ABROGATED FOLATE METABOLISM INDUCES MALFORMATION OF THE FACE 
Due to the known role of folate metabolism in neural tube closure, it has 
been postulated that the facial defects induced by folate deficiency are a 
consequence of interference with this process and subsequent specification of 
cranial neural crest cells (Finnell, Greer et al. 1998; Finnell, Shaw et al. 2004). 
Studies in both mice and Xenopus show that knockdown of the folate receptors 
results in craniofacial defects induced by abnormal development of cranial neural 
crest cells (Tang, Santillano et al. 2005; Li, Shi et al. 2011). However, I show that 
DHFR is required in the development of the orofacial region later in facial 
specification and morphogenesis, after neural tube closure is complete. Not only do 
I show expression of DHFR in the face during embryonic mouth and facial 
prominence specification, but I also show significant malformation of the Xenopus 
face when a DHFR antagonist was applied to embryos during this timeframe.  
Folate metabolism is important in synthesizing components for many crucial 
metabolic processes such as DNA synthesis and repair, and methylation of DNA, 
RNA and protein (reviewed in (Lucock 2000)). It is possible then, that inhibition of 
the key enzyme early in the folate pathway, DHFR, would globally impact growth, 
cell survival, and epigenetic regulation in the developing embryo. After my initial 
results described above, our lab undertook a series of experiments to investigate 
this in more detail. We found that the largest contributor to the defects induced by 
decreased DHFR function was DNA damage induced by increased apoptosis in the 
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facial tissues (Wahl, Kennedy et al. 2015). Indeed, dying cells were localized to 
regions of the face that correlated with the shape changes identified in my 
morphometric analysis. This is similar to what has been observed in tumor cells 
treated with Methotrexate, as well as the increased DNA damage in the palate of 
children with folate deficiency (Martin, McCarthy et al. 2009; Brooklyin, Jana et al. 
2014). In addition, retinoic acid receptors are also expressed in the same region we 
saw folate deficiency induced cell death (Kennedy and Dickinson 2012), thus we 
proposed that folate metabolism may also regulate gene expression in the 
developing face.  
D) FOLATE METABOLISM MAY INTERACT WITH RETINOIC ACID SIGNALING 
DURING OROFACIAL DEVELOPMENT 
Recently a link between retinoic acid signaling and folate was found in 
cancer cells (Qi and Ratnam 2006), and our previous work showed RA inhibition 
during facial specification in Xenopus results in median facial clefts (Kennedy and 
Dickinson 2012). The overlap of retinoic acid and folate function during orofacial 
development led to the question of whether a link exists between these signaling 
pathways in orofacial clefting. Alternatively, retinoic acid and folate could affect 
orofacial development through different mechanisms. Our lab has shown that 
manipulated folate levels in our established retinoic acid-inhibition-induced model 
of orofacial clefts resulted in morphological consequences (Wahl, Kennedy et al. 
2015). For example, the median cleft in retinoic acid inhibited embryos was 
ameliorated by concurrent treatment with folinic acid, a reduced folic acid 
analogue. Further, the converse experiment, in which both folate metabolism and 
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RA signaling were decreased resulted in an exacerbation of RA-inhibition-induced-
median clefts (Wahl, Kennedy et al. 2015). While it is possible that folate 
metabolism is required for retinoic acid signals in the face, it is also plausible that 
the two pathways converge on similar processes, such as proliferation or apoptosis, 
to profoundly affect the size and shape of the face. Regardless of the mechanism, 
the defects in folate metabolism during embryonic development may “bring out” a 
genetic predisposition or worsen the effects of exposure to a chemical agent in 
humans. Therefore, our lab has created a useful model for better understanding how 
gene-environment interactions can influence complex developmental processes and 
a method by which to quantify this.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
Using a comprehensive quantitative analysis combining size measurements 
and morphometrics has allowed me to best describe the anatomical changes in 
orofacial region when development is disrupted. Thus, this work provides some 
insight into the mechanisms underlying primary palate development and clefting. 
However, I still have only just scratched the surface in understanding how the 
complex morphogenesis of midface development is regulated across vertebrates. 
Several other signaling pathways have also been shown to play a role in orofacial 
development; however, whether or how they interact is less clear. Therefore, future 
studies directed in understanding the interrelationships of these signaling pathways 
will be essential to fully understanding orofacial development. Importantly, 
incorporation of quantitative analyses of orofacial anatomy into such future 
molecular and developmental studies will aid in dissecting the mechanisms 
governing the complex morphogenetic processes that take place during craniofacial 
development. 
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FIGURES 
 
 
 
 
Figure 2.1.1. Perturbation of 
retinoic acid signaling induces a 
variety of craniofacial anomalies.  
(A–E)  Frontal views; (A'–E')  
Lateral views; (A,A')  Control 
tadpoles treated with DMSO alone; 
(B,B')  All-trans retinoic acid 
(ATRA) treated tadpoles; (C,C')  
Tadpoles treated with the retinoic 
acid receptor inhibitor,  BMS-453; 
(D,D')  Tadpoles injected with 
standard control antisense 
morpholino; (E,E')  Tadpoles 
injected with antisense morpholino 
to the enzyme, RALDH2. Scale 
bars   =   200 µM. cg=cement gland. 
Mouth opening outlined in red 
dots.  
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Figure 2.1.2. Effect of perturbed retinoic acid signaling on orofacial dimensions.  (A–E)  
Schematics depicting each measurement taken; (A'–E')  Bar graphs showing relative changes in 
measurements between control and treatment groups; to graphically compare measurements,  
values for treatment groups were scaled so that controls equaled 100; (A,A')  Snout length; (B,B)  
Midface area; (C,C')  Midface angle; (D,D')  Face width; (E,E')  Face height;  (F,F')  Mouth 
roundness; (G,G')  Mouth width; (H,H')  Mouth height.  Asterisks denote significance as 
determined by a t-test  assuming equal variance between un-scaled values of treatment groups 
with respective controls.  (I,  J)  Line graphs showing how the proportions of the mouth and face 
dimensions change between each treatment group and its  respective control;  (I)  Proportions of 
height to width; blue diamonds   =   face height/face width, red squares   =   mouth height/mouth width; 
(J)  Proportions of height to width for the face and mouth; blue diamonds   =   face height/mouth 
height;  red squares   =   face width/mouth width; (K, L)  Scatterplots showing correlations between 
various facial  dimensions; (K)  Correlations between midface angle and face width or face height,  
blue diamonds   =   face width, red squares   =   face height;  (L)  Correlations between snout length and 
mouth roundness or midface area, blue diamonds= mouth roundness,  red squares   =   midface area; 
cg, cement gland. 
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Figure 2.1.3.  Principal component analysis (PCA) of treatment groups. (A–C)  PCA results for 
orofacial landmarks. (A)  Bivariate plot of PC1 and PC2 of orofacial landmarks. (B)  Transformation 
grid of PC1 for orofacial landmarks, scale factor   =   −0.25; (C)  Transformation grid of PC2 for orofacial 
landmarks, scale factor =0.1. (A’-C’)  PCA results for mouth landmarks; (A’)  Bivariate plot of PC1 and 
PC3 of mouth landmarks; (B’)  Transformation grid of PC1 for mouth landmarks, scale factor   =   −0.25; 
(C’)  Transformation grid of PC2 for mouth landmarks, scale factor   =   0.1. Red arrow indicates landmark 
shift  associated with median cleft .  Closed circle end of vector represents the treatment groups. The line 
of the vector represents the change in position of that landmark relative to controls.  
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Figure 2.1.4. Canonical variate analysis (CVA) and 
discriminant function analysis of treatment groups. 
(A)  CVA results for orofacial landmarks; (B–D)  DFA 
results for orofacial landmarks, scale factor   =   −0.1; 
(A)  Bivariate plot of CV1 and CV2 of orofacial 
landmarks; (B)  Transformation grid of DFA between 
ATRA treated tadpoles and controls;  (C)  
Transformation grid of DFA between RAR-inhibitor 
treated tadpoles and controls;  (D)  Transformation grid 
of DFA between RALDH2 morphants and control 
morphants;  (E)  CVA results for mouth landmarks; (F–
H) DFA results for mouth landmarks, scale factor 
=1.0; (E) Bivariate plot of CV1 and CV2 of mouth 
landmarks; (F)  Transformation grid of DFA between 
ATRA treated tadpoles and controls;  (G)  
Transformation grid of DFA between RAR-inhibitor 
treated tadpoles and controls;  (H)  Transformation grid 
of DFA between RALDH2 morphants and controls.  
Closed circle end of vector represents the given 
treatment group. The line of the vector represents the 
change in position of that landmark relative to the 
respective control.  
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Figure 2.2.1. in-situ hybridization of folate pathway 
components in Xenopus laevis.  Images of whole embryos  (A-
E) ,  side views  (A’-E’) ,  and frontal views (A”-E”)  showing 
expression of antisense probe targeting DHFR. (A-A”) Stage 20 
embryos (18 hpf).  (B-B”)  Stage 24 embryos (26 hpf).  (C-
C”)Stage 26 embryos (29 hpf).  (D-D”)Stage 29 embryos (35 
hpf).  (E-E”)Stage 35 embryos  (50 hpf).  cg = cement gland, ov 
= otic vesicle.  
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Figure 2.2.2. Pharmacological inhibition of DHFR alters size and shape of the face.  (A)  Schematic 
of the experimental design. (B-E)  Representative frontal views of faces treated with DMSO (B) ,  
220uM MTX (C ,  E)  and 220uM MTX + folinic acid (FA) (D) .  All  images were taken at same 
magnification (scale bar =150µm). Mouth is outlined in red dots.  (F)  Schematic of the facial 
dimensions measured. (G)  Bar graphs of the quantification of facial  dimensions for 2 experiments 
(n=20).  Asterisks designate statistical difference when compared to control (all  p values ≤  0.001).  
(H)  Landmark locations for morphometric analysis.  (I)  Canonical variate analysis of landmark 
coordinates.  Statistically significant for 2 experiments,  n=10, p value ≤0.05).  (J)  Transformation grid 
showing the change in landmark position in MTX treated embryos compared to controls.  
 
  80 
Figure 2.2.3.  Pharmacological inhibition of DHFR induces similar size and shape changes of the 
face at earlier tadpole t imepoints.  (A)  Schematic of the experimental design. (B)  Left  panel:  Bar graph 
of the quantification of facial  dimensions for 2 experiments (n=20).  Asterisks designate statistical 
difference when compared to control (all  p values ≤  0.001).  Right panel:  Landmark locations for 
morphometric analysis.  Transformation grid showing the change in landmark position in MTX treated 
embryos compared to controls.  Statistically significant for 2 experiments,  n=10, p value ≤0.05).   
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Table 2.1. CVA of orofacial and mouth opening shape changes after perturbation of retinoic acid signaling. Matrix 
of MorphoJ computed Procrustes distances and P-values (in parentheses and italics). Lightly shaded cells contain 
orofacial shape comparisons and darkly shaded cells contain mouth opening comparisons. Statistical significance is 
indicated by an asterisk. 
  Control 
trt 
ATRA RAR 
inhibitor 
Control 
MO 
RALDH2 
MO 
Control 
trt 
  0.3169 
(<0.0001)* 
0.2621 
(<0.0001)* 
0.0960 
(0.0008)* 
0.3206 
(<0.0001)* 
ATRA 0.4801 
(<0.0001)* 
  0.2069 
(<0.0001)* 
0.3738 
(<0.0001)* 
0.2594 
(<0.0001)* 
RAR 
inhibitor 
0.1235 
(0.0083)* 
0.3641 
(<0.0001)* 
  0.3436 
(<0.0001)* 
0.1380 
(0.0008)* 
Control 
MO 
0.1305 (0. 
0002)* 
0.6066 
(<0.0001)* 
0.2477 
(<0.0001)* 
  0.3968 
(<0.0001)* 
RALDH2 
MO 
0.4249 
(<0.0001)* 
0.0970 
(0.0363)* 
0.3134 
(<0.0001)* 
0.5497 
(<0.0001)* 
  
 
Table 2.2.   DFA P-values of pairwise comparisons between tadpoles with altered retinoic acid 
signaling compared to their respective controls.  
 Orofacial 
landmarks 
Mouth landmarks 
Control vs. ATRA <0.0001* <0.0001* 
Control vs. RAR inhibitor <0.0001*   0.0060* 
Control MO vs. RALDH2 MO <0.0001* <0.0001* 
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CHAPTER III: UTILIZING A SMALL MOLECULE LIBRARY TO 
SCREEN FOR NOVEL GENES REGULATING OROFACIAL 
DEVELOPMENT  
 
 
 
The etiology of orofacial clefting is complicated by genetics, environment, 
and maternal nutrition. For example, I have shown in the previous chapter that 
inappropriate amounts of retinoic acid or folic acid during Xenopus orofacial 
development can result in orofacial anomalies, including median clefts. However, 
the results of these studies only begin to unravel the complex interactions 
regulating primary palate development and the formation of orofacial defects.  
Therefore, in this final chapter, I take a chemical genomics approach to identify 
other regulators of orofacial development. I then investigate potential interactions 
between these regulators and retinoic acid signaling in order to elucidate some of 
the multifactorial relationships underlying median facial clefts.  
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INTRODUCTION 
 
 
 
Disruption of early primary palate can result in orofacial defects, such as 
median facial clefts (Diewert and Wang 1992; Meng, Bian et al. 2009; Dickinson 
2016). Several factors have been attributed to this process such as maternal vitamin 
deficiency, exposure to environmental toxins, and perturbation of signaling 
pathways (Jiang, Bush et al. 2006; Meng, Bian et al. 2009; Dixon, Marazita et al. 
2011). Given the multifactorial nature of these defects makes identification of novel 
factors paramount to uncover.  
The fully formed embryonic face arises from growth and fusion of the five 
prominences surrounding the embryonic mouth (stomodeum); the frontonasal 
prominence, and the first pharyngeal arch derived paired maxillary and mandibular 
prominences (Jiang, Bush et al. 2006). Early in development, neural crest cells 
delaminate from the epithelium of the neural tube and migrate into these 
prominences where they contribute to neural, skeletal, dermal, and mesenchymal 
structures (Cordero, Brugmann et al. 2011). Later in development (5th week in 
humans, E10 in mice), the medial nasal prominence forms from ectodermal 
thickening on the ventrolateral edge of the frontonasal prominence, and the 
maxillary prominences lateral to the stomodeum enlarge and proliferate medially 
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(Meng, Bian et al. 2009). It is the fusion of the medial nasal and maxillary 
prominences at the midline of the face that establishes the entire primary palate and 
upper lip (Meng, Bian et al. 2009). Further contributing to the morphology of the 
orofacial region are the cartilages derived from these prominences (Papka 1995). 
The maxillary prominence gives rise to the ethmoid plate and palatoquadrates that 
support the primary palate and upper jaw. The mandibular prominence gives rise to 
components such as the paired Meckel’s and infrarostrals that articulate to create 
the lower jaw (Altig and McDiarmid 1999). Finally, the basihyal and cerathoyal 
cartilages that support the floor of the mouth arise from second pharyngeal arch 
(Papka 1995; Rose 2009).  Arches three though six are the brachial arches and give 
rise to four pairs of gills (ba; Altig and McDiarmid 1999). 
This process is tightly regulated by signals from ectoderm, mesenchyme, and 
neural crest (Richman and Lee 2003). Additionally, cues from morphogens and 
developmental signaling pathways are crucial for proper orofacial patterning (Mina 
2001; Brugmann, Goodnough et al. 2007). Disruption of these cues can lead to 
failure of the facial prominences to fuse properly and subsequently leads to 
orofacial clefts (Kennedy and Dickinson 2012). In the previous chapter, I show that 
retinoic acid (RA) signaling is important during palate development, and deficiency 
in RA signaling results in a median cleft.  However, there is still much to uncover 
about how this defect arises, and the complexity of interactions that regulate the 
development of the orofacial region. Therefore, a non-biased approach such as 
chemical genomics could be particularly powerful in elucidating some of these 
interactions. 
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Chemical genomic screens employ the use of small molecule compounds to 
interfere with protein function in a living system (Wheeler and Brandli 2009). One 
such technique is the phenotype-driven forward screen, which is modeled on 
classical genetic screens but has several advantages over the latter (Tomlinson, 
Rejzek et al. 2009). Both genetic and mutagenesis screens are expensive and time 
consuming, and are limited in scope due to their lack of temporal control. For 
example, mutations uncovered by genetic screens often reflect the first time and 
location a gene is necessary during development (Wheeler and Brandli 2009). Since 
the same biological pathways are frequently employed several times throughout 
development, this approach is not ideal for studying later morphological events 
(Davidson, Rast et al. 2002; Van Raay and Vetter 2004; Reya and Clevers 2005).  
The advantages of chemical genomics make this method particularly 
attractive to developmental biologists; it has largely been utilized in zebrafish 
(reviewed in (Rennekamp and Peterson 2015)), but has emerged as a useful tool in 
other organisms not amenable to classic genetic approaches such as chick and 
Xenopus (Tomlinson, Guan et al. 2009; Tomlinson, Rejzek et al. 2009). Of these, 
Xenopus is the highest vertebrate with free-living embryos, and is therefore ideal 
for such in-vivo chemical screens (Tomlinson, Field et al. 2005; Wheeler and Liu 
2012). In addition, Xenopus embryos are much larger than zebrafish but can still be 
arrayed in 48 or 96-well dishes, allowing for robust and statistically relevant assays 
(Wheeler and Liu 2012). Xenopus eggs are easily obtained in large quantities and 
chemical compounds readily diffuse across the Xenopus epithelium (Wheeler and 
Liu 2012). Indeed, several studies have been carried out in Xenopus using chemical 
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genomics, and these have uncovered candidate proteins involved in a variety of 
morphogenesis events such as melanophore development, lymphogenesis, 
angiogenesis, axis development, and metamorphosis (Adams and Levin 2006; Fini, 
Le Mevel et al. 2007; Kalin, Banziger-Tobler et al. 2009; Tomlinson, Guan et al. 
2009; Tomlinson, Rejzek et al. 2009). The Levin group has adapted a unique 
chemical genomics strategy in Xenopus that they describe as an “inverse drug 
screen” (Adams and Levin 2006). In this method, candidate targets for a process of 
interest are grouped into functional categories. Next, established, pharmacological 
inhibitors that broadly inhibit pathways in these categories are applied to Xenopus 
embryos. If a phenotype associated with the process of interest is observed, then 
subsequent assays are employed with inhibitors of increasing specificity to 
components of the pathway (Adams and Levin 2006). This is a useful way to 
identify individual proteins involved in a developmental process; however, it 
requires some prior knowledge as to the categories regulating the process of 
interest.  
In this chapter, I combine the forward chemical genomics approach with 
Levin’s inverse screen strategy to develop a non-biased approach to identify 
regulators of Xenopus orofacial development. First, I utilize a small molecule 
library to identify functional categories that induce orofacial defects. I then treat 
embryos with established inhibitors to pathways in these categories and fully 
characterize the orofacial and palatal defects that result. Finally, I investigate 
potential interactions between pathways uncovered in the screen with retinoic acid 
(RA) signaling to determine how RA-deficiency induces median clefts. This study 
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will not only provide insight into the factors driving orofacial specification and 
morphogenesis, but also aims to uncover novel proteins involved in orofacial 
defects, such as cleft palate.  
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METHODS 
 
 
 
1. ADULT XENOPUS LAEVIS 
Adult male and female Xenopus laevis were housed and cared for according 
to IACUC protocol as described in Chapter 1.  
2. TADPOLE COLLECTION AND CARE  
Eggs were collected and cultured using standard methods described in 
Chapters 1 and 2 (Sive, Granger et al. 2000). Prior to treatment, the vitelline 
membrane was mechanically removed using two pairs of sharpened forceps. 
3. PRIMARY CHEMICAL SCREEN 
An initial screen was performed using the National Cancer Institute (NCI) 
Cancer Diversity Set II small molecule library (NCI). Briefly, compounds were 
received distributed in 96-well plates labeled with the National Service Center 
(NSC) number of each compound. These NSC numbers serve as identifiers for all 
compounds submitted and tested at the NCI. Next, 5-6 embryos at stage 24 (26 hpf) 
were arrayed in 0.1X MBS and 1% DMSO in 24-well culture dishes. Each 
compound from the 96-well plates was then added to embryo media with the 
corresponding well in the 24-well plate for a final concentration of 30 µM. Embryos 
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were incubated at 23°C from stage 24 to stage 40 (26-67 hpf). Immediately 
following treatment, embryos were fixed in 4% PFA at 4°C overnight and then 
washed out with PBT 3 X 1 hour. Fixed embryos heads were dissected by making 
two incisions with a scalpel- the first was on the posterior side of the gut to release 
pressure from the scalpel and the second was on the anterior side of the gut, behind 
the heart to completely remove the head. Circular depressions were made in a clay-
lined dish filled with PBT using a glass pipette tool. Using two pairs of forceps, 
heads were positioned into these circular holes posterior side down, such that they 
were facing the camera and are not tilted backward or to either side.  These were 
then imaged and analyzed for orofacial defects using a Stemi 2000-C stereoscope 
(Zeiss) fitted with an AxioCamICC1 camera. 
4. PRIMARY SCREEN ANALYSIS  
NSC numbers of compounds that induced orofacial defects were identified.   
These numbers were used to determine IUPAC names on PubChem (NCI, 
pubchem.ncbi.nlm.nih.gov). Using PubChem’s bioassay database, the targets of 
these compounds were also identified. Using Excel, targets for each compound were 
organized by their function (Fig 3.1.1A). Components of the “cell signaling” 
category were further classified by pathway (Fig 3.1.1B).  
5. FOLLOW UP CHEMICAL TREATMENTS FOR SECONDARY  
Validated chemical inhibitors were identified for the four signaling pathways 
that were most highly represented by targets from compounds in the NCI library 
(Fig 3.1.1B, bold). Stock solutions were created in DMSO of PI3 kinase inhibitor 
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(LY294002, Fischer, cat. no: NC9642062, 50 mM), PDGFRα inhibitor (AG1296, 
Fisher, cat. no: 50-230-7882, 10 mM), Haloperidol (Sigma-Aldrich, cat. no: H1512 
5G,100 mM), INDY (Fischer, cat.no: 49-971-0R, 100 mM), and Trichostatin A 
(TSA, Sigma-Aldrich,cat. no: T8552, 50 mM).  
For further validation, 20 tadpoles retrieved from two different fertilization 
events (four mothers total) were exposed to each inhibitor from stage 24 (26 hpf) to 
stage 37 (53 hpf). Ten per well were incubated in 6-well culture dishes in a 4 mL 
volume of 0.1X MBS with each inhibitor in total of 1% DMSO 0.1X MBS. Controls 
were treated with 1% DMSO alone. At stage 37 (53 hpf), tadpoles were washed out 
and transferred to 15 mm petri dishes containing 0.1XMBS. At stage 43 (80 hpf) 
treated and control tadpoles were fixed overnight in 4% PFA at 4°C, then washed at 
least three times for 1 hour each in phosphate buffered saline with 0.1% Tween 
(PBT). 
6. ANALYSIS OF INTERCANTHAL DISTANCE IN TADPOLES 
Axiovision40 V.4.8.1.0 software (Zeiss) was used to measure intercanthal 
distance on frontal images of tadpole faces. The intercanthal distance was measured 
as the length between the medial edges of each eye. Student’s t-tests assuming 
unequal variance were used to determine statistical significance between treatment 
groups and their respective controls using Microsoft Excel. Data collected for the 
treatment groups were normalized to control samples. This allowed graphically 
comparisons of measurements. 
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7. GEOMETRIC MORPHOMETRICS 
Discrete landmarks of the orofacial region were established on tadpole faces. 
A total of 42 orofacial landmarks were placed on tadpole faces using the 
Pointpicker plugin of ImageJ (NIH). Landmarks 1-4 were placed along the midline 
of the face from the top of the eyes to the top of the cement gland. The next ten 
landmarks were placed to capture the shape of the eyes. Landmarks 18,19,22-25 
were placed along the periphery of the face. To capture the position of the eyes 
relative to the midline, landmarks 20 and 21 were placed in between the medial eye 
landmarks and the midline landmark. Finally, 16 landmarks were used to outline the 
mouth. Using MorphoJ, these landmarks were then assigned coordinates and aligned 
via Procrustes superimposition to eliminate information about size and orientation, 
as described in Chapters 1 and 2 (Klingenberg, Wetherill et al. 2010). Discriminant 
function analysis (DFA) was also performed using MorphoJ to statistically compare 
inhibitor treated embryos to controls. Significance was determined as p<0.05. 
8. ALCIAN BLUE STAINING 
Cartilages were stained using standard protocols with some modifications 
(W.R. Taylor 1985). Briefly, embryos were fixed overnight in Bouins fixative at 
4°C. After several washes in 70% Ethanol, embryos were incubated in Alcian blue 
stain (0.1 mg/ml Alcian Blue in 20% acetic acid in EtOH for 4 days at room 
temperature. Embryos were then washed in 1% HCL in 70% EtOH for 1-2 days, 
bleached with 3% H2O2, and cleared in a 2% potassium hydroxide and glycerol 
series. Facial cartilages were imaged in 100% glycerol. 
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9. ANTIBODY LABELING AND CONFOCAL MICROSCOPY 
 After embryos were fixed overnight at 4°C, they were washed in PBT 3X1 hr, 
embedded in 5% low melt agarose overnight at 4°C, and sectioned into 200 µm 
sections using a Leica VT100P vibratome. Sections were incubated in a 1:500 
solution of monoclonal e-cadherin primary antibody in PBT (DSHB, cat.no: 5D3). 
After a washout with PBT, sections were incubated in secondary antibody, a 1:1000 
solution of Alexa-flour 568 (Life Technologies, cat. no: A11004), overnight at 4°C. 
Following another PBT washout, Phalloidin (Invitrogen, cat.no: A12379) was added 
at a 1:40 concentration overnight at 4°C. Embryos were washed in PBT and imaged 
using a Nikon C1 confocal microscope. 
10. RAR INHIBITOR SYNERGY EXPERIMENTS 
 For synergy experiments, a 10 mM stock solution of BMS-453 was made in 
DMSO. Tadpoles from two different fertilization events were exposed to low 
concentrations of BMS-453 (50 nM), LY294002 (4 µM), AG1296 (10 µM), 
Haloperidol (5 µM), INDY (5 µM), or TSA (13 µM) in 1% DMSO and 0.1X MBS. 
Through a series of experiments testing a range of concentrations, I determined that 
even very low concentrations of the RAR inhibitor always elicited a median cleft 
when embryos were treated from stage 24 to stage 37 (26-53 hpf), but this was 
alleviated when the treatment was ended at stage 30 (35 hpf). I therefore treated 
embryos with a 50 nm concentration of the RAR inhibitor from stage 24 to stage 30 
(26-35 hpf) in combination with low concentrations of dopamine, Dyrk1a, PI3K, 
PDGFRα, or HDAC inhibitors from stage 24 to stage 37 (26-53 hpf). At stage 30 
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(35 hpf), embryos were washed out of each treatment. Dopamine, Dyrk1a, PI3K, 
PDGFRα, or HDAC inhibitors were added back to the media while the RAR 
inhibitor was not (Fig. 3.2.1) until stage 37 (53 hpf). They were then washed out as 
described above, cultured until stage 43 (87 hpf) and fixed in 4% PFA overnight at 
4°C.  After three washouts with PBT, tadpole faces were imaged and analyzed.  
11. ANALYSIS OF MOUTH ANGLE IN TADPOLES  
 Mouth angle of embryos in RAR synergy experiments was measured in 
ImageJ. This angle was taken as the angle at the center of the dorsal lip from either 
corner of the mouth. To determine overall significance, a one-way ANOVA was 
performed using the web-based platform, VassarStats (Lowry, Vassarstats.net). If 
the ANOVA P-value was less than the alpha value 0.01, a post-hoc Tukey HSD test 
was then performed for pairwise assessment of statistical significance. Alpha value 
for Tukey HSD test was 0.01. Means and standard deviations summarized in Table 
3.2.  
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RESULTS 
PART 1. 
 
 
 
A.1) LARGE-SCALE CHEMICAL SCREENING IDENTIFIES POTENTIAL REGULATORS 
OF OROFACIAL DEVELOPMENT IN XENOPUS EMBRYOS 
In an initial forward chemical genomics screen, two former students in our 
lab (Jeremy Thompson and Molly Allen) treated Xenopus embryos with small 
molecule compounds from the NCI Cancer Diversity Set II library during facial 
specification and early morphogenesis (Stage 24-40, 26- 66 hpf). After treatment, 
embryos were fixed, analyzed for defects, and catalogued based on type and 
severity of the defects. All of these images are available on the Dickinson lab 
public wikispaces page for reference (https://dickinsonlab.wikispaces.com), but 
here I address only those with orofacial defects.  
   Of the over 1400 compounds from the NCI library, approximately 40 
compounds induced triangular mouth shapes consistent with median clefting in 
Xenopus embryos. NCBI Pubchem was then used to identify the IUPAC name of 
each compound and any known biological targets based on a database of bioactivity 
assays. Fifteen compounds did not show activity in any bioassay and were excluded 
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from further analysis. Targets of the remaining 25 compounds were manually 
classified into functional categories such as cell cycle/growth, post-translational 
modifications, DNA repair, apoptosis, stress response, endocrine response, ion 
channels, cellular metabolism, and mRNA processing (Fig 3.3.1A). The largest of 
these categories included components of key developmental signaling pathways 
(Fig 3.3.1B). The top five pathways in this list (Fig 3.3.1B, bold) were the most 
highly represented among the biological targets of the NCI library compounds.  I 
next validated these five pathways in an approach similar to the “inverse drug 
screen” technique, in which I identified commercially validated inhibitors that have 
been shown to specifically target these pathways. I began by treating Xenopus 
embryos with a range of concentrations for each inhibitor during a window of 
orofacial development just prior to palatogenesis, in which the neural crest is 
migrating and differentiating in the facial prominences (Table 3.1; stage 24 to 37, 
26-53 hpf). Controls were cultured in 1% DMSO in 0.1X MBS alone. After 
treatment, embryos were washed out and allowed to develop to stage 43 (87 hpf) for 
fixation and assessment. Concentrations of each inhibitor that induced an orofacial 
phenotype, but did not kill the embryos were then chosen for subsequent analyses 
(Table 3.1 bold). The experimental paradigm described above was then repeated, 
and embryos were fixed at stage 43 (87 hpf) or stage 46 (98 hpf) for morphological, 
quantitative, immunohistochemical, or histological analyses. While I treated 
embryos with the ideal concentration of inhibitors for multiple experiments (Table 
3.1), here I quantify the effects of each one on Xenopus orofacial morphology from 
two experiments that were performed at the same time, from four different mothers, 
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to ensure consistent results. Orofacial phenotypes from all inhibitor treatments are 
summarized in Table 3.8.     
B.1) INHIBITION OF DOPAMINE RECEPTORS INDUCES CHANGES IN OROFACIAL 
MORPHOLOGY 
 Dopamine receptor type 2 (D2) was one of the most common targets of 
compounds from the NCI library that induced orofacial defects. Dopamine belongs 
to the catecholamine family of neurotransmitters; its signaling is critical for several 
neural processes such as motor function, endocrine modulation, and cognitive 
behavior (Prakash and Wurst 2006; Bromberg-Martin, Matsumoto et al. 2010). 
There is no evidence that dopamine signaling directly regulates facial development 
in any vertebrate system. I therefore began my investigation into the effects of 
decreased dopamine signaling during Xenopus orofacial development by treating 
embryos with Haloperidol following the experimental paradigm outlined above. 
This pharmacological agent is used to stabilize overactive dopamine signaling in 
patients with psychosis by antagonizing D2 –like receptors and subsequently 
prevents dopamine ligand binding; particularly the D2 receptor itself at high 
affinity (Katzung 2001).  
B.1.1) QUALITATIVE AND QUANTITATIVE DESCRIPTION OF THE OROFACIAL REGION IN 
HALOPERIDOL TREATED EMBRYOS 
Xenopus embryos treated with a 50 µM Haloperidol during orofacial 
development displayed several severe facial malformations by early tadpole stages 
(Stage 43, 87 hpf,). These embryos exhibited eye anomalies, embryonic mouth 
malformation, head edema, and midface hypoplasia (Fig. 3.1.2A-D; 2 experiments, 
n= 20). Control embryos developed normally (Fig. 3.1.2A,B).  
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Haloperidol treated embryos had a significantly narrower face than controls, 
as captured by a 1.12-fold decrease in intercanthal distance from controls (Fig. 
3.1.2E; t-test, p < 0.0001). To ascertain changes in facial shape upon dopamine 
inhibition, I utilized geometric morphometric analysis on faces at stage 43 (87 hpf). 
Discriminant function analysis (DFA) was performed to distinguish shape changes 
in the orofacial region of inhibitor treated embryos compared to controls. DFA 
describes the variation between groups of a sample set relative to the variance 
within each group (Darlington 1973). By categorizing samples into discrete groups 
a priori, DFA reduces the within-group variance and thereby maximizes differences 
between them. DFA of Procrustes landmarks in Haloperidol treated embryos and 
controls showed that the facial shape generated by decreased dopamine signaling 
was significantly different than the shape seen in controls (Procrustes distance= 
0.4053, p-value < 0.0001). These differences were best illustrated when DFA results 
were superimposed as vectors onto a transformation grid, in which the flat end of 
the vector represented the average landmark position in control embryos and the 
closed circle end represented the average position of that same landmark in the 
inhibitor treated embryos. In this way, shifts in landmark position and the 
subsequent warping of the grid show regions of significant changes in shape. The 
most dramatic shifts in landmark position occurred at the periphery of the midface, 
as well as the regions directly surrounding the eyes (Fig. 3.1.2F). Additional 
warping of the grid dorsal and lateral to the mouth shows shape changes associated 
with the midface hypoplasia seen in dopamine receptor inhibited embryos. Shifts in 
mouth landmark position reflect that the mouth shape in inhibitor treated embryos 
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was more square and narrow compared to the broad, flat shape of control mouths 
(Fig. 3.1.2F).  
B.1.2) PALATE MORPHOLOGY AND INTERNAL FACIAL STRUCTURES 
 To examine palate morphology in dopamine receptor inhibited embryos and 
controls, transverse sections were taken through the midface of stage 43 (87 hpf) 
embryos. A marker for e-cadherin was used to label the oral epithelium, and a 
marker for F-actin was used to visualize internal structures like the facial 
musculature (3 experiments, n= 15). In control embryos, the ventral edge of the 
brain was clearly separated from the dorsal edge of the oral cavity by a layer of 
cells, comprising the tissue of the primary palate (Fig. 3.1.2G). In addition, the jaw 
muscles could clearly be seen as organized actin bundles lateral to the oral cavity 
(Fig. 3.1.2G, green). Embryos with depleted dopamine signaling however, showed a 
reduction in the size of ventral facial muscles as well as the tissues lateral to the 
mouth opening (Fig. 3.1.2H). The amount of tissue that will contribute to the 
primary palate appeared similar to controls (Fig. 3.1.2G,H). This suggests that 
while dopamine inhibition clearly alters facial morphology, it does not appear to 
greatly influence the formation of the palatal tissue at the level examined.  
B.1.3) DEVELOPMENT OF FACIAL CARTILAGES 
Facial cartilages further support the structure and shape of the embryonic 
face. To investigate whether malformation of cartilages correlated to the shape 
changes in inhibitor treated embryos, I next performed Alcian Blue staining on 
stage 45 (98 hpf) embryos (2 experiments, n= 30). In controls, the anterior most 
infrarostral (ir) cartilage can be seen to articulate with the paired Meckel’s (mk) 
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cartilages on the lower jaw (Fig. 3.1.2Ii-iii). The ethmoid plate (eth) and paired 
palatoquadrates (pa) that support the palate and upper jaw can also be seen just 
dorsal to the Meckel’s and infrarostrals (Fig. 3.1.2ii,iii). Control embryos also 
showed normal development of the floor of the mouth, which is characterized by a 
separation of the paired cerathoyal (ch) cartilages by the basihyal (bh) cartilage at 
the midline (Fig. 3.1.2Ii, iv). Finally, all four pairs of gill cartilages (ba) developed 
normally in control embryos. In embryos in which dopamine signaling had been 
inhibited, several facial cartilages were malformed and reduced in size (Fig. 
3.1.2Iv-viii). The size of both palate-supporting cartilages, the palatoquadrates and 
ethmoid plate, were smaller than controls (Fig. 3.1.2Ii-iii, v-vii). The Meckel’s 
cartilages on the lower jaw were also decreased in size and the infrarostrals could 
not be seen (Fig. 3.1.2Iii, iii, vi, vii). The basihyal and cerathoyal cartilages on the 
ventral side of the face appeared intact in these embryos; however, both structures 
were slightly diminished compared to controls (Fig. 3.1.2Ii, ii, iv, v, vii). The gill 
cartilages of Haloperidol treated embryos also appeared much smaller than those 
seen in controls (Fig. 3.1.2Ivii). Taken together, these data suggest a role of 
dopamine signaling during facial development.  
C.1) INHIBITION OF DYRK1A SIGNALING INDUCES SEVERE MALFORMATIONS OF 
THE FACE AND PALATE 
Dual specific tyrosine kinase type 1A (Dyrk1a) was another one of the most 
prevalent targets of the compounds in the NCI library inducing a triangular shaped 
mouth opening. As the name implies, DYRKs have dual substrate specificities: 
autophosphorylation of a tyrosine residue within their own catalytic domain as well 
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as the serine/threonine residues of target proteins (Becker and Joost 1999). DYRKs 
play a key role in enhancing activity of transcription factors necessary for several 
cellular processes such as proliferation and survival (Dierssen and de Lagran 2006). 
Therefore, I utilized a competitive ATP inhibitor of Dyrk1a, INDY (Ogawa, Nonaka 
et al. 2010), to investigate whether decreased Dyrk1a signaling during orofacial 
development would lead to an orofacial or palate defect.  
C.1.1) QUALITATIVE AND QUANTITATIVE DESCRIPTION OF THE OROFACIAL REGION IN 
INDY TREATED EMBRYOS 
Examination of stage 43 (87 hpf) embryos treated with 25 µM INDY during 
early facial development (stage 24-37, 26-53 hpf) showed severe facial 
malformations compared to controls (1% DMSO), which developed normally (Fig. 
3.1.3A-D; 2 experiments, n= 20). These defects included midface hypoplasia, eye 
abnormalities, extreme facial narrowing, and a misshapen mouth (Fig. 3.1.3C,D). 
A 1.44-fold decrease of the intercanthal distance in Dyrk1a deficient embryos 
relative to controls was observed (Fig. 3.1.3E; t-test, p = 1.513E-28). DFA of facial 
landmarks showed that Dyrk1a inhibition generated a significantly different 
orofacial shape compared to control embryos (Procrustes distance = 0.4762, p < 
0.0001).  As seen by superimposition of these results on a transformation grid, there 
was a shift in position of all landmarks that corresponded to the narrowing of the 
entire face (Fig. 3.1.3F). In addition, warping of the grid was seen in the region 
directly dorsal to the mouth opening and reflects the extreme midface hypoplasia of 
INDY treated embryos (Fig. 3.1.3F). Mouth landmarks also showed relative 
changes in position that reflected a more round mouth shape in Dyrk1a inhibitor 
treated embryos compared to controls (Fig. 3.1.3F).  
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C.1.2) PALATE MORPHOLOGY AND INTERNAL FACIAL STRUCTURES 
Transverse sections through the midface of stage 43 (87 hpf) embryos showed 
a loss of palatal tissue when Dyrk1a activity was reduced, as indicated by direct 
contact between the oral epithelium and the forebrain at the level assessed in these 
embryos (Fig. 3.1.3H; 3 experiments, n = 15). Dyrk1a inhibitor treated facial 
muscles were reduced in size and misshapen compared to controls (Fig. 3.1.3G,H). 
Control palate morphology appeared normal (Fig. 3.1.3G).  
C.1.3) DEVELOPMENT OF FACIAL CARTILAGES 
Alcian Blue staining of stage 45 (98 hpf) embryos showed that Dyrk1a 
inhibition resulted in almost a complete loss of all facial cartilages, while controls 
developed normally (Fig. 3.1.3I; 2 experiments, n= 30). None of the first 
pharangeal arch derived cartilages (infrarostrals (ir), Meckel’s (Mk), palatoquadrate 
(pq), ethmoid plate (eth)) formed when Dyrk1a signaling was inhibited (Fig. 
3.1.3Iv-viii). Only the cerathoyal cartilages formed on the floor of the mouth, and 
these were misshapen and smaller in size compared to controls (Fig. 3.1.3Ii, ii, v, 
vi). Dyrk1a inhibition also severely diminished development of the gill cartilages 
(ba; Fig. 3.1.3Iiv, viii). These results clearly demonstrate a role of Dyrk1a 
signaling in facial and palate development.   
D.1) INHIBITION OF PI3K SIGNALING INDUCES DEFECTS IN THE FACE AND 
PALATE 
Phosphoinositide 3-kinase (PI3K) is a membrane-associated enzyme 
responsible primarily for the conversion of PIP2 to PIP3, which is necessary for 
recruitment, phosphorylation, and activation of AKT (Vanhaesebroeck, Stephens et 
al. 2012). PI3K-mediated AKT activation is necessary for numerous cellular events 
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such as migration, proliferation, and survival (Hare, Schwarz et al. 2015). PI3K was 
one of the most prevalent targets of compounds used in the initial screen. To further 
test whether PI3K/AKT signaling has a role in orofacial development, I treated 
embryos with the well-established PI3K inhibitor, Ly2940002, following the 
experimental paradigm described above. This small molecule inhibitor has been 
used in an array of studies to specifically diminish enzymatic activity of PI3K both 
in-vitro and in-vivo (Gupta, Cerniglia et al. 2003; Bradham, Miranda et al. 2004; 
Mei, Li et al. 2009; Ueno, Ueno et al. 2011; Lee, Lee et al. 2014).  
D.1.1) QUALITATIVE AND QUANTITATIVE DESCRIPTION OF THE OROFACIAL REGION IN 
LY294002 TREATED EMBRYOS 
Embryos treated with 19 µM PI3K inhibitor during orofacial development 
showed a variety of facial defects such as midface hypoplasia, eye anomalies, a 
misshapen mouth, and lack of snout extension, compared to controls (Fig. 3.1.4), 
Control embryos, on the hand, developed normally (Fig. 3.1.4A,B; 2 experiments, 
n= 20).  
Further, the intercanthal distance was reduced significantly in PI3K-inhibitor 
treated embryos (0.97-fold decrease; Fig. 3.1.4E; p = 7.140E-10). DFA of face 
landmarks showed a significant difference in the shape generated by reduced PI3K 
signaling compared to the control (Procrustes distance = 0.3036; p < 0.0001). When 
these results were superimposed onto a transformation grid, dramatic shifts in 
position of landmarks along the periphery of the face corresponded to facial 
narrowing (Fig. 3.1.4F). Moreover, warping of the transformation grid in the 
midface and just around the mouth correlates with the midface hypoplasia of PI3K 
deficient embryos (Fig. 3.1.4F). Shifts in the position of mouth landmarks reflected 
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a more triangular shaped mouth in these embryos compared to controls (Fig. 
3.1.4F). 
D.1.2) PALATE MORPHOLOGY AND INTERNAL FACIAL STRUCTURES 
 The triangular shaped mouth seen in PI3K inhibitor treated embryos 
suggested a possible cleft in the primary palate. To assess this, I examined 
transverse sections through the midface at stage 43 (87 hpf) labeled for actin and e-
cadherin (3 experiments, n= 15). The malformation of the mouth did indeed extend 
through the primary palate as a higher arch (Fig. 3.1.4H). In addition, inhibitor 
treated embryos had an apparent reduction in the amount of tissue separating the 
oral epithelium from the ventral base of the forebrain (Fig. 3.1.4G,H). Inhibitor 
treated embryos also exhibited reduction in the size of the orofacial muscles at the 
level examined (Fig. 3.1.4HF).   
D.1.3) DEVELOPMENT OF FACIAL CARTILAGES 
 Alcian Blue staining of stage 45 (98 hpf) embryos showed that while controls 
exhibited normal development of jaw and palate cartilages, all PI3K inhibitor-
treated embryos had cartilage structures that were reduced in size (Fig. 3.1.4I; 2 
experiments, n= 30). While the Meckel’s (Mk) cartilages remained intact on the 
lower jaw, the angle at which they articulated with the reduced infrarostral (ir) was 
narrower compared to controls (Fig. 3.1.4Iiii, iv, vii, viii). Further, the ethmoid 
plate (eth) of the palate supporting cartilages appeared extremely reduced in 
inhibitor treated embryos; however the laterally located palatoquadrates (pq) 
appeared mostly normal (Fig. 3.1.4Ivi, vii). Taken together, these data suggest that 
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PI3K signaling is important in the development of the primary plate, particularly at 
the midline of the face.  
E.1) DECREASED PDGFR SIGNALING RESULTS OROFACIAL ANOMALIES  
 Platelet derived growth factor (PDGF) signaling plays a key role in cell 
processes such as migration, proliferation, and survival (McCarthy, Wetherill et al. 
2013). Binding of the PDGFA ligand to one of its receptor tyrosine kinases, 
PDGFRα, initiates both the Ras/MEK/ERK and PI3K pathways (He and Soriano 
2013; Fantauzzo and Soriano 2014). Several components of PDGFA signaling were 
identified as a result of the primary screen. I therefore utilized the well-established 
inhibitor, AG1296, which preferentially inhibits PDGFRα receptor tyrosine kinase 
activity (Kovalenko, Ronnstrand et al. 1997).  
E.1.1) QUALITATIVE AND QUANTITATIVE DESCRIPTION OF THE OROFACIAL REGION IN 
AG1296 TREATED EMBRYOS 
Embryos treated with 100µM AG1296 exhibited reduced snout extension, a 
slight median cleft on the dorsal edge of the mouth and a prominent median cleft on 
the ventral edge (Fig. 3.1.5A-D; 2 experiments, n= 20).  
Measurement of intercanthal distance revealed a significant decrease in 
midface size of inhibitor treated embryos (Fig. 3.1.5E; 0.20-fold decrease; p = 
0.0007). DFA of mouth landmarks showed that the shape of this region was highly 
significantly different (Procrustes distance = 0.1892, p < 0.0001). The 
transformation grid of DFA results showed that the largest shifts in landmark 
position occurred primarily on the ventral side of the face and these were 
accompanied by warping in the regions lateral to the mouth (Fig. 3.1.5F). There 
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was some additional warping just dorsal to the mouth, although not as dramatic. 
Mouth landmarks also showed changes in position that corresponded to both the 
dorsal and ventral median clefts (Fig. 3.1.5F). These suggest that the majority of 
shape changes induced by PDGFR inhibition occur specifically in the region around 
the mouth. 
E.1.2) PALATE MORPHOLOGY AND INTERNAL FACIAL STRUCTURES 
 Transverse sections through the midface of stage 43 embryos (87 hpf) that 
had been fluorescently labeled for actin and e-cadherin showed that the ventral 
median cleft extended caudally through the head of inhibitor treated embryos. The 
dorsal cleft also extended through the palate, but appeared more broad than the 
triangular shape seen at the surface of the face (Fig. 3.1.5H; 3 experiments, n= 15). 
The dorsal epithelium of the oral cavity was directly juxtaposed with the forebrain 
at the level examined, indicating a loss of proper development of future palatal 
tissue in embryos with reduced PDGFR signaling (Fig. 3.1.5G,H). The orofacial 
muscles in inhibitor treated embryos appear mostly normal; however, they were 
smaller and positioned closer to the mouth opening (Fig. 3.1.5G,H).  
E.1.3) DEVELOPMENT OF FACIAL CARTILAGES 
Alcian Blue staining of stage 45 (98 hpf) embryos showed that PDGFR 
inhibition induced a complete loss of the palate and upper jaw supporting ethmoid 
plate (eth) and palatoquadrate (pq) cartilages (Fig. 3.1.5Iv, vi; 2 experiments, n= 
30). On the lower jaw, Meckel’s (Mk) cartilages were extremely reduced in size and 
misshapen compared to controls, which developed normally (Fig. 3.1.5Iii, vi). 
There was a loss of the basihyal (bh) cartilage, but not the cerathoyal (ch) cartilages 
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on the ventral side of the face. The absence of this median-most cartilage could 
partially contribute to the ventral facial cleft seen in inhibitor treated embryos.  
F.1) BROAD SPECTRUM INHIBITION OF HDACS INDUCES A MEDIAN CLEFT 
One of the key factors in gene expression regulation by transcription factors 
is the chromatin structure of genes (de Ruijter, van Gennip et al. 2003). 
Modification of this structure is extremely complex and dynamic, and is regulated 
by a number of epigenetic regulators (Hendrich and Bickmore 2001). The histone 
deacetylases belong to one superfamily of such regulators. These proteins target 
histone tails to remove acetyl groups that typically allow the chromatin to exist in 
an open conformation (Wade 2001). Thus, deacetylation is classically associated 
with transcriptional repression (Forsberg and Bresnick 2001). There are several 
classes of vertebrate deacetylases that include both sirtuins and HDACs (de Ruijter, 
van Gennip et al. 2003). These enzymes can work independently or together as part 
of a complex to condense the chromatin of genes in various tissues to silence 
transcription (de Ruijter, van Gennip et al. 2003; Michan and Sinclair 2007). 
Several compounds from the NCI library targeted sirtuins and histone residues 
associated with acetylation. Thus, I used the canonical HDAC inhibitor, 
Trichostatin A (TSA), to broadly inhibit Class I and II deacetylase activity during 
Xenopus facial development.  
F.1.1) QUALITATIVE AND QUANTIATIVE DESCRIPTION OF THE OROFACIAL REGION IN TSA 
TREATED EMBRYOS 
HDAC inhibition via treatment with 48 µM TSA during orofacial 
development induced severe abnormalities in the Xenopus face (2 experiments, n= 
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20). In addition to an overall decrease in size, TSA treated embryos also exhibited 
eye malformation, midface narrowing and hypoplasia, brain edema, and a 
prominent, median facial cleft (Fig. 3.1.6C,D). Control embryos developed 
normally (Fig. 3.1.6A,B).  
Embryos treated with the HDAC inhibitor exhibited a decrease in midface 
size and this was found to be significant (0.826-fold decrease of the intercanthal 
distance; Fig. 3.1.6E; t-test, p = 1.570E-24).  
DFA of facial landmarks showed the orofacial shape generated by HDAC 
inhibition was also significantly different than controls (Procrustes distance = 
0.3074, p < 0.0001). When DFA results were superimposed onto a transformation 
grid, the most drastic shifts in landmark position were seen around the periphery of 
the face. This reflects the overall narrowing of the face under HDAC deficient 
conditions. Subsequent warping of the grid around the mouth opening further 
corresponds with this narrowing, as well as the midface hypoplasia seen in these 
embryos. Finally, shifts in mouth landmark position are consistent with the median 
cleft induced by HDAC inhibition.  
F.1.2) PALATE MORPHOLOGY AND INTERNAL FACIAL STRUCTURES 
 The median clefts observed in TSA-treated embryos were found to extend 
into the early primary palate via transverse sections through the midface of stage 43 
(87 hpf) embryos (Fig. 3.1.6H; 2 experiments, n= 10). In addition, the tissue of the 
primary palate in inhibitor treated embryos was reduced compared to their control 
counterparts at the level examined (Fig. 3.1.6G,H). These embryos also showed a 
loss of orofacial muscles and swelling in the forebrain (Fig. 3.1.6H).  
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F.1.3) DEVELOPMENT OF FACIAL CARTILAGES 
Alcian Blue staining of stage 45 (98hpf) embryos revealed severe reduction 
of the facial cartilages in inhibitor treated embryos compared to controls, which 
developed normally (Fig. 3.1.6I, 2 experiments, n= 30). On the lower jaw, only 
remnants of the Meckel’s (Mk) cartilages remained while the infrarostrals (ir) were 
not seen (Fig. 3.1.6Ivi-viii). The ethmoid plate (eth) also appeared to be absent 
from the palatal cartilages, while the remaining palatoquadrates (pq) were 
extremely small and misshapen (Fig. 3.1.6Iv-viii). The two ventral most cartilages, 
the cerathoyal (ch) and basihyal (bh) structures, were both present in inhibitor 
treated embryos; however, they were severely reduced in size (Fig. 3.1.6Ivii, viii). 
The gill cartilages (ba) appeared not to have formed in inhibitor treated embryos 
(Fig. 3.1.6Iviii). These data suggest a prominent role of HDAC signaling in the 
developing face, particularly in the palate and upper jaws.  
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PART 2. 
 
 
 
A.2) RETINOIC ACID SIGNALING MAY INTERACT WITH PATHWAYS IDENTIFIED IN 
NCI LIBRARY SCREEN 
Retinoic acid (RA) signaling is known to regulate a variety of processes 
during development, including facial formation (Rhinn and Dolle 2012; Okano, 
Udagawa et al. 2014). We have previously established that perturbation of this 
pathway induces a variety of orofacial defects in Xenopus that are accompanied by 
significant changes in facial dimensions and midface shape (Chapter 2; (Kennedy 
and Dickinson 2014; Kennedy and Dickinson 2014; Tahir, Kennedy et al. 2014). 
Specifically, we found that inhibition of the retinoic acid receptor gamma 
consistently induces a median facial cleft (Kennedy and Dickinson 2012). I was 
next interested in whether retinoic acid signaling might interact with the pathways 
uncovered by my secondary screen described in Part 1.  
We have previously established that application of BMS-453, a retinoic acid 
receptor (RAR) inhibitor, to Xenopus embryos from stage 24-30 (26-35 hpf) induced 
median clefts (Kennedy and Dickinson 2012). I next tested whether I could induce 
this same phenotype with concurrent application of a sub-optimal concentration of 
BMS-453 and each of the inhibitors described. To do this, I treated embryos with a 
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range of low concentrations of RAR, dopamine, Dyrk1a, PI3K, PDGFRα, or HDAC 
inhibitors to establish a dose that would not elicit any phenotype in the primary 
palate. Treatment with any of these low doses alone did not elicit a cleft or other 
obvious orofacial defects. In this way, combination of low doses of these inhibitors 
with a low dose of the RAR inhibitor should induce a similar cleft phenotype to that 
seen in embryos treated with high levels of RAR inhibitor, if RA signaling interacts 
with the pathways targeted by each inhibitor. Here I quantify the results from two 
different experiments carried out simultaneously, and these are summarized in 
Table 3.8. 
To capture mouth shape changes consistent with a median cleft, I measured 
the mouth angle, which was taken as the angle at the middle of the dorsal edge of 
the mouth from either corner. In this way, mouth angle is much more acute when a 
dorsal median cleft is present. To determine overall statistical significance among 
the four treatment groups (controls; embryos treated with a low concentration of 
RAR inhibitor; embryos treated with a low concentration from dopamine, Dyrk1a, 
PI3K, PDGFRα, or HDAC inhibitors; and embryos treated with a combination), I 
first performed a one-way ANOVA on mouth angle measurements. If ANOVA 
results were significant with an alpha value less than 0.01, I then performed a 
Tukey’s HSD post-hoc test to determine which groups accounted for this difference. 
Alpha value for this test was also 0.01. Means and standard deviations of all 
treatments are summarized in Table 3.2.    
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B.2) LOW DOSES OF DOPAMINE RECEPTOR AND RA RECEPTOR INHIBITORS DO 
NOT SYNERGIZE 
 Interaction between dopamine and retinoic acid during orofacial development 
has not been previously investigated; however our lab determined that dopamine 
receptors, D1 and D2, were down-regulated in response to reduced RA signaling. 
Treatment of embryos with the dopamine D2 receptor antagonist, Haloperidol, 
induced midface hypoplasia, decreased intercanthal distance, and eye anomalies 
similar to the defects seen in embryos treated with a high concentration of RAR 
inhibitor (Fig. 2.1.1C,C’, Fig. 3.1.2C,D). Comparison of the morphometric analyses 
between Haloperidol treated embryos versus controls and RAR inhibitor treated 
embryos versus controls also shows similar changes in midface for shapes. Both 
DFA transformation grids show similar shifts in the position of landmarks 
surrounding the eyes, which is reflective of the narrowing of the face in this region 
(Fig. 2.1.4E and Fig. 3.1.2F). Therefore, I hypothesized that low dose of dopamine 
and RA inhibitors may synergize. To test this, I treated embryos with low doses of 
either RAR inhibitor (50 nm) or dopamine inhibitor (5 µM) alone. Neither treatment 
produced an obvious orofacial phenotype, and embryos resembled controls (Fig. 
3.2.2A-C). Similarly, combination of both inhibitors also did not result in a median 
cleft or defect in any of the embryos, excluding one embryo that died during 
treatment (Fig. 3.2.2D; 2 experiments, n= 20). This was likely due to developmental 
defect, rather than the treatment itself.  
 I next analyzed embryos by measuring the mouth angle to capture shape 
changes occurring along the dorsal edge of the mouth. One-way ANOVA resulted in 
no significant difference in means among controls, embryos treated with a low 
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concentration of RAR inhibitor, embryos treated with a low concentration of 
Haloperidol, or embryos treated with both together (F(3,61) = 0.53, p = 0.663; 
Table 3.3, Fig. 3.2.2E). While the high concentration of dopamine inhibitor 
induced a variety of orofacial defects (Fig. 3.1.2C,D), it appears to do so through a 
different mechanism than interacting with the retinoic acid signaling pathway.  
C.2) COMBINATION OF DYRK1A INHIBITION AND RA DEFICIENCY INDUCES  
MEDIAN CLEFTS 
  Dyrk1a has also not previously been described to interact with RA signaling; 
however, treatment with a high concentration of the Dyrk1a inhibitor, INDY, 
induced a loss of palatal tissue similar to the effects of high RAR inhibitor 
treatment (Fig. 3.1.3H; Kennedy and Dickinson 2012). Further, the shape changes 
INDY treatment induced in the midface and mouth were strikingly similar to those 
seen in embryos with genetically reduced RA signaling activity. Comparison of 
transformation grids generated by DFA of INDY treated embryos and RALDH MO 
versus their respective controls show changes in landmark positions consistent with 
facial narrowing (Fig. 2.1.4E, Fig. 3.1.3F). The mouth landmarks also show similar 
landmark position changes in both transformation grids that reflect a more oblong, 
narrow mouth shape upon treatment (Fig. 2.1.4E,F, Fig. 3.1.3F). As a result, I 
hypothesized that Dyrk1a signaling interacts with RA signaling in the developing 
palate and that combined inhibition of these two pathways would result in a median 
cleft. To test this, I treated embryos with both inhibitors following the paradigm 
described above (2 experiments, n = 20). While low concentrations of either RAR 
(50 nm) or Dyrk1a (5 µM) inhibitor did not induce an obvious orofacial defect, 
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combination of both produced a median facial cleft in 56% of embryos (Fig. 
3.2.3A-D). Two embryos treated with both inhibitors together had defects so severe 
that they did not survive the entire treatment and could not be analyzed further.  
Mouth angle was statistically significantly different among the four treatment 
groups as determined by one-way ANOVA (F(3,65) = 63.8, p < 0.0001; Table 3.4, 
Fig. 3.2.3E). The results from the Tukey HSD post-hoc test showed that the mean 
of embryos treated with both inhibitors together was statistically significantly 
different from controls, embryos treated with a low dose of RAR inhibitor alone, 
and embryos treated with a low dose of INDY alone (p-vals < 0.01). The means of 
embryos treated with either inhibitor alone were not statistically significantly 
different from each other, nor were they statistically significantly different from 
controls. These results indicate that it is likely that the median cleft seen in 
embryos treated with both inhibitors reflects a combined effect of both decreased 
RA signaling and Dyrk1a signaling.  
D.2) EMBRYOS TREATED WITH LOW DOSES OF BOTH PI3K AND RAR INHIBITORS 
EXHIBIT MEDIAN FACIAL CLEFTS 
 PI3kinase signaling has been shown to regulate palate development, and there 
is evidence that it interacts with retinoic acid signaling in cellular differentiation 
(Bertagnolo, Neri et al. 1999; Bastien, Plassat et al. 2006; Cho, Cho et al. 2008; 
Lee, Lee et al. 2014). Embryos treated with a high concentration of PI3K inhibitor 
showed a triangular shaped mouth and loss of palatal tissue similar to treatment 
with a high concentration of RAR inhibitor (Fig. 2.1.1C,C’, Fig. 3.1.4C,D; 
Kennedy and Dickinson 2012). Comparison of morphometric analyses further 
  114 
demonstrates the similarities in these phenotypes. The DFA transformation grid 
generated by comparing PI3K inhibitor treated embryos to controls showed warping 
in the regions lateral to the mouth, similar to warping seen in transformation grids 
comparing RAR inhibitor treated embryos and controls. Further, transformation 
grids from both of these analyses showed shifts in mouth landmark position 
consistent with a median cleft (Fig. 2.1.4E,F, Fig. 3.1.4F). As a result, I 
hypothesized that combined inhibition of PI3K and RA signaling would induce a 
median cleft. To test this, I treated embryos with low concentrations of both the 
PI3K (4 µM) and RAR (50 nm) inhibitors such that either inhibitor alone did not 
induce an apparent orofacial defect (Fig. 3.2.4A-C). In combination, however, 70% 
of embryos presented with a drastic median facial cleft (Fig. 3.2.4D). These 
embryos also exhibited other facial anomalies such as a narrow midface and eye 
defects (Fig. 3.2.4C,D; 2 experiments, n=15).  
One-way ANOVA of all four treatment groups determined an overall 
statistically significant difference in mean mouth angle (F(3,55) = 72.16, p < 
0.0001; Table 3.5, Fig. 3.2.4E). Tukey HSD post-hoc analysis revealed that this 
difference was due to statistically significant mouth angles between embryos treated 
with both inhibitors together and the other three groups (p < 0.01). Embryos treated 
with a low dose of either inhibitor alone, however, were not statistically different 
from each other or controls.  
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E.2) COMBINED TREATMENT WITH LOW DOSES OF PDGFRα AND RAR INHIBITORS 
RESULTS IN SYNERGY 
 PDGF signaling has been previously shown to be important in palate 
development (He and Soriano 2013; McCarthy, Wetherill et al. 2013). However, a 
relationship between signaling initiated by PDGFRα and retinoic acid signaling has 
not been established. I observed that inhibition of this receptor during orofacial 
development produced a median cleft in Xenopus embryos similar to the effects of 
decreased retinoic acid (Fig. 2.1.1C,C’, Fig. 3.1.5C,D). In addition, the 
transformation grid generated by DFA of PDGFR inhibitor treated embryos versus 
controls was similar to that generated by DFA of RAR inhibitor treated embryos 
versus controls. In both analyses, shifts in peripheral landmark position reflected an 
overall narrowing of the face and warping of the grid dorsal to the mouth reflected 
midface hypoplasia (Fig. 2.1.4E,F, Fig. 3.1.5F). Therefore, I tested whether 
treating embryos with this inhibitor at the same time as RAR inhibition would 
recapitulate a similar phenotype. To test this, I combined a 10 µM concentration of 
PDGFα inhibitor with 50 nM RAR inhibitor (2 experiments, n= 20). Here again, 
two embryos treated with both inhibitors together had extremely severe defects and 
did not survive for further analysis. Controls and embryos treated with the RAR 
inhibitor exhibited no orofacial defects, and embryos treated with the low 
concentration of PDGFR inhibitor exhibited a very minor defect on the ventral 
mouth edge (Fig. 3.2.5A-C). Combination of inhibitors results in 61% of treated 
embryos with a severe cleft on the dorsal edge of the mouth, and a minor median 
cleft on the ventral (Fig. 3.2.5D).  
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An overall statistically significant difference was determined by one-way 
ANOVA of mean mouth angle across the four treatment groups (F(3,66) = 107.74, p 
< 0.0001; Table 3.6, Fig. 3.2.5E). Tukey HSD post-hoc analysis revealed that the 
difference between the means of embryos treated with both inhibitors together were 
statistically significantly different from controls, embryos treated with a low dose 
of RAR inhibitor alone, and embryos treated with a low dose of PDGFR inhibitor 
alone (p-vals < 0.01). However, the means of embryos treated with either inhibitor 
alone and controls were not statistically significantly different from each other. 
This suggests that the dorsal median cleft seen in embryos treated with both 
inhibitors together may be due to a combined effect of decreased RA and PDGF 
signaling in the orofacial region.  
F.2) LOW AMOUNTS OF HDAC AND RAR INHIBITORS SYNERGIZE TO PRODUCE A 
MEDIAN CLEFT  
Retinoic acid receptors have been postulated to recruit HDAC complexes to 
repress transcription in the absence of the retinoic acid ligand (Kishimoto, Fujiki et 
al. 2006). When embryos were treated with TSA to inhibit HDAC signaling during 
orofacial development, they developed a severe median cleft that extended into the 
palate. These resembled clefts in RAR inhibited embryos (Fig 2.1.1C,C’, Fig. 
3.1.6C,D). Further, the transformation grid generated by DFA of TSA treated 
embryos versus controls showed shifts in landmark position consistent with facial 
narrowing and narrowing of the mouth opening. Similar landmark position changes 
were also seen in DFA transformation grids of embryos with genetically decreased 
RA signaling (Fig. 2.1.1E,E’, Fig. 3.1.6F). For these reasons, I predicted that 
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concomitantly inhibiting retinoic acid receptors and HDAC signaling would produce 
similar orofacial defects. Analogous to the abovementioned experiments, I treated 
embryos with low doses of either the RAR inhibitor (50 nm) or Trichostatin A 
(TSA, 13 µM), such that either inhibitor alone produced no visible phenotype. 
When these inhibitors were combined, however, embryos developed a severe 
median facial cleft in 90% of treated embryos. Additionally, all of these embryos 
had a narrow midface and exacerbated eye anomalies (Fig. 3.2.6A-D; 2 
experiments, n=20).  
The four treatment groups had an overall statistically significant difference in 
mean mouth angle as established by one-way ANOVA across the four treatment 
groups (F(3,66) = 107.74, p < 0.0001; Table 3.7, Fig. 3.2.6E). Pairwise assessment 
of mean mouth angle via Tukey HSD post-hoc test showed that the mean of embryos 
treated with both inhibitors together was statistically significantly different from 
controls, embryos treated with a low dose of RAR inhibitor alone, and embryos 
treated with a low dose of HDAC inhibitor alone (p-vals < 0.01). There was no 
statistically significant difference among means of embryos treated with either 
inhibitor alone or controls. In addition, the median cleft induced by combination of 
low concentrations of RAR inhibitor and HDAC inhibitor was more severe than 
treatment with high doses of either inhibitor alone (Fig. 2.1.1C,C’, Fig. 3.1.6C,D), 
which suggests a synergistic effect of these two inhibitors in the developing palate.   
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DISCUSSION 
 
 
 
 In this chapter, I used a chemical genomics approach to identify regulators of 
orofacial development in Xenopus embryos. Treatment of Xenopus embryos with 
compounds from a small molecule library during facial development uncovered 
components of dopamine, Dyrk1a, PI3K, PDGFRα, and HDAC signaling pathways. 
A follow up assay using validated inhibitors to each of these pathways showed a 
variety of palate and jaw defects, supporting the hypothesis that they are important 
in the development of the orofacial region (Table 3.8). I also showed that 
simultaneous inhibition of retinoic acid signaling with inhibition of Dyrk1a, PI3K, 
PDGFRα, or HDAC signaling results in a synergistic phenotype, suggesting that 
these pathways may interact during palate and orofacial development (Table 3.8).  
A) DOPAMINE MAY HAVE NON-NEURONAL FUNCTIONS DURING FACIAL 
DEVELOPMENT 
Inhibition of the dopamine D2 receptor via Haloperidol during Xenopus 
orofacial development induced eye anomalies and decreased facial size consistent 
with previous studies in other species (Jurand and Martin 1990; Abd-Elmagid and 
Al-Ghamdi 2009). In addition, Haloperidol treatment induced midface hypoplasia 
and mouth malformation corresponding to reduction of palatal cartilages. Similar 
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orofacial defects have only previously been described in one study in Xenopus 
development (Sullivan and Levin 2016).  
Dopamine signaling is important during neural development; it has regulatory 
roles as a neuromodulator, as well as serving as the direct precursor to the other 
catecholamines: norepinephrine and epinephrine (Daubner, Le et al. 2011). 
Dopamine signaling through the D2-like receptors (D2-D4) suppresses cellular 
cAMP levels and is therefore a critical modulator of cell survival and 
differentiation pathways in neurons. Mice deficient in D2-receptor mediated 
dopamine signaling show developmental delays and reduced growth (Jurand and 
Martin 1990). While other neurotransmitters, such as serotonin and acetylcholine, 
have been implicated to have non-neuronal functions in palatal fusion (Zimmerman, 
Wee et al. 1981), expression of the catacholamines, including dopamine, have not 
been described in the developing palate in any vertebrate system. Thus, it seems 
likely that the orofacial defects induced by dopamine signaling suppression are 
secondary to defects in the formation of the brain. Brain and facial morphogenesis 
occur simultaneously, with the brain providing molecular and structural input to the 
neighboring facial tissue (Hu and Marcucio 2009; Vandenberg, Adams et al. 2012; 
Aoto and Trainor 2015). Indeed, disruption of signaling in the developing CNS has 
been shown to induce cleft palate in mice, and this is thought to be secondary to a 
reduction in fetal movements (Oh, Westmoreland et al. 2010).  Thus, it is possible 
that a similar scenario is induced upon Haloperidol treatment, in which 
malformation of the brain decreases neuronal output and leads to subsequent defects 
in the orofacial region.  
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B) DOPAMINE SIGNALING DOES NOT INTERACT WITH RETINOIC ACID SIGNALING 
IN THE DEVELOPING PALATE 
Combined inhibition of both RA signaling and Dopamine signaling did not 
induce orofacial defects in Xenopus embryos. This further supports the hypothesis 
that dopamine and its receptors are likely not present in the developing palate, and 
that the effect of dopamine signaling on facial morphogenesis is secondary to the 
effects exerted in the developing brain. Indeed, evidence of retinoic acid interaction 
with dopamine has been only been described in neuronal tissue (Samad, Krezel et 
al. 1997; Osuala, Baker et al. 2012; Yin, Shen et al. 2012; Occhi, Regazzo et al. 
2014; Reiner, Yu et al. 2014).  
C) DYRK1A SIGNALING IN CRITICAL IN PRIMARY PALATE DEVELOPMENT 
In this chapter, I show that inhibition of Dyrk1a during early facial 
development induced severe malformation of the Xenopus face, supporting a role of 
this pathway during facial development. Dyrk1a lies on the Down’s Syndrome 
sensitive region in humans and its effects are known to be highly dosage sensitive. 
Overexpression is associated with the neurological and facial features of Down’s 
Syndrome, while deficiency is associated with microcephaly and other craniofacial 
anomalies (Epstein 2006; Hammerle, Elizalde et al. 2008). Perturbation of Dyrk1a’s 
phosphorylation activity of the transcription factor, NFAT (Nuclear factor of 
activated T-cells), is thought to contribute to these defects (Richtsmeier, Baxter et 
al. 2000; Ogawa, Nonaka et al. 2010); (Hogan, Chen et al. 2003; Epstein 2006; 
Gwack, Sharma et al. 2006).  
  121 
Several components of the Dyrk1a pathway are expressed in the developing 
facial tissues. Dyrk1a itself has been shown to have ubiquitous expression during 
embryonic development, including the neural crest, cranial placodes, and otic 
vesicles (Guimera, Casas et al. 1999; Okui, Ide et al. 1999; Hammerle, Elizalde et 
al. 2008). The Dyrk1a phosphorylation target, NFAT, is also highly expressed in the 
Xenopus embryonic face as well as the developing mouse head (Gray, Fu et al. 
2004; Borchers, Fonar et al. 2006). Further, there is also evidence that binding of 
Dryk1a with the conserved WD40 repeat domain-containing protein, Wdr68, in the 
nucleus is crucial for regulating downstream pathways necessary for zebrafish 
craniofacial development (Nissen, Amsterdam et al. 2006; Miyata and Nishida 
2011).  Thus, it seems likely that Dyrk1a regulates palate development separately 
than its effects in the developing brain.  
D) THE DYRK1A AND RETINOIC ACID SIGNALING PATHWAYS INTERACT DURING 
PALATOGENESIS 
Embryos treated with low levels of both Dyrk1a and RAR inhibitors 
displayed a prominent median facial cleft, suggesting an interaction of these two 
pathways (Fig. 3.2.3). Previously, our lab performed a microarray on faces 
dissected from embryos treated with a high dose of RAR inhibitor. I surveyed the 
data generated by this microarray and found that several members of the Dyrk1a 
signaling pathway showed differential expression in response to retinoic acid (RA) 
depletion in facial tissue including Dyrk1a, NFAT, and Wrd68 (known as dcaf7 in 
Xenopus). It is possible that these two pathways converge on a similar process 
during palate development, such as cell proliferation. Retinoic acid is known to 
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regulate proliferation in the developing palate (Kennedy and Dickinson 2012), and 
Dyrk1a is expressed in neural progenitors progressing through the cell cycle in mice 
(Hammerle, Elizalde et al. 2008). Further, embryos treated with a high 
concentration of Dyrk1a inhibitor showed a notable loss of the tissue contributing 
to the primary palate (Fig. 3.1.3), which may correspond to a decrease in 
proliferation similar to RA deficient embryos (Kennedy and Dickinson 2012).  
E) PI3K SIGNALING IS IMPORTANT DURING PALATOGENESIS AND OROFACIAL 
DEVELOPMENT 
Inhibition of PI3K signaling during Xenopus palate development results in a 
variety of orofacial anomalies including a triangular shaped mouth and a decrease 
in the amount of palatal tissue (Fig. 3.2.4). While the role of PI3K/AKT signaling 
in the developing Xenopus face has not been characterized, this is consistent with 
mouse models of cleft palate in which PI3K pathway components are downregulated 
(Kang and Svoboda 2003). In addition, phosphorylated forms of several pathway 
components are expressed in the developing murine palate, including PI3K (Cho, 
Cho et al. 2008). Developmentally, this pathway is crucial for proper neural and 
glial development. Activation of downstream targets of PI3K occurs primarily 
through catalyzing the conversion of PIP2 to PIP3, which is necessary for activation 
of AKT. PTEN (phosphatase and tensin homolog deleted on chromosome 10) 
catalyzes the opposite reaction and thus is an important negative regulator of PI3K-
mediated AKT activation (Chalhoub and Baker 2009). AKT then plays roles in 
stimulation of many downstream effectors such as those necessary for cell cycle, 
apoptosis, cytoskeletal rearrangement, and DNA repair. Moreover, PI3K activation 
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itself can be induced by stimulation of a variety of cell surface receptors including 
growth factors, cytokines, B-cell receptors, and GPCRs (Hemmings and Restuccia 
2012). It is therefore difficult to postulate which of these mechanisms is responsible 
for proper palatal development based on inhibition of PI3K alone. PDGFRα-
mediated PI3K activation is thought to be the primary interaction during facial 
development and is discussed further below (He and Soriano 2013; McCarthy, 
Wetherill et al. 2013). Future studies investigating expression of factors both 
upstream and downstream to PI3K signaling in Xenopus aim to elucidate this 
mechanism.  
F) PI3K AND RA SIGNALING INTERACT IN THE PRIMARY PALATE 
While in-vitro evidence suggests that PI3K signaling and RA signaling 
interact in the cellular differentiation of teratocarcinoma cell lines, little has been 
investigated of this interaction in the developing palate (Bertagnolo, Neri et al. 
1999; Bastien, Plassat et al. 2006; Cho, Cho et al. 2008; Lee, Lee et al. 2014). Both 
PI3K and PTEN were downregulated in our microarray of facial tissue from RA-
deficient embryos. This, in addition to my results showing a median cleft in 
embryos treated with a combination of low doses of PI3K and RAR inhibitors, 
bolsters the hypothesis that these two pathways interact during palatogenesis. This 
is consistent with studies done in mouse embryonic palate mesenchyme cells in 
which application of excess retinoic acid resulted in decreased levels of 
phosphorylated AKT and subsequently a loss of differentiation in these cells 
(Bastien, Plassat et al 2006). It is unclear, however, if this is due to transcriptional 
regulation of PI3K, or a non-genomic effect of retinoic acid. There is some 
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evidence that the retinoic acid receptor can bind to the catalytic subunit of PI3K 
and translocate to the cell surface where activated PI3K can exert its cellular 
activity (Masia, Alvarez et al. 2007). However, it is also possible that retinoic acid 
regulates PI3K activation in a more canonical fashion by regulating transcription of 
PI3K or the upstream receptors that stimulate its activation.  
G) PDGF SIGNALING REGULATES FACIAL DEVELOPMENT 
Inhibition of PDGFRα induced numerous orofacial defects and malformation 
of Xenopus cranial cartilages (Fig. 3.1.5). Similar observations were made in 
zebrafish PDGFRα mutants, in which the ethmoid plate cartilage was also absent 
(McCarthy, Wetherill et al. 2013). Likewise, mouse mutants for the PDGFRα ligand 
also exhibited orofacial malformations, including cleft palate (Ding, Wu et al. 
2004). While PDGFRα signaling can initiate a number of downstream pathways, its 
main effector in the developing mouse face is PI3K (He and Soriano 2013; 
McCarthy, Wetherill et al. 2013). In zebrafish, PDGFRα-mediated PI3K signaling 
has been identified as necessary for neural crest function, and is a major driver of 
proliferation in the median nasal prominence in mice (He and Soriano 2013; 
McCarthy, Wetherill et al. 2013). In this chapter, I show that inhibition of either 
PI3K or PDGFRα in Xenopus results in similar, but distinct, orofacial defects. 
While both experiments resulted in median clefts, embryos treated with the PDGFR 
inhibitor did not display as much midface reduction as those treated with the PI3K 
inhibitor. This can be attributed to the fact that PI3K can be activated by numerous 
receptors, and therefore retains partial activity when only PDGF receptors are 
blocked. Additionally, PDGFR inhibitor treated embryos also displayed a median 
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cleft on the ventral lip as well as loss of lower jaw cartilages that were not seen in 
PI3K inhibitor treated embryos, suggesting an additional role of this signaling 
pathway in development of the lower face.  
H) RETINOIC ACID SIGNALING AND PDGF SIGNALING INTERACT DURING FACIAL 
DEVELOPMENT 
Simultaneous treatment of embryos with low doses of pharmacological 
inhibitors to both PDGFR and RA signaling pathways induced a number of 
craniofacial abnormalities, including a median facial cleft on the dorsal and ventral 
edges of the mouth (Fig. 3.2.5). Despite the known role of both of these pathways 
in the developing palate, there has been very little evidence of an interaction 
between them; the evidence that does exist is inconclusive (Wang, Kelly et al. 1990; 
Han, Li et al. 2006). Wang et al found that application of extra retinoic acid 
increases transcription of PDGFRα in mouse cells, yet the Han group reported 
transcriptional suppression of this receptor as well as its ligands in mouse embryos 
(Wang, Kelly et al. 1990; Han, Li et al. 2006). Our own microarray results show 
PDGFRα, as well has the ligands PDGFA and PDGFB were down-regulated in 
RAR-depleted facial tissue. We have previously shown that high doses of RAR 
inhibitor induce median facial clefts. Interestingly these embryos exhibit a subtle 
median cleft on the ventral lip similar to embryos treated with a high concentration 
of PDGFR inhibitor (Kennedy and Dickinson 2012). Further, the PDGFRA ligand 
has a retinoic acid response element (RARE) very far upstream of its promoter in 
the rat genome (Pedigo, Zhang et al. 2007).  
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I) HDACS REGULATE THE DEVELOPING XENOPUS EMBRYO FACE 
The HDAC family of histone modifiers removes acetyl groups from histone 
tails and is crucial for condensing chromatin to silence transcription. Several human 
diseases that display craniofacial defects are associated with defects in repressive 
chromatin modification including ATRX syndrome (OMIM 301040), Sutherland-
Haan (OMIM 309470), and others characterized by both developmental delay and 
craniofacial abnormalities such as microcephaly and cleft palate (Hendrich and 
Bickmore 2001). In this chapter, I show that inhibition of Class I and Class II 
HDACs during a specific window of Xenopus orofacial development results in a 
median facial cleft. My findings contribute to a growing body of evidence that these 
epigenetic modifiers are important during craniofacial development. For example, 
zebrafish HDAC1 mutants exhibit loss of palatal and upper jaw cartilages as well as 
craniofacial malformations similar to my findings in Xenopus (Pillai, Coverdale et 
al. 2004; Ignatius, Unal Eroglu et al. 2013). These defects were phenocopied in 
zebrafish treated with TSA, suggesting that HDAC1 is the primary HDAC 
regulating expression during facial development (Ignatius, Unal Eroglu et al. 2013). 
Further, both HDAC1 mutants and TSA-treated zebrafish showed proper 
specification of the neural crest but defects in the later differentiation of these cells 
(Pillai, Coverdale et al. 2004; Ignatius, Unal Eroglu et al. 2013). HDAC1 has been 
shown to have ubiquitous expression early in mouse development, but this becomes 
restricted to the CNS and pharyngeal arches later as morphogenesis begins 
(Ignatius, Unal Eroglu et al. 2013; Ohata, Matsukawa et al. 2014; Yu, Wu et al. 
2016). Similar expression of HDAC1 in the developing head has also been reported 
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in zebrafish and Xenopus (Damjanovski, Sachs et al. 2000; Thisse and Thisse 2008). 
In addition, genetic knockdown of the neural crest gene, FOXN3, in Xenopus also 
induces craniofacial and cartilage malformations, and this was shown to be through 
recruitment of HDAC1 (Schuff, Rossner et al. 2007). Thus, it seems likely that the 
defects I observed in HDAC-inhibited embryos are similarly a result of a defect in 
neural crest differentiation.  
J) RETINOIC ACID SIGNALING INTERACTS WITH HDACS IN THE DEVELOPING 
PALATE 
Combination of low doses of HDAC and RAR inhibitors results in a severe 
median cleft that suggested a possible interaction between the two pathways. 
Additionally, our microarray showed that HDACs 1 and 2 were downregulated in 
facial tissue when retinoic acid receptors were bound with the RAR antagonist. It 
has been suggested by in-vitro that retinoic acid receptors recruit co-repressor 
complexes that associate with HDACs to prevent transcription in the absence of the 
retinoic acid ligand (Weston, Blumberg et al. 2003). Binding of this ligand then 
releases this complex to allow transcription factors access to genes and initiate 
transcription (Kishimoto, Fujiki et al. 2006). It is thought that this interaction is 
crucial for proper development, particularly in the anterior-posterior patterning of 
the embryonic head (Weston, Blumberg et al. 2003). My results show that 
disruption of both RA and HDAC signaling in the anterior-most region of the head- 
the palate- provide further evidence to support this hypothesis.  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
In this chapter, I develop an innovative chemical genomics strategy that 
combines forward and inverse screening techniques developed by others 
(Tomlinson, Field et al. 2005; Adams and Levin 2006).  I show that Xenopus is 
ideal for such chemical genomics studies, and my results provide insight into 
potential novel regulators of orofacial development. Prior chemical genomics 
studies in Xenopus have largely focused on other aspects of development, and 
detection of factors involved in human clefting has relied heavily on linkage and 
association studies (reviewed in (Stuppia, Capogreco et al. 2011; Wheeler and Liu 
2012)).  Therefore, I employ chemical genomics as a strategy to identify pathways 
involved in the etiology of orofacial defects. Further, I have begun to elucidate the 
complicated interactions involved by combinatorial inhibition of new pathways of 
interest with inhibition of a pathway known to be important in orofacial 
development, retinoic acid signaling. The data I provide here is only the beginning 
of several long-term studies aimed to unravel the complexity of signaling during 
orofacial development. The power of this chemical genomics based approach lies in 
the ability to control the timing of inhibition; however, complementary studies 
utilizing genetic morpholino-induced knockdown or overexpression studies are 
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imperative to fully understand the consequences of these pathways during 
development. Further, chemical screening produced several classifications of 
potential orofacial regulators, but my work in this chapter addresses only those that 
were components of developmental signaling pathways. Similar studies should also 
investigate targets of interest from the other categories as well.  
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Figure 3.1.1. Classification of targets from NCI small molecule compound library.  A)  Functional 
categories of targets from compounds inducing an orofacial  defect.  B) Pathways included in the Cell  
Signaling group of functional categories.   
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Figure 3.1.2.  The effect of dopamine receptor (DR) inhibition via Haloperidol on tadpole 
orofacial development.  A-D)  Frontal and side l ight microscope images of control embryos (A,B)  
and Embryos treated with 50 µM Haloperidol (C,D) .  E)  measurement of the intercanthal distance 
(ID). Average ID of controls was set to 100 and average ID of treated embryos normalized to i t .  
Asterisk indicate significance from Student’s unpaired t-test  assuming unequal variance on un-
normalized data.  F)  Geometric morphometric landmarks and discriminant function analysis (DFA) 
transformation grid.  Flat end of vector in transformation grid represented average control landmark 
postions.  Closed circle represented average inhibitor-treated landmark positions.  G,H)  Transverse 
sections through the midface of control (G)  and inhibitor treated (H)  embryos. F-actin is  labeled in 
green and e-cadherin is  labeled in red. I)  Alcian Blue staining of cranial carti lages in controls (i-
iv)  and inhibitor treated embryos (v-viii) .   
cg= cement gland; DR= dopamine receptors;  ir= infrarostral ,  mk= Meckel’s carti lages; pq= 
palatoquadrate;  eth= ethmoid plate;  ch= cerathoyal;  bh= basihyal;  ba= brachial  
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Figure 3.1.3. The effect of DYRK1A inhibition via INDY on tadpole orofacial development.  A-D)  
Frontal and side light microscope images of control embryos (A,B)  and Embryos treated with 25 µM 
INDY (C,D) .  E)  measurement of the intercanthal distance (ID). Average ID of controls was set to 100 
and average ID of treated embryos normalized to i t .  Asterisk indicate significance from Student’s 
unpaired t-test  assuming unequal variance on un-normalized data.  F)  Geometric morphometric 
landmarks and discriminant function analysis (DFA) transformation grid.  Flat end of vector in 
transformation grid represented average control landmark postions.  Closed circle represented average 
inhibitor-treated landmark positions.  G,H)  Transverse sections through the midface of control (G)  
and inhibitor treated (H)  embryos. F-actin is  labeled in green and e-cadherin is  labeled in red. I)  
Alcian Blue staining of cranial carti lages in controls (i-iv)  and inhibitor treated embryos (v-viii) .   
cg= cement gland; DR= dopamine receptors;  ir= infrarostral ,  mk= Meckel’s carti lages; pq= 
palatoquadrate;  eth= ethmoid plate;  ch= cerathoyal;  bh= basihyal;  ba= brachial  
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Figure 3.1.4. The effect of PI3K inhibition via LY294002 on tadpole orofacial development.  A-D)  
Frontal and side l ight microscope images of control embryos (A,B)  and Embryos treated with 19 
µM LY294002 (C,D) .  E)  measurement of the intercanthal distance (ID). Average ID of controls was 
set to 100 and average ID of treated embryos normalized to i t .  Asterisk indicate significance from 
Student’s unpaired t-test  assuming unequal variance on un-normalized data.  F)  Geometric 
morphometric landmarks and discriminant function analysis (DFA) transformation grid. Flat  end of 
vector in transformation grid represented average control landmark postions.  Closed circle 
represented average inhibitor-treated landmark positions.  G,H)  Transverse sections through the 
midface of control (G)  and inhibitor treated (H)  embryos. F-actin is  labeled in green and e-cadherin 
is  labeled in red. I)  Alcian Blue staining of cranial carti lages in controls (i-iv)  and inhibitor treated 
embryos (v-viii) .   
cg= cement gland; DR= dopamine receptors;  ir= infrarostral ,  mk= Meckel’s carti lages; pq= 
palatoquadrate;  eth= ethmoid plate;  ch= cerathoyal;  bh= basihyal;  ba= brachial  
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Figure 3.1.5. The effect of PDGFRα  inhibition via AG1296 on tadpole orofacial development.  A-
D)  Frontal and side l ight microscope images of control embryos (A,B)  and Embryos treated with 
100 µM AG1296 (C,D) .  E)  measurement of the intercanthal distance (ID). Average ID of controls 
was set to 100 and average ID of treated embryos normalized to i t .  Asterisk indicate significance 
from Student’s unpaired t-test  assuming unequal variance on un-normalized data.  F)  Geometric 
morphometric landmarks and discriminant function analysis (DFA) transformation grid.  Flat end of 
vector in transformation grid represented average control landmark postions.  Closed circle 
represented average inhibitor-treated landmark positions.  G,H)  Transverse sections through the 
midface of control (G)  and inhibitor treated (H)  embryos. F-actin is  labeled in green and e-cadherin 
is  labeled in red. I)  Alcian Blue staining of cranial carti lages in controls (i-iv)  and inhibitor treated 
embryos (v-viii) .   
cg= cement gland; DR= dopamine receptors;  ir= infrarostral ,  mk= Meckel’s carti lages; pq= 
palatoquadrate;  eth= ethmoid plate;  ch= cerathoyal;  bh= basihyal;  ba= brachial  
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Figure 3.1.6. The effect of HDAC inhibition via Trichostatin A on tadpole orofacial development.  
A-D)  Frontal and side l ight microscope images of control embryos (A,B)  and Embryos treated with 
48 µM TSA (C,D) .  E)  measurement of the intercanthal distance (ID). Average ID of controls was 
set to 100 and average ID of treated embryos normalized to i t .  Asterisk indicate significance from 
Student’s unpaired t-test  assuming unequal variance on un-normalized data.  F)  Geometric 
morphometric landmarks and discriminant function analysis (DFA) transformation grid.  Flat  end of 
vector in transformation grid represented average control landmark postions.  Closed circle 
represented average inhibitor-treated landmark positions.  G,H)  Transverse sections through the 
midface of control (G)  and inhibitor treated (H)  embryos. F-actin is  labeled in green and e-cadherin 
is  labeled in red. I)  Alcian Blue staining of cranial carti lages in controls (i-iv)  and inhibitor treated 
embryos (v-viii) .   
cg= cement gland; DR= dopamine receptors;  ir= infrarostral ,  mk= Meckel’s carti lages; pq= 
palatoquadrate;  eth= ethmoid plate;  ch= cerathoyal;  bh= basihyal;  ba= brachial  
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Figure 3.2.1. Paradigm for synergy  experiments .  At stage 24 (26 hpf),  embryos were 
simultaneously treated with a 50 nM concentration of RAR inhibitor as well  as a low dose of 
Haloperidol,  INDY, LY294002, AG1296, or TSA. RAR inhibitor was washed out at  stage 29/30 
(35 hpf),  while the other inhibitors were replenished at the same concentration. DMSO was also 
replenished for all  treatment groups and controls.  Volume of RAR was replaced with DMSO. 
At stage 37 (53 hpf),  the remaining inhibitors were washed out and embryos were allowed to 
develop until  late tadpole stages for analysis.   
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Figure 3.2.2.  Combined inhibition of RA signaling and Dopamine signaling does not 
induce a significant change in mouth shape.  Frontal images of (A)  control embryos 
treated with DMSO, (B)  embryos treated with 5 µM Haloperidol,  (C)  embryos treated 
with 50 nM BMS-453, (D)  embryos treated with 5 µM Haloperidol and with 50 nM BMS-
453 concurrently.  (E)  Mouth angle was taken at the middle of the dorsal l ip from either 
corner of the mouth. Average mouth angle of controls was set to 100 and average mouth 
angle of treated embryos normalized to i t.  One-way ANOVA was performed on 
unnormalized data,  but no significance was found among treatment groups. 
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Figure 3.2.3.  Combined inhibition of RA signaling and Dyrk1a/NFAT signaling 
significantly alters mouth shape and produces a median cleft .  Frontal images of (A)  
control embryos treated with DMSO, (B)  embryos treated with 5 µM INDY, (C)  embryos 
treated with 50 nM BMS-453, (D)  embryos treated with 5 µM INDY and with 50 nM 
BMS-453 concurrently.  (E)  Mouth angle was taken at the middle of the dorsal l ip from 
either corner of the mouth. Average mouth angle of controls was set to 100 and average 
mouth angle of treated embryos normalized to i t .  Asterisks denote significance from one-
way ANOVA and post-hoc  Tukey HSD analysis on unnormalized data.  α=0.01. 
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Figure 3.2.4.  Combined inhibition of RA signaling and PI3K signaling induces a 
median cleft .  Frontal images of (A)  control embryos treated with DMSO, (B)  embryos 
treated with 4 µM LY294002, (C)  embryos treated with 50 nM BMS-453, (D)  embryos 
treated with 4 µM LY294002 and with 50 nM BMS-453 concurrently.  (E)  Mouth angle 
was taken at the middle of the dorsal l ip from either corner of the mouth. Average mouth 
angle of controls was set to 100 and average mouth angle of treated embryos normalized 
to i t .  Asterisks denote significance from one-way ANOVA and post-hoc  Tukey HSD 
analysis on unnormalized data.  α=0.01. 
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Figure 3.2.5. Combined inhibition of RA signaling and PDGFR signaling 
significantly alters mouth shape.  Frontal images of (A)  control embryos treated with 
DMSO, (B)  embryos treated with 4 µM LY294002, (C)  embryos treated with 50 nM 
BMS-453, (D)  embryos treated with 4 µM LY294002 and with 50 nM BMS-453 
concurrently.  (E)  Mouth angle was taken at the middle of the dorsal l ip from either 
corner of the mouth. Average mouth angle of controls was set to 100 and average 
mouth angle of treated embryos normalized to i t .  Asterisks denote significance from 
one-way ANOVA and post-hoc  Tukey HSD analysis on unnormalized data.  α=0.01. 
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Figure 3.2.6.  Combined inhibition of RA signaling and HDAC signaling produces a 
prominent median cleft .  Frontal images of (A)  control embryos treated with DMSO, (B)  
embryos treated with 13 µM Trichostatin A, (C)  embryos treated with 50 nM BMS-453, 
(D)  embryos treated with 13 µM Trichostatin A and with 50 nM BMS-453 concurrently.  
(E)  Mouth angle was taken at the middle of the dorsal l ip from either corner of the 
mouth. Average mouth angle of controls was set to 100 and average mouth angle of 
treated embryos normalized to i t .  Asterisks denote significance from one-way ANOVA 
and post-hoc  Tukey HSD analysis on unnormalized data.  α=0.01. 
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Table 3.1.  Range of  inhibi tor  concentrat ions tested and el ic i ted phenotypes.  
Drug Concentrat ions 
tes ted (µM) 
Number of  
experiments  
Total  n  % with orofacial  
defect  
% dead % normal 
Haloperidol  10 
20 
1 
2 
18 
9 
-  
-  
-  
-  
100 
100 
 30 
50  
70 
100 
1 
6 
1 
1 
4 
59 
4 
18 
-  
100 
100 
27.8 
-  
-  
-  
27.8 
100 
-  
-  
-  
INDY 10 
15 
1 
1 
19 
3 
-  
100 
-  
-  
100 
-  
 20 
25  
30 
50 
70 
100 
1 
5 
2 
1 
1 
1 
4 
54 
8 
4 
4 
20 
50 
98.15 
-  
-  
-  
-  
50 
1.85 
100 
100 
100 
100 
-  
-  
-  
-  
-  
-  
Ly294002 10 
12 
1 
2 
20 
8 
-  
-  
-  
-  
100 
100 
 15 
19  
20 
30 
50 
70 
100 
2 
3 
3 
1 
1 
1 
1 
8 
35 
17 
8 
8 
8 
20 
-  
97.14 
29.41 
-  
-  
-  
-  
12.5 
2.86 
52.94 
100 
100 
100 
100 
87.5 
-  
-  
-  
-  
-  
-  
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Table 3.1 cont .  Range of  inhibi tor  concentrat ions tested and el ic i ted phenotypes. 
Drug	   Concentrations	  
tested	  (µM)	  
Number	  of 	  
experiments	  
Total 	  n	   %	  with	  
orofacial 	  defect 	  
%	  dead	   %	  normal	  
AG1296	   10	  
100	  
1	  3	   5	  50	   -­‐ 	  100	   -­‐ 	  -­‐ 	   100	  -­‐ 	  
Trichostatin	  A	   2.5	  5	  6 .5 	  8 	  10	  
48	  100	  
1	  1	  1 	  2 	  1 	  3 	  1 	  
4 	  4 	  4 	  8 	  18	  70	  19	  
-­‐ 	  -­‐ 	  -­‐ 	  3 	  22.22	  100	  5.26	  
-­‐ 	  -­‐ 	  -­‐ 	  -­‐ 	  11.11	  -­‐ 	  5 .26	  
100	  100	  100	  62.5	  50	  -­‐ 	  89.47	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Table 3.2.  Mean mouth angle and standard deviation of treatment groups in synergy 
experiments. 
Treatment 
Group 
Mean Standard Deviation 
Controls 145.3821 ±3.1373 
50 nM RAR inhibitor 144.0204 ±4.6456 
5 uM Haloperidol 144.9484 ±5.7608 
5 uM INDY 144.0349 ±5.563 
4 uM LY294002 142.0349 ±5.2896 
100 uM AG1296 144.0474 ±4.5061 
14 uM Trichostatin A 
 
141.6258 ±3.9237 
5 uM Haloperidol +  
50 nM RAR inhibitor 
143.5656 ±4.7865 
5 uM INDY +  
50 nM RAR inhibitor 
120.3016 ±9.6595 
4 uM LY294002 +  
50 nM RAR inhibitor 
96.9935 ±20.2413 
100 uM AG1296 +  
50 nM RAR inhibitor 
106.7114 ±13.3598 
14 uM Trichostatin A 
+  
50 nM RAR inhibitor 
98.9384 ±8.5997 
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Table 3.3.  Output from one-way ANOVA of mean mouth angle from Controls,  treatment with 50 nM 
RAR inhibitor,  treatment with 5 uM Haloperidol,  and treatment with 50 nM RAR inhibitor + 5 uM 
Haloperidol.   α  = 0.01. 
Source df SS MS F p 
Between 
groups 
3 34.5691 11.523 0.53 0.6634 
Within 
groups 
61 1313.8567 21.5386   
Total 64 1348.4257    
 
Table 3.4.  Output from one-way ANOVA of mean mouth angle from Controls,  treatment with 50 nM 
RAR inhibitor,  treatment with 5 uM INDY, and treatment with 50 nM RAR inhibitor + 5 uM INDY.   
α  = 0.01. 
Source Df SS MS F p 
Between 
groups 
3 7488.0296 2496.0099 63.8 <0.0001 
Within 
groups 
65 2542.8616 39.1209   
Total  68 10030.8912    
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Table 3.5.  Output from one-way ANOVA of mean mouth angle from Controls,  treatment with 50 nM 
RAR inhibitor,  treatment with 4 uM LY294002, and treatment with 50 nM RAR inhibitor + 4 uM 
LY294002.   α  = 0.01. 
Source Df SS MS F p 
Between 
groups 
3 21110.0212 7036.6737 72.16 <0.0001 
Within 
groups 
55 5363.4764 97.5178   
Total  58 26473.4977    
 
Table 3.6.  Output from one-way ANOVA of mean mouth angle from Controls,  treatment with 50 nM 
RAR inhibitor,  treatment with 100 uM AG1296, and treatment with 50 nM RAR inhibitor + 100 uM 
AG1296.   α  = 0.01. 
Source Df SS MS F p 
Between 
groups 
3 19063.0064 6354.3355 107.74 <0.0001 
Within 
groups 
66 3892.6491 58.9795   
Total  69 229556554    
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Table 3.7.  Output from one-way ANOVA of mean mouth angle from Controls,  treatment with 50 nM 
RAR inhibitor,  treatment with 14 uM TSA, and treatment with 50 nM RAR inhibitor + 14 uM TSA.   α  
= 0.01. 
Source Df SS MS F p 
Between 
groups 
3 28177.8112 9392.6037 279.59 <0.0001 
Within 
groups 
62 2082.8226 33.5939   
Total  65 302606338    
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Table 3.8.  Summary of orofacial phenotypes induced by inhibitors of dopamine (Haloperidol),  Dyrk1a 
(INDY), PI3K (Ly294002),  PDGFR (AG1296),  or HDAC (Trichostatin A) signaling.  
 Intercanthal 
distance 
Midface 
shape 
changes 
Palate 
morphology 
Palate and 
upper jaw 
cartilages 
Synergy 
with RAR 
inhibitor 
Haloperidol decreased yes unaffected reduced no 
INDY decreased yes tissue loss loss yes 
LY294002 decreased yes tissue loss reduced/ 
loss 
yes 
AG1296 decreased yes tissue loss reduced/ 
loss 
yes 
Trichostatin A decreased yes tissue loss; 
median cleft 
reduced/ 
loss 
yes 
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CONCLUDING REMARKS 
 
 
 
These studies demonstrate the power of Xenopus as a system in which to 
study orofacial development. In the first chapter, I established a method to measure 
size and shape changes of the orofacial region during normal Xenopus facial 
development. Next, I utilized this method in Chapter 2 to identify changes in facial 
dimensions when either retinoic acid signaling or folate metabolism were perturbed. 
Chapter 3 exhibited the use of Xenopus in chemical genomics to identify other 
signaling pathways regulating orofacial development. Finally, I investigated 
potential interactions between these pathways and retinoic acid signaling in the 
developing palate.  
The quantification protocol I developed in the first two chapters of this 
dissertation is a powerful way to assess the effects of many different conditions on 
orofacial development. Moreover, I have shown that orofacial defects such as 
median clefts are also associated with changes in dimensions and shape of the face. 
Therefore, a similar quantification protocol of human orofacial morphology has the 
potential for earlier diagnosis of such defects and implementation of therapeutic 
strategies. Here, I used this method to describe effects of perturbed developmental 
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signaling pathways, but it could be extended to future studies examining the effect 
of environmental agents such as natural substances, herbicides, or toxins. Other 
applications could also include using this protocol for comparing closely related 
species for evolutionary or ecological studies. While the examples I provide here 
utilize this protocol to describe analysis of the orofacial region, it could easily be 
modified for analysis of other regions, organs, or structures. Clearly, this orofacial 
quantification protocol has many applications and will become a valuable resource 
for the research community.  
The chemical genomics strategy carried out in chapter 3 also demonstrates 
the utility of Xenopus as a system to study orofacial development. Through this 
screen, I uncovered several regulators of facial development, and characterized the 
defects produced by inhibition of these regulators via my quantification protocol. In 
addition, experiments combining inhibition of each of these regulators with 
inhibition of retinoic acid signaling revealed potential gene-gene interactions in the 
developing palate. A similar strategy could be implemented in a future study to 
investigate the effects of environmental toxins on orofacial development, such as 
exposure to cigarette or e-cigarette smoke, alcohol, or contaminants.  These toxins 
could then be applied to embryos in combination with inhibitors to the 
developmental signaling pathways described in chapters 2 and 3 to determine 
potential gene-environment interactions contributing to orofacial defects.  
Taken together, these studies begin to make inroads as to the complex 
interactions underlying orofacial defects, such as median clefts.  This has potential 
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not only for understanding how developmental signaling pathways regulate normal 
palate development, but also for understanding how defects in this region arise. 
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APPENDIX A 
 
 
 
Disrupted retinoic acid signaling has been implicated in disorders that 
present with orofacial malformations. For example, the retinoic acid induced-1 (rai) 
gene is transcriptionally regulated by retinoic acid signaling, and found on the 
chromosome region that is deleted in Smith-Maginis syndrome (SMS). This genetic 
disorder arises occurs in 1 in 25,000 births and is characterized by neurobehavioral 
issues as well as craniofacial defects such as a tented lip and reduced midface 
(Juyal, Figuera et al. 1996; Juyal, Kuwano et al. 1996).  
DECREASED RAI1 ALTERS FACIAL SIZE AND SHAPE DURING EMBRYONIC 
DEVELOPMENT 
Malformation of the face and mouth is the most clinically recognizable 
feature in SMS patients (reviewed in (Elsea and Girirajan 2008)). In our Xenopus 
model of SMS, a former lab member (Raiha Tahir) knocked down RAI1 function 
using translation blocking antisense oligos stabilized by morpholino rings. 
Morpholinos were injection into one-cell stage embryos at a concentration of 5ng. 
Control embryos were injected with standard control morpholinos (injections 
performed by Amanda Dickinson). Controls exhibited no obvious defect and 
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resembled uninjected siblings (Fig. A1i, ii). Rai1 morphants (MO) exhibited several 
abnormalities in craniofacial development. For example, Rai1 morphants had a 
narrower face, rounder mouth, and lack of upper jaw extension dorsal to the mouth 
(Fig. A1Aiii, iv). Notably, midface hypoplasia in Rai1 morphants resulted in an 
apparent protrusion of the region of the head containing the forebrain (Fig. A1Aiv, 
outlined in white dots). To make our qualitative observation that Rai1 knockdown 
affects facial dimensions and shape more robust, I performed a quantitative analysis 
of the face. In this analysis, I used the traditional measurements described in 
Chapter 1 to assess changes in size. I also utilized geometric morphometrics as 
described in Chapters 1,2 and 3 to assess changes in shape of the face (n = 20 in 2 
experiments; (Kennedy and Dickinson 2014; Kennedy and Dickinson 2014). 
In mice, decreased Rai1 function results in a shortening of snout length (Bi, 
Ohyama et al. 2005; Yan, Bi et al. 2007). Therefore, I measured an analogous 
region of the embryonic frog face that incorporates the cartilages lining the base of 
the brain, nostrils, and upper jaw. The Rai1 morphant snout length was significantly 
decreased by 1.91-fold compared to the controls (t-test, p= 1.25E-12, Fig. A1Bi). In 
humans, SMS patients have midface hypoplasia that is associated with 
abnormalities in this region of the face. Therefore, I measured the area, width, and 
height of the midface region in X. laevis to determine if Rai1 has a conserved role 
in midface development. The midface area and width were reduced 1.38- and 1.44-
fold, respectively, in the rai1 morphants compared to controls (t-tests, p = 6.18E-10 
and p = 1.17E-11, respectively; Fig. A1Bii, iii). Conversely, in these morphants, the 
midface height was not significantly different (t-test, p = 0.027, Fig. A1Biv). SMS 
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affected individuals also have a tented upper lip that changes the shape of the 
mouth opening. Xenopus Rai1 morphants also have an abnormal mouth opening 
shape, where the mouth does not close and remains more rounded (see Fig. 
3A1Biii). Therefore, I quantified roundness using an inverse aspect ratio generated 
in Image J (Kennedy and Dickinson 2014; Kennedy and Dickinson 2014). Indeed, 
Rai1 morphants had a 2.44-fold rounder-shaped mouth opening compared to the 
controls (t-test, p = 2.36E-09, Fig. A1Bv). In summary, these data reveal that Rai1 
morphants have narrowing in the midface region and a rounder mouth. 
Since this traditional analysis does not provide a sophisticated view of how 
the shape of the embryonic orofacial region changes in response to reduced Rai1, I 
next used a geometric morphometric analysis (Kennedy and Dickinson 2014; 
Kennedy and Dickinson 2014) to better define orofacial shape changes in Rai1 
morphants. Thirty-eight landmarks were assigned coordinates as described 
previously (Kennedy and Dickinson 2014; Kennedy and Dickinson 2014) and then 
aligned via Procrustes superimposition to eliminate information regarding size or 
orientation using MorphoJ software (Klingenberg, Wetherill et al. 2010). The 
variance within each group was examined by performing a principal component 
analysis (PCA). By translating variables into orthogonal principal components (PC), 
this multivariate statistical method describes the complexity of a sample while 
simultaneously reducing the number of variables (Abdi and Williams 2010). The 
first two principal components account for the most variance within each group, and 
similar samples cluster together when these components are plotted against each 
other. Rai1 morphants were distinguished from controls along both the PC1 and 
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PC2 axes (Fig. A1Ci). Individuals within the Rai1 morphant group were widely 
distributed, suggesting a large amount of variation. Such variance may be attributed 
to slightly different quantities or distribution of morpholino in each individual 
embryo, as well as other factors such as genetic background. Individuals in the 
control group were less widely distributed, but the variance can once again be 
explained by slight developmental differences in each embryo.  
To visualize the statistical differences in the shape of the orofacial region 
between Rai1 and control morphants, a discriminant function analysis (DFA) was 
performed. The procrustes distance was used to generate a statistical measure (p < 
0.001) as well as a transformation grid to visualize the shape differences between 
the two groups (Fig. A1Cii). The lengths of the vectors illustrate how landmarks 
shift in the control (end of line) to the Rai1 morphants (closed circle). Dramatic 
shifts in the landmarks outlining the orofacial region indicate a narrowing of the 
face shape respective to the height (Procrustes distance= 0.2213, p<0.0001; Fig. 
A1Cii). Also notable are the outward shift of the nasal landmarks (Fig. A1Cii, 
arrows) that reveal drastic abnormality in nostril position consistent with the failure 
of snout outgrowth. Shifts in the landmarks defining the dorsal edge of the mouth 
opening demonstrate the rounder shape of the mouth. In addition to vector shifts, 
the transformation grid also creates a warping pattern that illustrates shape change. 
Warping in the midface region is dramatic and consistent with midface hypoplasia 
in Rai1 morphants (Fig. A1Cii). The results of DFA analysis revealed shape 
changes consistent with our qualitative observations and traditional size 
measurements such as narrow faces and increased mouth roundness. In summary, 
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these results reveal size and shape changes in the frog Rai1 morphant embryo that 
are remarkably similar to craniofacial abnormalities in humans with SMS and 
mouse models, suggesting a conserved function for Rai1 in orofacial development. 
XENOPUS AS A MODEL FOR SMS 
 The craniofacial abnormalities typically associated with SMS patients include 
midface hypoplasia, depressed nasal bone, a tented upper lip, and upslanting 
palpebral fissures (Elsea and Girirajan 2008). It is thought that these features arise 
due to failure of the nasal capture to form which leads to a subsequent reduction in 
maxillary and frontonasal prominence development (Ocampo, Dolbier et al. 1997). 
This results in a malformed midface, as well as an apparent “widening” of the face. 
In mice, this can be seen as a shorter, broader snout due to loss of this nasal bone. 
Indeed, analyses of Xenopus facial dimensions upon Rai1 knockdown are consistent 
with both human and mouse models. For example, I found significant shape changes 
in the midface and mouth opening. Further, I found an overall decrease in facial 
size, analogous to the frontal bossing and micrognatia seen in SMS patients. In 
summary, my quantitative analysis of Rai1 morphants not only supports a role of 
this gene in orofacial development, but also supports the use of Xenopus as an 
appropriate disease model for SMS.  
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Figure A1.  Rai1 is required for normal orofacial development.  Rai1 morphants injected with 5 ng of 
morpholino were analyzed at stage 42.  (A)  Representative frontal views (i ,  i i i)  and lateral views ( i i ,  iv)  of 
embryos injected with 5 ng of Rai1 and control MO. The mouth is outlined in red dots ( i  and i i i)  or 
indicated with a red arrow ( i i  and iv) .  In lateral views ( i i  and iv)  the head is outlined with white dots to 
emphasize the protruding forehead. The snout appears shorter and the mouth is  smaller and rounder in the 
Rai1 morphants than controls.  Abbreviations: cg; cement gland. (B)  Traditional measurements of facial  
dimensions in Rai1 morphants verses controls.  Schematics indicate where measurements were taken. Data 
as bar graphs (i–v) ,  show statistically a shorter snout,  smaller midface area, a narrower face,  and rounder 
mouth. (C)  Morphometric analysis of orofacial shape in Rai1 morphants supports tradition measurements 
and provides details  of changes in orofacial  shape. (i)  Principal component analysis shows distinct 
separation of orofacial shapes in Rai1 morphants and controls.  Control morphants are in black and Rai1 
morphants are in red. ( i i)  Discriminant function analysis showing the statistically significant procrustes 
distance and p-value as well  as the transformation grid of the changes in landmark location. Note the 
dramatic shift  in nostri l  landmarks (arrows) and corresponding warping in the midface indicative of midface 
hypoplasia.  Also notable is  the shifts  in mouth landmarks consistent with a rounder shape mouth. 
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APPENDIX B 
 
 
 
CONSERVATION OF DHFR GENE AND PROTEIN STRUCTURE 
Xenopus laevis has become a useful tool in studying the orofacial region. Not 
only do they produce large quantities of easily visible eggs, but many processes 
governing early orofacial development are highly conserved across vertebrates 
(Tomlinson, Field et al. 2005; Kennedy and Dickinson 2012). I used bioinformatics 
to compare the mouse DHFR gene structure and that of the two Xenopus species and 
found nearly identical alignment of the transcriptional start site as well as the exon-
intron boundaries (Fig. B1A). Unsurprisingly, the mouse gene is larger due to the 
increase in non-coding material that is characteristic of mammalian DNA 
(Shabalina and Spiridonov 2004). I also performed a multiple sequence alignment 
of the DHFR protein sequence from several vertebrates and found many regions 
enriched in highly conserved amino acid residues (Fig. B1B). When I did pair-wise 
analyses between the Xenopus DHFR protein sequence and that of other vertebrates, 
I found the highest percentage of similarity with the other species of Xenopus, 
followed by mouse and rat (Fig. B1C). While the percent similarity between 
Xenopus and human DHFR is only 65%, their homology is supported by structural 
analysis. Human DHFR is a tetrameric protein consisting of four identical subunits 
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with two binding pockets (Klon, Heroux et al. 2002). When both NADPH and 
dihydrofolate occupy these pockets, the enzyme undergoes a conformational change 
to allow interaction of the two ligands. NADPH transfers a hydrogen atom to 
dihydrofolate, thereby reducing it to tetrahydrofolate (Abali, Skacel et al. 2008). 
Using bioinformatics, I superimposed the consensus sequence of the protein 
multiple sequence alignment onto this known three-dimensional structure of human 
DHFR in the software program, JMol.  I then assigned each residue in the alignment 
a value in bits to reflect the likelihood that residue will appear in all sequences in 
the alignment. A higher bit value indicates a higher likelihood, and thus a higher 
amount of conservation. As seen in Figure B1D, residues with the highest amount of 
conservation (>3.5 bits) are those surrounding the ligand binding pockets, 
suggesting conserved DHFR function. 
VARIABILITY IN THE MTX PHENOTYPE 
To investigate DHFR function in the developing face, embryos were treated 
with the pharmacological inhibitor, Methotrexate (MTX) at concentrations from 50 
µM to 440 µM during facial morphogenesis (st. 20–31, 22–37 hpf; 2 experiments, n 
= 40). At each concentration, embryos exhibited a range of phenotypes from normal 
to severe, and these were accompanied by decreasing intercanthal distance (Fig. 
B2A). Nearly 100% of controls were classified as normal or mild (Fig. B2Ai, Bi). 
At the lowest MTX concentration (50 µM), about 65% of the embryos were normal, 
5% mildly effected, 10% moderately affected and 20% severely affected (Fig. 
B2Aiii,iv,v,Bii). Embryos treated with 110 µM MTX were more evenly distributed, 
with about 30% in normal, moderate, and severe classes, but only 9% considered 
mildly affected (Fig. B2Aiii,iv,v,Biii). About three quarters of the embryos treated 
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220 µM of MTX were severely affected, with the remaining 25% split between 
moderately and mildly affected. No embryos were normal at this concentration (Fig. 
B2Ai-iv, Biv). At the highest concentration (440 µM), all embryos were severely 
affected (Fig. B2Axii, xiii, Bv). There are several possible reasons for this 
variability such as decreased folate transporter function or increased DHFR 
expression potentially as a result of gene amplification. We routinely saw about 
25% of embryos with a very mild or normal phenotype, which suggests the 
possibility that our frogs are carriers for a mutation in a gene that could render 
them less susceptible to MTX treatment. 
DHFR INHIBITION DOES NOT AFFECT NEURAL CREST SPECIFICATION OR 
MIGRATION 
Folic acid metabolism has long been known for its role in the regulating 
closure of the developing neural tube (Smithells, Sheppard et al. 1976; Prevention 
2012). Migratory neural crest (NC) cells, which contribute to cranial mesenchyme, 
are specified on the dorsal edge of the neural tube and delaminate from the 
neuroepithelium after it closes (Minoux and Rijli 2010). It has therefore been 
predicted that folate may also play a role in NC development (Li, Shi et al. 2011). 
While my treatment timeframe occurs after neural crest specification, I wanted to 
determine if DHFR inhibition perturbed its migration (Mayor, Morgan et al. 1995), 
Therefore, I treated embryos with 110 or 220 µM MTX as described above and in 
Chapter 2 (St. 20-29, 22-35 hpf, 2 experiments, n=10 embryos per treatment). 
Directly following treatment, I fixed embryos and performed in-situ hybridization 
using the NC marker, AP-2 (Sive, Grainger et al. 2000). Briefly, standard in-situ 
protocol was performed (Sive, Granger et al. 2000), omitting the proteinase K 
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treatment. DHFR cDNA used to transcribe in-situ hybridization probe was from 
Open Biosystems and Dharmacon (Clone Id: 6933368, Genbank # BC084841.1). 
This 812 kb sequence was very specific to DHFR and had less that 4% sequence 
identity with other genes in Xenopus laevis. 
Control embryos showed enrichment of AP-2 in the migrating NC streams of 
the face, as well as the regions surrounding the mouth opening (Fig. B3A,A’). This 
pattern was identical in embryos treated with either MTX concentration, suggesting 
that neural crest specification and migration are not impaired by DHFR inhibition 
(Fig. B3B,B’,C,C’). Quantification of the AP-2 expression domain on frontal 
images of controls and MTX treated embryos showed no statistical difference (Fig. 
B3D, p-values: Controls vs. 110 µM MTX= 0.286, controls vs. 220 µM MTX = 
0.638). While the AP-2 expression pattern appears unchanged by MTX treatment, 
quantitative RT-PCR analysis of facial tissues showed a slight, but significant 
decrease in AP-2 expression in embryos treated with MTX compared to controls 
(Wahl, Kennedy et al 2015). This may correspond to the phenotypic variability in 
severity; however, whether this reflects a decreased ability of the neural crest to 
migrate or a decrease in neural crest proliferation prior to migration remains 
unclear. I also examined expression pattern of AP-2 in MTX-treated embryos at 
stage 40 (66 hpf) and found that there was a more dramatic loss of the marker 
around the mouth (Fig. B3). These results seem to indicate that there is a gradual 
reduction in neural crest in the orofacial region after it is specified and has 
migrated. 
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DHFR INHIBITION DECREASES CELL PROLIFERATION IN THE DEVELOPING 
OROFACIAL TISSUE 
Given the expression of DHFR in the developing facial prominences (Fig. 
2.2.1) and the decrease in orofacial size observed in MTX treated embryos (Fig. 
B4), DHFR inhibition may decrease proliferation in the orofacial region. To 
investigate this, I treated embryos with 220 µM MTX as described (st. 20-29, 22-35 
hpf), fixed embryos immediately after treatment, took sagittal sections of fixed 
embryo heads in agarose, and fluorescently labeled mitotic cells with an antibody to 
phosphohistone H3 (pH3). I used propidium iodide as a counter-stain to label all 
nuclei. My results show a decrease in proliferating cells in the orofacial region in 
MTX treated embryos (Fig. B4). As with my morphological assessment (Fig. B2), I 
saw variability in the number of mitotic cells in MTX treated embryos. Therefore, I 
examined the region between the cement gland and the anterior portion of the brain 
(Fig. B4, white boxes), and separated embryos into three groups based on the 
number of dividing cells present: 1) more than 4 dividing cells, 2) 1-3 dividing 
cells, or 3) no dividing cells. Nearly all control embryos were classified as group 1 
(Fig. B4Ai,ii). On the other hand, only 10% of MTX treated embryos were 
classified in group 1, 40% in group 2, and about 50% of MTX in group 3 (Fig. 
B4Bi-iv). This preliminary data shows that DHFR is necessary for cell proliferation 
in the facial prominences, which could suggest a potential relationship between 
DHFR and the cell cycle. Indeed, follow up experiments performed in our lab 
confirm this, with DHFR deficient embryos exhibiting decreased proliferation and 
altered cell cycle profiles (Wahl, Kennedy et al 2015).  
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DHFR INHIBITION DOES NOT APPEAR TO AFFECT GLOBAL DNA 
METHYLATION PATTERNS 
To test the hypothesis that DHFR inhibition decreases the amount of methyl 
groups produced, I worked with another student in the lab (Catie Mavilia) to assess 
global methylation differences between controls and embryos treated with MTX. 
We did this by extracting genomic DNA from stage 29 (35 hpf) embryos directly 
following treatment with 110 or 220 µM MTX (treatment time: St. 20-29, 22-35 
hpf). Next, we digested DNA with either HpaII or MspI- two restriction 
endonucleases that cleave the same sequence of DNA with differential sensitivity to 
methylation status. When internal cytosine residues are methylated, cleavage by 
HpaII is blocked while MspI cleavage is unaffected. We then ran digested DNA, as 
well as uncut DNA as a control, on an agarose gel. We expected an increase in the 
amount of genomic DNA digested with HpaII in MTX treated embryos, and this 
would be reflected on the gel by a decrease in size or intensity of the genomic band 
of MTX treated DNA digested with HpaII compared to controls. However, we saw 
no difference in this band (Fig. B5A). Since MspI cleaves the same recognition 
sequence regardless of methylation status, there was no genomic band in either 
control or MTX treated DNA, as the smaller digested fragments migrate further 
down the gel (Fig. B5A). Quantification of the pixel intensity of these bands 
revealed no statistical difference in the amount of DNA cleaved by HpaII between 
controls and MTX treated embryos (Fig. B5B, p= 0.95). While these results suggest 
DHFR inhibition does not influence DNA methylation patterns, there are several 
things to consider. First, we are still optimizing this protocol to overcome technical 
issues. Second, we currently lack a positive control (such as DNA extracted from 
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embryos treated with a methylation inhibitor) to ensure functionality of these 
enzymes and sensitivity of the assay. Finally, changes in methylation patterns 
induced by MTX may be so subtle that this assay cannot detect them.  
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Figure B1. DHFR structure and function is conserved across vertebrates .  (A)  Structure of DHFR 
gene. Black boxes are exons, l ines are introns.  Numbers are number of nucleic acid residues.  (B)  
Vertebrate DHFR protein multiple sequence alignment.  Dark purple residues are highly conserved. 
(C)  Percent similarity between X. laevis  DHFR protein sequence and other vertebrates.  (D)  Protein 
multiple sequence alignment superimposed onto 3D structure of human DHFR. Residues are colored 
based on amount of information at each position. Red is more than 3.5 bits  of information, Yellow is 
3-3.4 bits ,  green is 2.5-2.9 bits ,  l ight purple is  2.0-2.4 bits .  Dark purple residues are the l igands 
folate and NADPH. ( i)  frontal view of protein structure.  ( i i)  rotated laterally 90o to show the folate 
binding pocket.  ( i i i)  Rotated laterally -90o to show the NADPH binding pocket.  ( iv)  rotated forward 
90o to show the interaction of both ligands.  
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 Figure 3. MTX induces a range of facial defects.  A) Representative images of i)  normal,  i i)  mild, i i i)  
moderate,  and iv) severe classifications.  White dotted lines represent intercanthal distance measurement.  
Red dots outline mouth. B) Bar graphs of percent embryos in each classification. i)  controls,  i i)  50 uM 
MTX, ii i)  110 uM MTX, iv) 220 uM MTX, v) 440 uM MTX. cg= cement gland. 
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Figure B2. The expression pattern of AP-2 is 
not changed by MTX treatment.  (A)  Schematic 
of the experimental design. (B)  in-
situ  hybridization for neural crest marker,  AP-2 ,  
frontal views ( i ,  i i)  and lateral views with 
anterior to the left  ( i i i ,  iv) .  All  images are at  the 
same magnification (scale bar=175 µm). 
Asterisk designates the region measured and 
graphed in C .  (C)  Bar graph showing 
quantification of the AP-2  domain in the face. 
There is no statistical significance in 
2experiments (n=12, p  value=0.64).   
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Figure B3. The expression pattern of AP-2 is not changed by MTX treatment 
at later stages.  in-situ  hybridization for neural crest marker,  AP-2 ,  frontal 
views (A,B)  and lateral views with anterior to the left  (C,D) .  MTX treated 
embryos (B,D)  exhibit  fainter AP-2 expression than control embryos (A,C)  at  
stage 40  exhibit  All  images are at  the same magnification. cg=cement gland. 2 
experiments,  n=10.  
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Figure B4.  Cell proliferation is decreased in MTX treated embryos .  
Immunohistochemistry of pH3 in representative lateral sections of the face from (A)  controls 
or (B)  embryos treated with 220uM MTX. (C)  Quantification of PH3 positive cells.  Asterisk 
represents statistical significance from Student’s t- test  assuming unequal variances.  p-value 
< 0.05.  
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Figure B5. Detection of global DNA methylation changes using restriction endonucleases.  A) 
Gel showing genomic DNA extracted from controls and embryos treated with either 110 or 220 
uM MTX. Cntl= control.  B) Values for pixel intensity were determined by normalizing each 
band in HpaII or MspI lands to the respective uncut control.  This was then expressed as the 
ratio Intensity of DNA cut with HpaII/  Intensity of DNA cut with MspI for DNA extracted from 
Controls and MTX treated.  
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APPENDIX C 
 
 
 
Chemical genomic screening of the NCI small-molecule library resulted in 25 
compounds that induced a median cleft phenotype. The targets of these compounds 
were classified into functional categories such as cell cycle/growth, post-
translational modifications, DNA repair, apoptosis, stress response, endocrine 
response, ion channels, cellular metabolism, and mRNA processing (Fig 3.1A). In 
chapter 3, I described a secondary screen to assess targets in the largest of these 
categories, developmental signaling pathways components (Fig 3.1B). I was also 
interested in the most prominent target in the cytoskeleton components category, 
the microtubule stabilizing, Taut (microtubule-associated Tau). Microtubules (MTs) 
regulate a number of important cell processes such as division, migration, vesicular 
transport, signal transduction, and ciliogenesis (Sharma, Kosan et al. 2011). These 
structures dynamically cycle between elongated and soluble conformations, thereby 
creating pools of polymerized or depolymerized tubulin in the cytosol (Sharma, 
Kosan et al. 2011). It has been suggested that the cell can regulate ciliary length by 
regulating the pools of soluble tubulin. Disruption of this dynamic, then, has the 
possibility of altering cilia form and function (Sharma, Kosan et al. 2011). In 
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humans, defects in cilia function have been associated with a number of 
developmental disorders, collectively known as ciliopathies (reviewed in (Zaghloul 
and Brugmann 2011)). Among these, include craniofacial defects such as orofacial 
clefts (Toriello and Franco 1993). Therefore, I assessed microtubule regulation of 
orofacial development by utilizing the well-known microtubule destabilizer, 
Nocodazole. The mechanism of this drug is not completely clear; however, it is 
thought to induce formation of nocodazole-tubulin dimers. These then increase 
GTP-ase activity to increase depolymerization of elongated microtubules (Vasquez, 
Howell et al. 1997). In-vitro studies have shown that higher concentrations of the 
Nocodazole induce rapid MT depolymerization and block cells in the G2-M 
transition (De Brabander, Van de Veire et al. 1976; Lee, Field et al. 1980). At lower 
concentrations, however, MT elongation is decelerated with a subsequent increase 
in MT catastrophe (Vasquez, Howell et al. 1997). I therefore began by testing a 
range of concentrations (10-100µM) of Nocodazole on embryos from stage 24 to 37. 
This is a timeframe in which the neural crest is migrating to the facial prominences 
and beginning to differentiate. The lowest concentration that elicited malformation 
was (10µM). These embryos exhibited extreme malformations of the head and body 
(3 experiments, n=25; Fig. C1B,B’). The mouth failed to perforate, and the eyes 
were extremely underdeveloped (Fig. C1B). There was also a failure of anterior-
posterior body axis extension, resulting in embryos being extremely truncated 
compared to controls (Fig. C1B’). Controls developed normally (Fig. C1A,A’). It is 
likely that Nocodazole treatment during this timeframe rapidly depolymerized the 
microtubules necessary for neural crest migration. It is also probable that treatment 
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locked neural crest cells in G2-M transition, thereby also preventing their 
proliferation.  
To investigate disruption of MT dynamics without inducing such severe 
effects on the neural crest, I next treated embryos with a concentration of 
Nocodazole for a shorter time frame after the neural crest has finished migrating 
from stage 30 (35 hpf) to stage 37 (55 hpf). This treatment resulted in slightly less 
severe defects, but embryos still exhibited orofacial and body axis anomalies (Fig. 
C1C,C’). The mouth opening was visible in these embryos; however the shape of 
the mouth appeared malformed. In addition, the midface appeared shorter and 
hypoplasic (Fig. C1C). The body axis was more extended than embryos treated 
during the first timeframe; however, it did not appear comparable to controls and 
embryos were bent ventrally (Fig. C1C’). Edema was present along the entire body, 
in the heart, gut, and eyes. These embryos also exhibited a loss of gut coiling and 
protrusion of the gut through the anal opening (Fig. C1C’). Because this treatment 
time occurs after the neural crest migrates, it is likely that these results are due to a 
failure of neural crest cells to proliferate after they have reached their destination 
tissues. It is also possible that increased pools of soluble tubulin interferes with 
cilia assembly, which could account for the edema seen in these embryos.  
Finally I was interested in perturbing microtubule dynamics such that the 
main consequence would be disruption of cilia function. I therefore treated embryos 
after neural crest development is complete, at a timeframe just prior to mouth 
perforation and cartilage differentiation (stage 37 (55 hpf) to stage 43 (87 hpf)). 
The effects of Nocodazole treatment on these embryos were notable less severe than 
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the prior two treatment windows (Fig. C1E,E’). They appeared only slightly 
truncated compared to controls, and exhibited only a slight loss of gut coiling (Fig. 
C1E’). The midface also appeared to be closer in size to controls; however, they 
still exhibited slight midface hypoplasia. The mouth shape was slightly misshapen, 
exhibiting a more square shape than controls (Fig. C1E). The most notable defects 
seen in these embryos were heart and face edema as well as protrusion of the lenses 
(Fig. D1E). It is likely that the extreme edema seen in these embryos are primarily 
due to a disruption in ciliary function.  
The experiments described above are preliminary, but suggest differential 
roles of microtubules in different phases of orofacial development. Future studies 
involving investigation of neural crest and cilia development and behavior would 
further clarify these roles. In addition, synergy studies with the RAR inhibitor, as 
described in chapter 3, would determine potential interaction between retinoic acid 
signaling and microtubule dynamics.  
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Figure C1. Effect of short-term and long-term exposure to Nocodazole on Xenopus 
development.  Frontal face (A-D)  and lateral whole body (A’-D’)  images of controls (A,A’) ,  
embryos treated with Nocodazole from stage 24-37 (B,B’) ,  embryos treated with Nocodazole 
from stage 30-37 (C,C’) ,  and embryos treated with Nocodazole from stage 37-43 (D,D’) .   Red 
dots outline mouth opening. Arrows indicate mouth opening on lateral images. cg = cement 
gland.  
  190 
 
 
 
VITA 
 
 
 
Allyson Elizabeth Kennedy was born November 6th, 1986 in Richmond, Virginia to 
Lois and David Kennedy. She received her Bachelor’s of Science in biology from 
the College of Arts and Sciences at James Madison University in May of 2009 in 
Harrisonburg, Virginia. She received her Master’s of Science in biology from the 
College of Arts and Sciences at Virginia Commonwealth University in August of 
2012 in Richmond, Virginia. 
